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Tissue engineered bone has become a relevant need for the unmet 
clinical needs for regenerating bone, wither in orthopaedic or maxillofacial 
area. However, despite the number of such limited products and bone grafts 
available today, which also extends to grafts of allogenic sources (eg. DBM). 
Today, autografts remain the gold standard despite its limited availability and 
disadvantages. This research was aimed at developing a novel bone graft 
alternative and strategy using engineering techniques and enhanced with 
commercially available biomolecules. It was hypothesised that the 
combination of rhBMP-2 and a 3D relevant bone complementing porous 
scaffold could be a suitable bone graft alternative for load bearing applications.  
For this purpose, the bioresorbable PCL and enhanced PCL/TCP 
scaffold systems designed and fabricated for bone regeneration. In the first 
study, the basic scaffold biomaterial and structure was found to be capable of 
supporting the attachment, proliferation and differentiation of primary 
mammalian bone marrow stromal cells. Cells remained viable and 
metabolically active through the 28-day study.  
As degradation and resorption are the key characteristics for the 
bioresorbable scaffold systems, yet this is an extremely dynamic process, the 
second experiment analysed thoroughly the degradation profile and 
mechanism the scaffold system. It was established that the scaffold system had 
functional structural stability up to 6 months, and complemented bone 
regeneration, transfer of load in a timely manner and did not release toxic 
byproducts beyond threshold limits.  
 viii
In the third experiment, mPCL/TCP bone scaffold system was used to 
reconstruct a critical-sized rat calvarial defect, with rhBMP-2, to assess the 
feasibility and performance of such a tissue engineering strategy. The scaffold 
structure on its own was able to restore the shape of the cranium, as well as 
functional stability and excellent integration to the host bone, tested via 
mechanical analyse. While its porous structure, revealed by histology, 
complemented the ingrowth of neo-bone and tissue, to achieve successful 
repair of the defect.  
In the forth experiment, scaffold system (a biocage) with rhBMP-2 was 
used, as a bone graft alternative, in a large animal load-bearing site for lumbar 
spinal fusion using the anterior lumbar interbody fusion (ALIF) technique. The 
clinical outcome showed functional fusion, with stiffness (resistance to motion) 
and histological neo-bone formation comparable to the autograft control. 
Semi-quantification by radiographic means revealed more mineralised bone. 
Results indicated that the biocages with lower than clinical rhBMP-2 doses, 
achieved functional fusion, in a safe manner. The bioresorbable scaffold 
systems that are designed to encourage rapid bone ingrowth and thus, 
promptly transfer of the load-bearing/sharing dynamics to new tissues, even at 
highly demanding sites of bone regeneration like the lumbar interbody fusion 
site. As there is an imperative need for “off the shelf” tissue engineering 
products to meet the current unmet clinical needs, the strategy of using the 
commercial mPCL/TCP biocage with rhBMP-2 could provide an immediate 
viable option as a bone graft alternative for a variety of bone engineering 
situations. Thus, this strategy of tissue engineering by stimulating host tissue 
and bone regeneration clearly surpasses other permanent implant strategies, 
 ix 
where the permanent implant could cause further material, stress or load 
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detected infiltrating into the scaffold in the longitudinal 
direction in the BMSC group, but no bridging was observed. 
  
Figure 6.13 Quantity of bone base on defect volume semi-quantified by 
µCT using Mimics. Bone measurements for autograft average 
about 70%, similarly the biocage alone and BMSC groups also 
averaged 22% and 20%, respectively, over the 9 months. Only 
the rhBMP-2 group exhibited significant difference in bone 
volume compared to the biocage and BMSC groups at all time 
points, which increased from 64% (3-mth), to 82% (6-mth) 
and 98% (9mth). *(p<0.05). 
  
Figure 6.14 Histological section of spinal segment showing implanted 
autograft or biocages, stained with basic fuchsin-methylene 
blue stain. The general anatomical orientation for the spine 
segments are posterior to anterior (where grafts were inserted), 
from left to right, respectively. All groups with biocages 
displayed good integration with upper and lower vertebrae and 
direct contact with bone, no fibrous tissue was detected. Based 
solely on histology sections, the biocage only and biocage 
with BMSC treatment showed no or minimal bone ingrowth 
into the porous scaffold system, only at 6 months for the 
BMSC group and at 9 months for both groups were some bony 
infiltration detected. Based solely on histology sections, the 
better performing treatment groups were the autograft and 
biocage with rhBMP-2, dense bony trabecular tissue was 
detected (integrated into the scaffold pores) as early at 3 
months. As implant time increases, a denser cortical-like 
region at the anterior surface (bridging of defect aperture) of 
mainly the autograft and rhBMP-2 group was observed; this 
could possibly be due to neo-tissue mimicking the 
neighbouring host tissue (the adjacent vertebrae) of the same 
structural configuration, this could also suggest an adequate 
biomechanical stimulation, support and response. In some 
samples from the biocage only and BMSC group, the anterior 
defect aperture (both gross and histological examination) was 
only closed with soft tissue or membrane. 
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Figure 6.15. Mechanical test for the range of motion for the spinal 
segments from 3 to 9 months. Flexion-extension (top), right-
left lateral bending (middle) and axial rotation (bottom). 
  
Figure 6.16. Molecular weight distribution of biocages implanted in the 
lumbar spine up to 9 months, both Mw and Mn were plotted 
on the graph. (Dark brown lines broken and unbroken, 
represents the trend for the mPCL/TCP scaffolds from the in 
vitro study.) A decrease in the molecular weight of the 
biocages (PCL/TCP scaffolds) was observed, similar to the in 
vitro study, the Mn decreased at a faster rate. Only the 
biocages from the rhBMP-2 group showed a reduction in rate 
of degradation after 3 months, this could be due to massive 
quantities of bone produced and regenerated around the 
composite structure thereby significantly reducing the amount 
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CHAPTER 1    
1.0 INTRODUCTION 
1.1. Background 
In this modern era of scientific and medical advancement, diseased and 
injuries to organs or tissues can be managed or treated and annually, this 
alone, costs the USA an estimated $400 billion [1]. In severe medical cases, 
treatments can range from removal, repair and replacement with graft 
transplants, combined with tailored rehabilitative and preventive therapies. 
However, availability of donor grafts, for bone as well as other soft tissues for 
tissue and organ treatments remains scarce, risky and costly to harvest. 
Further, these could represent a limitation in certain therapeutic strategies in 
addition to the inherent risk of disease transmission and adverse host response 
[2].  
In bone repair and orthopaedic therapies, there is an increasing demand 
for solutions, driven by aging demographics, increased awareness, 
globalisation, technological and product advances, increasing number of sport 
injuries and improved patient care strategies. However, ideal solutions for 
bone diseases (defined as: a disordered or incorrectly functioning bone, part, 
structure, or whole skeletal system of the body, resulting in a harmful, 
depraved, or morbid condition) has eluded us for many years and continue to 
pose a significant challenge for orthopaedic, trauma and maxillofacial 
surgeons. Many of these diseases have great influence over the quality of life 
and could be fatal in extreme cases. To address this need to improve our 
awareness, prevention and treatment, and eventually to preserve our quality of 
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life, the United Nations (UN) and the World Health Organisation (WHO) 
declared 2000–2010 as the Bone and Joint Decade [3].    
Bone plays an important role in the human body; being a major 
component of the musculoskeletal system, composed of a network of muscles, 
bones, joints, tendons, and ligaments that provide us with the ability to 
perform daily tasks. It acts as a rigid support and protective framework for the 
organs and soft tissues, and also a system of mechanical levers for full 
mobility. Musculoskeletal disorders and diseases significantly impact the 
quality of life. More than 100 million in the USA have musculoskeletal 
conditions with limitations of function that are chronic and permanent, which 
costs society billions of dollars annually. The human cost, however, goes 
beyond dollars. Limitations of activity, nagging or severe pain, unsightly 
deformity, or the inability to function normally each have enormous impact on 
the quality of life [4]. 
After blood transfusion, bone is the next most required and 
transplanted tissue in the human body, with an estimated 600,000 grafts 
performed annually. The market for bone graft substitutes is estimated to be 
worth more than $1 billion [5]. The total US orthopaedic market reached a 
value of $11.4 billion in 2008. Spine implants accounted for the largest 
segment (39.1%) of the total revenue, knee implants was 28.4%, hip 20.3%, 
trauma 10.6% and shoulder 1.5%. In 2012, the global orthopedics market is 
forecast to have a value of $22.9 billion, an increase of 41.7% since 2007 [6]. 
Biodegradable orthopaedic implants are set to drive growth of the trauma 
fixation devices market which was valued at $2.2 billion in 2008 and is 
expected to grow by 6.5% annually to reach $2.8 billion by 2012 [7].  
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Autologous bone grafting dates back to the ancient Egyptian times and 
the modern use and scientific study of this “gold standard" implant material 
for bone regeneration for bone began in the early 19th century [5]. When a 
bone graft is required to repair a defect, autogenous bone graft is frequently 
performed during surgery as it possesses the three main ideal traits, identified 
by Marshall Urist, for bone healing [8, 9].  
 
(a) Osteoinduction, ability to induce bone formation through delivery of 
signals (biofactors) which influences stem cells to differentiate for 
bone repair and formation. These factors have been identified as 
mainly bone morphogenic proteins (BMPs), which play a significant 
role, and other molecules and proteins, such as transforming growth 
factor beta (TGF-β).  
(b) Osteoconduction, refers to capability of the implanted matrix material 
to interact favourably with cells, supporting the ingrowth of capillaries 
and cells from the host into the graft or scaffold structure to form bone, 
and thus guides repair in a location where normal healing will not 
occur if left untreated.  
(c) Osteogenicity, refers to the graft’s ability to form bone by way of its 
cellular elements, whether through differentiation of mesenchymal 
cells or recruitment of osteoblasts. Hence, living cells would be a 
constituent of the transplanted bone graft or alternative.  
Additionally, in situations where structural support is required, cortical 
autografts could be harvested as a block. However, vascularised grafts and 
cortico-cancellous bone chips have been reported to have shorter healing time 
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compared with a nonvascularised grafts or a massive cortico-cancellous bone 
block [10, 11]. Despite autografts possessing osteoinductivity, 
osteoconductivity and osteogenicity; the success of bone grafting also depends 
on how adequately the graft is incorporated into the defect site and host, these 
are influenced by many factors, such as type of graft (chips, block, vascular or 
avascular), site of transplantation, quality of transplanted bone and host bone, 
host bed preparation, preservation techniques, systemic and local disease, 
which would severely impact the quality of graft integration and rehabilitation 
of patient [12].  
Furthermore, regardless of donor site, though the iliac crest is the most 
common donor site, complications related to the harvest of autograft bone 
include arterial injury, herniation, ureteral injury, nerve injury, infection, 
fracture, pelvic instability, cosmetic defects, hematoma, tumor transplantation 
and chronic pain for years after procedure were reported. Thus, this could 
result in impairing the patient’s quality of life, of which the initial surgery was 
set out to remedy. Consequently the high incidence of complications and 
morbidity during autogenous graft harvest may make the use of synthetic 
grafts viable, without the immunological and pathological risks associated 
with allografts and xenografts [12, 13]. Alternatives to bone grafts have long 
been considered for treating moderate to large defects in orthopaedic 
applications, especially for the two most frequent procedures: long bone non-
unions and spinal fusions. Furthermore, based on the growing numbers of 
research and publications over the decade, there is an impending need to find a 
suitable alternative to bone grafts [2, 14-19]. 
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1.2. Bone Tissue Engineering 
One of the most promising, advanced multidisciplinary, fields that 
could revolutionise health care is tissue engineering and regenerative 
medicine. Its success could mean a potential solution to repair and regenerate 
diseased body parts, and even whole organs. The concept of regenerative 
medicine/tissue engineering is defined as a field involving the life, physical 
and engineering sciences that seeks to develop functional cell, tissue, and 
organ substitutes to repair, replace or enhance biological function that has 
been lost due to congenital abnormalities, injury, disease, or aging [20, 21]. 
Fundamentally, it encompasses (a) development of novel biomaterials and 
scaffolds, (b) identification of optimal cell sources, particularly stem and 
progenitor cells, and techniques to direct their proliferation and differentiation 
and immunological manipulation, (c)  biomolecules, such as angiogenic 
factors, growth factors, differentiation factors, and morphogens. Over the 
years, they have also included (d) engineering methods and design to expand, 
upscale cell and tissue growth, cell encapsulation, bioreactor technology, 
vascularisation and mass transport issues, preservation, storage, and shipping 
of cells and engineered tissues, and biomechanical properties and 
mechanobiological signaling, (e) functional assessment of 
regenerated/engineered tissues for function, efficacy and safety, and (f) 
informatics as applied to tissue engineering.  
Accordingly, tissue engineering techniques and principles could 
eventually offer solutions to the many current constraints, such as scarcity of 
suitable donor organs, life-long dependence on immuno-suppression drugs and 
risk of transmission of diseases and could very well provide customisable 
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therapies to patients or off the readily shelf products. However, there are still 
many challenges and concerns to be addressed, such as upscale to treat large 
defects, regulatory issues and efficacy of therapies. Encouraging results have 
been shown in several tissue types including skin, cartilage, bone, nerves, 
muscle, heart, bladder and liver; also, it has given new hope to many in the 
initial landmark trials [22-26].  
Essentially, the main objective of bone regeneration is to restore and 
maintain the form and biomechanical function of bone. This would require the 
use of a support matrix of adequate mechanical properties to fill the defect 
gap, so as not only to bridge the defect but also enable osteoconduction of 
cells and prevent infiltration of fibrous tissue. It must also act as temporary 
mechanical load-bearing support until neo-bone tissue can function 
adequately. Therefore, as pointed out by Vacanti et al. one of the main focus 
of tissue engineering is to imitate nature by making an exact or closely 
approximated biologic replica that exhibits similar basic properties of the 
original tissue at the time it is implanted, provide a well-developed precursor 
biological substitute [27]. To achieve this, there are three main approaches to 
bone tissue engineering [28-30]: (1) use of a structural matrix or scaffold alone 
that will support tissue regeneration by host tissue; (2) use of a cell/tissue-
scaffold construct to enhance the osteogenic potential of the scaffold, the use 
of cells and cell substitutes could replace limited biochemical functions; (3) 
use of growth factor(s) loaded scaffold to deliver osteoinductive factors for 
enhanced and accelerated regeneration, which stimulates the appropriate cells 
present in vivo to migrate to the defect site, proliferate, differentiate and 
perform the desired regeneration and repairs.  
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Thus, the very core principle for bone tissue engineering revolves 
around the scaffold used. Additionally, it should be three dimensionally (3D) 
porous and interconnected for cell proliferation, nutrient and waste exchange. 
Besides, the mechanical properties of the scaffold should complement the 
defect and treatment methodology, while retaining biodegradability such that 
all foreign material would be eliminated when neo-tissue matures and defect 
heals completely [29, 31]. Therefore, bone tissue engineering should offer an 
alternative to bone regeneration as opposed to replacement. It could also 
attempt to solve problems of vascular insult by being bioactive and 
complementary, and eliminate the effects of stress shielding and mismatch 
resultant of permanent implant throughout implant life. It will resolve the 
tacky issue of tissue shortage. Ultimately, for more comprehensive and holistic 
considerations for synthetic graft development, the optimised functional “bone 
graft alternative” should essentially be easily mass produced for economies of 
scale and consistency, meet regulatory requirements and deliverable to the 
masses as an “off the shelf” product for clinical treatments. Further, the graft 
system should adapt well to the current clinical procedures and situations, easy 
implanted and manipulated and possibly meet the “one size fits all” requisite 
to cut the cost and time associated with customisation of an individual product 
for surgery [32].  
 
1.2.1. The Scaffold 
In guided tissue or bone regeneration, porous 3D bioresorbable 
scaffolds play an essential role as the structural templates to guide tissue and 
bone formation. Scaffolds serve the basic function of a temporary support 
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framework for cells to attach, multiply and be delivered into the body. They 
also serve as mechanical supports for the surrounding tissues at the defect site 
until full regeneration has occurred [29]. Majority of bone graft surgeries are 
performed using autogenous bone, which has the advantage of immuno-
compatibility, osteoconductivity and osteoinductivity [33, 34]. Strategies 
could be adopted or formulated for scaffolds incorporating these factors. These 
additional osteoinductive factors in the form of progenitor cells or growth 
factors could also be used together with a scaffold system for the regenerative 
medicine therapy. However, every specific cell-tissue type and disease 
situation would require a unique and original scaffold to cater to its unique 
circumstances, thus utilising the rapid prototyping technique, the scaffold 
geometry and architecture could be designed and fabricated as desired to 
complement not only as a carrier for cells but also neo-tissue ingrowth. In this 
study, novel 3D porous poly(ε-caprolactone) (PCL) scaffold was developed. 
By incorporation of bioactive β-tricalcium phosphate (TCP), mechanical 
properties of composite polycaprolactone/tricalcium phosphate (PCL/TCP) 
scaffolds were enhanced. These scaffolds with a fully interconnected pore 
network were fabricated utilising computer controlled rapid prototyping 
principles and techniques, such as the fused deposition modeling (FDM) 
technology [35-37]. Scaffolds for osteogenesis should mimic bone 
morphology, structure and function in order to optimise integration into 
surrounding tissue. Trabecular bone morphology and structure is a porous 
environment (porosity of 50 - 90%) and pore sizes in the order of 1mm, which 
could easily be matched by the FDM technique [13].  
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The primary reason for the use of US Food and Drug Administration 
(FDA) approved PCL and TCP is their established clinical use and acceptance. 
These fundamental factors would shorten the time for these scaffold systems 
to reach the patient. In many instances, having the right scaffold design and 
biomaterial composition, tissues could be stimulated and coaxed to regenerate 
without additional factors, such as cells or biomolecules. However, these 
usually are defects of small dimensions and uncomplicated tissue organisation 
and structures [38-40]. For the case of larger defects (eg. critical-sized) and 
tissue with more complex organisation, the scaffold system would need to be 
enhanced with additional signaling cues to stimulate regeneration, with the 
inclusion of cells or biomolecules. Bioresorbable implants are set to drive 
growth particularly in the trauma fixation devices market ($2.2 billion in 
2008) and expected to grow by 6.5% annually to reach $2.8 billion in 2012. 
With the prospects and potential of these bioresorbable devices, the 
technological landscape is set for significant change in clinical devices. 
Superior technology, patient comfort and procedure simplicity are expected to 
drive acceptance by patients and clinicians alike [7].  
 
1.2.2. Cells 
Living cells, the basic building blocks of life, when utilised 
appropriately can aid significantly in regenerating damaged tissues. Although 
differentiated cells, such as osteoblasts and chondrocytes, can be used in cell-
based therapies, they have numerous limitations due to their differentiated 
state. Derived from the mesoderm, one of the three primary germ cell layers, 
adult mesenchymal stem cells (MSC) hold greater potential and promise [41, 
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42]. Under normal conditions, these self-renewable adult stem cells function to 
replace cells lost from normal tissue turnover or damage, thus hold greater 
healing and regenerative potential than differentiated cells [42].  
MSCs are found in a variety of tissues in the human body, including 
bone marrow, muscle and adipose tissue, and possess the ability to 
‘regenerate’ cell types specific for these tissues [43-46]. The bone marrow has 
a rich source of MSCs and bone marrow aspiration is a common clinical 
procedure with minimal host morbidity, that could be performed for harvest, 
processing and immediate transplantation of MSCs [46, 47]. MSCs also 
exhibits immuno-privileged characteristics and do not express cell surface 
markers that elicit T cells reaction [48]. The multipotent potentiality of adult 
MSCs has been reported and MSCs could be purified and expanded, then 
differentiated along osteogenic, chondrogenic, adipogenic, tenogenic lineages, 
and also a mature stromal phenotype which supports haematopoietic 
differentiation, presenting exciting prospects for cell-based tissue engineering 
and regeneration [49-53]. However, the major drawbacks and challenges 
include the quantity of MSCs that could be derived from an individual, 
quantities decline over age and for larger or multiple defects, the difficulty of 
obtaining sufficient cell numbers for a significant therapeutic effect [48, 54].   
 
1.2.3. Biomolecules (Growth Factors) 
During bone formation (from embryogenesis) and repair, tissues and 
cells have subserviently responded to biochemical cues dispatched by 
themselves (autocrine) or neighbouring cells (paracrine). The biological tissue 
formation and remodeling are extremely dependent on the actions of growth 
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factors [55]. Bone is the only tissue that could heal, remodel and regenerate 
itself without a scar tissue, and this involves a complex cascade of signaling 
factors and morphogens. In bone and fracture healing, this cascade of growth 
factor signaling is even more elaborate to activate pluripotent progenitor cells 
(local and distant), direct angiogenesis, collagen formation and mineralisation, 
regulate osteoblastic and osteoclastic activities, etc. The main potent bone 
forming and bone inducing cytokine involved is the bone morphogenetic 
protein-2 (BMP-2), a member of the multifunctional cytokine BMP family. 
This belongs to the transforming growth factor-β (TGF-β) peptide growth 
factor superfamily. Fundamentally, most of these active growth factors are 
produced by osteoblasts in an autocrine manner [34, 56, 57]. To date the most 
potent and effective bone inducing BMPs in humans are BMP-2 and BMP-7 
(OP-7), and there have been numerous clinical studies demonstrating their 
efficacy [58-60].  
BMPs regulate bone healing basically by recruiting MSC to the local 
defect site (chemotaxis), promote proliferation of these MSCs to harness 
sufficient numbers for regeneration (mitosis) and they induce MSCs (or stem 
cells) to differentiate down the chondrogenic or osteogenic lineage. RhBMP-2 
has been reported to be successfully delivered by polymeric scaffolds for 
calvarial and ulna non-union regeneration [59, 61]. Currently, rhBMP-2 has 
been approved by the FDA for clinical use for spinal fusion and non-unions 
[62].  
Ultimately, whether bone tissue engineering constructs are scaffold 
systems combined with cells, rhBMP-2 or both, they should meet the 
necessary requirements, encompass the essential properties and deliver the 
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functionalities of the gold standard (autograft) to produce comparable or 
superior clinical outcome. Success in these approaches will offer the 
possibility of realising an “off the shelf” functional bone graft alternative 
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1.3. Hypothesis & Objectives 
The hypotheses for this proposed research project are:  
i)  Bioresorbable composite polycaprolactone (PCL)-based scaffold, 
fabricated using rapid prototyping techniques, possess the potential 
to support growth and differentiation of osteo-progenitor cells. 
ii) Bioresorbable PCL-based scaffolds are stable and safe for long-term 
implantation.  
iii) Porous PCL-based scaffolds with collagen mesh, is capable of 
efficient delivery of rhBMP-2 for bone engineering applications.  
iv) PCL-based scaffolds together with rhBMP-2 are capable of 
engineering bone in a pre-clinical large animal model.  
 
Based on this hypothesis, the specific objectives were identified:  
1) Characterisation of composite PCL/TCP scaffolds for bone 
engineering   
Composite (PCL/TCP) scaffolds with enhanced mechanical properties 
over PCL scaffolds would be fabricated and characterised. Primary 
porcine bone marrow stromal cells (pBMSCs) would be cultured on 
the scaffolds to assess compatibility and scaffold’s capability to 
support growth and differentiation of pBMSCs.  
 
2) Degradation studies: Long-term in vitro & in vivo  
Degradation and bioresorption are the key characteristics for the 
scaffold system. Yet this is an extremely dynamic process, influenced 
by numerous factors, interplayed by many equilibrium states as the 
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intrinsic and extrinsic properties evolve in a very complex manner. 
Thus, it is paramount to study and understand the realistic behaviour 
(chemical and mechanical aspects) over the lifetime of the scaffold 
implant, and envisage how the scaffold system could be strategically 
utilised. There is a need to understand, approximate and assess that the 
scaffold system (from design, fabrication to usage) is able to meet the 
requirements to serve as a bone engineering scaffold pertaining to 
strength, stability and safety of the implant until full resorption. 
 
3) Performance of scaffold system in a small animal model 
The proof of concept, for the effective scaffold system delivery of 
rhBMP-2, for the bone engineering approach would be evaluated via 
the calvarial reconstruction of a critical-sized rat cranial defect, with 
and without growth factors (rhBMP-2). The key objective is to assess 
its feasibility and performance when incorporated as a part of a tissue 
engineering strategy. 
 
4) Performance of scaffold system in a clinical relevant spinal fusion 
model 
The bone scaffold system would be used in a load-bearing site in a 
large animal model for spinal fusion using the anterior lumbar 
interbody fusion (ALIF) technique. The key objective is to ascertain its 
performance in a clinically relevant spinal fusion situation when 
compared to control autografts; importantly, the overall performance: 
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clinical feasibility and effective fusion as a bone graft alternative 









2. BACKGROUND AND SIGNIFICANCE 
2.1. The Human Bone 
2.1.1. Function of Bone  
Bone is a living and adaptable tissue. Its structure continuously 
undergoes subtle remodelling, responding to functional and mechanical 
stimulus. Its major difference from other tissues in the body is its hardness for 
structural requirements. This is the result of the deposition of primarily 
collagen and hydroxyapatite to form a complex biopolymer-bioceramic 
composite, whose complex structure contains a wealth of mechanically 
relevant details. Other types of cells and tissues can also be found integrated 
into the bone matrix, including marrow, endosteum and periosteum, nerves, 
blood vessels and cartilage.  
The main function of bone in the musculoskeletal system is structural 
and mechanical. This rigid architectural frame, which keeps the shape and 
form of the human body, not only provides support for soft tissues and vessels 
to grow, it also performs a protective role for the organs and soft tissues of the 
body. Specific hard and soft tissues (bone, cartilage, muscles, tendons and 
ligaments) also form a system of mechanical levers for generation and transfer 
of forces to achieve motion. In addition, bone tissue (medullary cavity and 
interstices of cancellous bone) is the principal location where blood cells 
(erythrocytes, leukocytes, platelets, etc) are produced by the haemopoietic 
stem cells in the red marrow. Also there, yellow marrow is found, which store 
energy, as lipids shown in Figure 2.1 [63].    
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Bone also serves an important function to metabolism as a storage and 
distribution centre; it is a reservoir for minerals, (particularly for calcium and 
phosphorus), which can be released into the blood stream when required. As a 
source of mineral ions, it also buffers and regulates the acid-base balance (pH) 
of the blood by absorbing or releasing ions and salts. Bone tissues can also 
store heavy metals and other elements, removing them from the blood and 
reducing their toxic effects. Mineralised bone matrix stores important growth 
factors, such as insulin-like growth factors (IGF), transforming growth factor 
(TGF), bone morphogenetic proteins (BMPs), etc. Bone tissue also plays a 
role in the balance and  supporting the endocrine system, it can control 
phosphate metabolism by releasing fibroblast growth factor-23 (FGF-23), 
which interacts with the kidneys to reduce phosphate resorption [64].  
 
2.1.2. Bone Physiology and Structure 
In order to engineer a functional bone graft alternative, the first 
consideration is to understand the characteristics of the bone that is intend to 
be replaced and repaired. From this, smart designs could be fabricated to 
emulate or complement the bone defect and its healing kinetics.  
At the ultrastructural level, bone is composed of mainly an organic 
component, collagen (90-95%) and the major inorganic mineral is 
hydroxyapatite. Collagen type-I (Col-I) is the main and most common 
connective protein found in the body and it holds bone tissue together as well. 
It is a fibrous protein with primary units of tropocollagen molecules, which is 
long and rigid with 3 spiral chains of peptide known as α-chains that are 
bonded by a triple helix. The length of a tropocollagen molecule is 300nm and 
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its width is 1.5nm, these are pre-cursors of collagen which align in a quarter-
stagger array with an overlap zone is of 26.5nm and the gap zone of ~37.5nm 
(Figure 2.2). A collection of tropocollagen molecules forms a collagen fibril 
(diameter 20~40nm), which bundles together to form fibres of diameter 0.2-
12µm [65].   
 
 
Figure 2.1. Bone marrow resides within the trabecular space of bone. 




Figure 2.2. Three-dimensional pentafibril schematic, indicating the 
quarter-stagger arrangement of the tropocollagen molecules, particularly 
the fibril overlaps and hole zones. 
 
This banding pattern across the different fibrils is an indication that the 
fibrils mechanically linked one another, connected by external and internal 
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molecular cross-linking. The collagen fibres are aligned primarily along 
tensional force directions, thereby giving bone its superior tensile strength [66-
68].  
Bone is a natural composite material of biopolymers and bioceramics, 
which by weight contains about 45-60% mineral, 20-30% matrix, and 10-20% 
water. While the organic matrix provides bone its flexibility, the inorganic 
material is predominantly responsible for the mechanical properties of bone. 
The major inorganic components is calcium and phosphorous in the form of 
hydroxyapatite (Ca10(PO4)6(0H)2). This insoluble bioceramic is deposited a 
crystalline form, each crystal is about 400Å long, 10Å to 30Å thick and 100Å 
wide. The crystals are shaped like a long, flat plate and the Ca/P ratio, based 
on weight fraction is between 1.3 and 2.0. These hydroxyapatite crystallites 
are initially deposited, with the longitudinal axis of the mineral plates well 
aligned with the collagen fibrils, in the holes between the heads and tails of the 
collagen molecules, and later deposited all over and within the collagen fibrils. 
This newly formed composite unit structure imparts the load-bearing 
capability of bone tissue [65].  
Two forms of bone microstructure can be identified on the microscope, 
based on the pattern of collagen and osteoid arrangements, woven bone and 
lamellar bone. The structure of woven bone exists in newborns, callus, and 
metaphyseal regions, it is laid down in a hasty manner, characterised by the 
haphazard organisation of the collagen fibers and is mechanically weak. 
Lamellar bone is more precisely, highly oriented and gradually laid down, it is 
characterised by a regular parallel alignment of collagen into sheets (lamellae) 
and is mechanically strong. Close to 100% of adult bone is lamellar bone. At 
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this level, the collagen-hydroxyapatite composite is formed into densely 
packed concentric cylindrical lamellar structures, with Haversian systems 
(containing blood vessels) or osteons (parallel columns) (Figure 2.3) [65, 69].  
There are several types of cells found in bone: osteoblasts, osteocytes 
and osteoclasts (Figure 2.4). Osteoblasts are bone-forming cells responsible 
for bone matrix synthesis.  They secrete a collagen rich ground substance 
essential for the mineralisation of hydroxyapatite [70]. Osteocytes form about 
90% of all the cells found in the human skeleton, and are key in controlling the 
extracellular concentration of calcium and phosphate. Osteocytes originate 
from osteoblasts that have migrated into and become trapped and surrounded 
by bone matrix that they themselves produce. The spaces they occupy are 
known as lacunae and are connected by canaliculi; fibre-like canals that 
radiate out in all directions to connect the lacunae with one another and, 
eventually, with the central canals, reaching other osteoblasts as well. These 
osteocytes communicate and respond to stimulus from these attachments and 
are involved in bone formation, matrix maintenance and calcium homeostasis. 
They have also been shown to act as mechano-sensory receptors regulating the 
bone's response to stress and mechanical load [67, 68]. Osteoclasts are the 
cells responsible for the breaking down of mineralised bone and bone 
resorption, central to the bone remodeling process. Osteoclasts are large, 
multinucleated, descended from the monocyte lineage and possess phagocytic-
like mechanisms similar to circulating macrophages, they resorb minerals, via 
secretion of acidic phosphatase against calcium minerals. They are usually 
located on bone surfaces in Howship's lacunae or resorption pits, left behind 
after the resorption the bone surface [69].  
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In terms of the macrostructure, two types of bone structures are 
typically observed: hard compact cortical bone and cancellous trabecular bone 
(spongy). Although both types comprise of the same basic tissues and 
minerals, each has different proportions of the collagen-hydroxyapatite 
packing density, degree of porosity and organisation. Cortical bones are found 
mainly in the shafts of long bones, in majority of flat bones and in the ends of 
long bones. They are densely packed and contain few spaces for marrow and 
vasculature, porosity is in the range of 5-10%, making them hard and impact 
resistant to provide high load-bearing functions and protect against mechanical 
stresses. Trabecular bone, on the other hand, is composed of an irregular 
latticework of thin plates of bone called trabeculae which is highly porous (30-
90%) and vascularised for bone red marrow storage and activities. Trabecular 
bone is always surrounded by cortical bone [71, 72]. The combination of 
cortical and trabecular bone varies according to the bone function at different 
musculoskeletal regions, which is dependent on the applied mechanical 
loading. Wolff’s Law stated that bone tends to remodel and adapt itself 
according to the surrounding biomechanical environment  [73]. Various bone 
tissue types have different mechanical characteristics that regulate apatite 
levels to bear various combinations of the loading modes: tensile, 
compressive, bending, torsion and fatigue. [74-76].  
 




Figure 2.3. Schematic showing structure and organisation of bone. Specific 
regions with compact and spongy bone exclusive to functional and loading 
requirements. Bone tissue composed of osteons, Haversian systems and 
vasculature being organised with different architecture and density (porosity) 
in regions of cortical or cancellous bone. Osteocytes dwell in lacunae to 





Figure 2.4. Diagram of bone cells: Osteoblasts, osteocytes and osteoclasts. 
 
2.1.3. Mechanical Properties of Bone  
Having understood bone’s dynamic structural (at multi-levels) and 
organisational composition, which gives its unique structural and 
biomechanical properties, the best description for its mechanical properties is 
– Functional. Essentially, bone is a rather linear and brittle material, yet it is 
anisotropic and viscoelastic; its mechanical properties are determined by its 
porosity, the degree of mineralisation, collagen fibre orientation and other 
structural details [65]. The microstructure of bone is typically oriented in the 
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direction of the highest biomechanical loading in situ (consistent with Wolff’s 
Law). This microstructural directionality gives bone anisotropy its mechanical 
properties. Thus, bone can be classified as an anisotropic composite with open 
micro-pores [73, 75, 77, 78]. The cortical bone is regionally more 
homogeneous the trabecular bone. Therefore, the bulk mechanical properties 
of cortical bones are more consistent in various skeletal regions [79].  Table 
2.1 shows the various mechanical properties of bone the whole.  
 
Table 2.1. Mechanical properties of bone [79, 80].  
Property Cortical Bone Trabecular Bone 
Compressive Strength (MPa) 100 - 230 2-12 
Flexural, tensile strength (MPa) 50 – 180 10-20 
Strain to failure (%) 1 - 3 5-7 
Fracture toughness (MPa.m1/2) 2 - 12 - 
Young’s modulus (GPa) 7- 30 0.5 - 0.05 
Density 1.8 - 2.2 0.3 – 1.9 
 
2.1.4. The Ossification Process 
The process of mineralisation to form bone is known as ossification. 
The process begins during early embryonic life and continues throughout 
adulthood. The process of ossification takes place via two methods: 
intramembranous or endochondral ossification. In intramembranous 
ossification, bone is laid down directly in connective tissue by osteocytes, 
while in endochondral ossification, a cartilaginous model precedes bone. 
These two kinds of ossification do not lead to differences in the structure of 
the mature bone. Instead, they are simply different methods of bone formation. 
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Both mechanisms involve the replacement of a pre-existing connective tissue 
with bone [63, 70].   
The intramembranous ossification pathway proceeds when multipotent 
mesenchymal stem cells (MSC) in fibrous connective tissue membranes 
cluster and differentiate into osteoblasts. These osteoblasts secrete the organic 
matrix (osteoid) of bone until they are completely surrounded by it and 
differentiate into osteocytes. Calcium and other mineral salts are deposited and 
eventually the matrix hardens or calcifies. As the bone matrix forms, it 
develops into trabeculae that fuse with one another to create the open 
latticework appearance of trabecular bone. The spaces between the trabeculae 
fill with vascularised connective tissue, which differentiate into red bone 
marrow. On the outside of the bone, vascularised mesenchyme condenses, and 
develops into the periosteum. Eventually, most surface layers of bone are 
replaced by cortical bone.  
Endochondral ossification is best observed in long bones and it 
proceeds when MSCs differentiate into chondroblasts, which form hyaline 
cartilage. In addition, a membrane called the perichondrium develops around 
the cartilage. The cartilage grows by interstitial and appositional growth as the 
long bone increases in length. The chondrocytes in mid-region calcified the 
matrix, vacates the lacunae and osteoblasts in perichondrium produce the 
periosteal bone collar. The periosteal bud which is the primary ossification 
centre and the medullary cavity forms. Secondary ossification centre develop 
in epiphysis and in the distal epiphysis of a long bone (the opposite ends). 
Remnants of hyaline cartilage act as articular cartilage and epiphyseal plate. 
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2.2. Bone Regeneration, Repair and Healing 
Defects in bone can occur as a result of injury, disease and surgical 
procedures, even though bone is the only tissue that can completely heal or 
“renew” itself, without scarring. Natural bone healing takes place slowly over 
time due to the decrease in blood supply at the fracture site and need for 
sufficient calcium and phosphorus to strengthen and harden new bone. Bone 
cells also grow and divide slowly. In addition, numerous factors can and will 
affect the rate of bone regeneration, such as metabolic factors, hormones and 
nutrition, genetics, age, other prevalent diseases and conditions, activity and 
load-bearing burden, applied stress and size of defects [70]. Further, metabolic 
bone diseases and aging may prohibit bone regeneration and escalate 
progressive loss of bone mineralisation instead, increasing risk of bone 
fracture and other pathologies.  Therefore, although bone can heal itself, it is 
not without limits, more often than not, it requires medical or surgical 
interventions to facilitate bone regeneration. Permanent bone implants can 
replace or assist in the function of bone, in cases where bone is beyond clinical 
repair.  
 
2.2.1. Bone Remodeling and Fracture Healing 
In order to assist and promote bone regeneration and healing, it is 
paramount to first understand the process and importance of bone remodeling 
before any strategy or intervention is taken. Essentially, bone remodeling is an 
ongoing process which allows bone to (a) respond to different biomechanical 
cues and stresses, (b) repair small damages in the tissue and (c) maintain the 
serum ion and mineral concentrations [81, 82]. Bone remodeling can be 
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defined as the continuous resorption of bone by osteoclasts followed by the 
deposition of new bone by osteoblasts. These events do not occur randomly; 
bone resorption and formation are strictly regulated in order to prevent 
excessive bone resorption (leading to osteoporosis) or excessive bone 
formation. The whole remodeling process is complex, governed by sensitive 
and specific biochemical, hormonal and mechanical factors. This remodeling 
event is crucial to ensure a perfect bony union at the fracture site and to allow 
the formation of lamellar bone, once again at the injured region.  
Fractured bone typically heals and remodels via the following cascade 
of events and processes. First a fracture clot and hematoma is formed at the 
site, leading to swelling and inflammation, as well as a considerable amount of 
cell death and debris. Neovascularisation occurs and capillaries grow into the 
clot delivering phagocytes and osteoclasts to remove the debris, dead cells and 
foreign elements in the traumatised area bringing about granulation tissue 
formation. This process takes up to a few weeks. This infiltration of blood 
vessels then organises it into a procallus. Fibroblasts invade this procallus, 
producing collagen fibres that help connect the broken ends of the bone. MSCs 
and osteoprogenitor cells develop into chondroblasts that produce 
fibrocartilage and the procallus is transformed into a fibrocartilaginous (soft) 
callus, which lasts for about 3 weeks. In more vascular environments, 
osteoprogenitor cells develop into osteoblasts that begin to produce bone 
trabeculae. This joins living and dead portions of the original bone fragments. 
With time, the fibrocartilage is converted to trabecular bone as the callus 
hardens, taking about 3-4 months. Finally, remodelling of the callus takes 
place, osteoclasts remove the redundant regions, woven bone transforms into 
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lamellar bone and cortical bone replaces the trabecular bone around the 
periphery of the fracture. The whole affair is orchestrated by a well 
coordinated series of biological events and responses, molecular and cellular 
signaling via cascades of biochemical cues; of mainly growth factors, 
cytokines, surface receptors, etc [63, 70, 83-86].  
In minor fractures that do not heal on its own, due to inability to heal 
or bridge naturally without immobilisation of the bone. It can be treated by 
using an external cast to minimise “excessive” motion while allowing 
“micromotions” to encourage and stimulate healing. In moderate fracture 
cases, for enhanced immobilisation, extensive internal or external metallic 
fixators would be necessary to facilitate bone repair. The stiffness of fixators 
used (eg. titanium, stainless steel), how they are positioned and designed to be 
administered would determine the degree of immobilisation of the bone and 
extent of “micromotions” allowed. These factors continually influence the 
bone remodeling process as well as the bone function after and beyond the 
regeneration process, in the case of a permanent implant. This is illustrated by 
the fact if a bone plate is too stiff; it would result in the resorption of cortical 
bone around it after the fracture heals due to the “stress shielding” effect. This 
reinforces the concept bone being a dynamic and function adapting tissue [73, 
83, 87-90]. The usage of fixative devices could be effective and achieve much 
success, only under controlled and specific conditions, such as maximum 
treatable defect size which could be stimulated to heal naturally. Still, this 
method is so effective, the procedure of distraction osteogenesis (both limb 
and mandible) leverages on it, to treat post-traumatic injuries and congenital 
limb conditions [5, 91-93]. These understandings reinforce the objective that 
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in facilitating bone repair and regeneration, methods used should be focused 
on leveraging the natural healing, bone formation capability of the patient and 
more importantly the medical devices used should complement and support 
the natural healing process, not replace bone function. Finally, any permanent 
implants should be removed after the bone has remodeled to its desired state.  
The above strategy relies on the patient’s own “limited” healing 
potential. This would not succeed with more severe injury nor should the 
“healing potential” be insufficient. Numerous factors can and will affect the 
rate of bone regeneration and activity of bone cells, such as metabolic factors, 
hormones and nutrition, genetics, age, other prevalent diseases and conditions, 
activity and load-bearing burden, applied stress and size of defects [70]. This 
could lead to a situation of nonunions or pseudoarthrosis, where the healing 
and fusion repair of the fractured bone stalls or turns into a cartilaginous joint 
instead, respectively. In such a case, surgery is required to treat the problem by 
better stabilisation or revision of the repair; even distraction osteogenesis was 
attempted as a treatment for nonunions [5, 94]. Injury sites also suffers from 
lack of vascularity which prevent efficient supply blood, cytokines and 
osteoprogenitor cells to the site; which are the osteogenic and potent healing 
factors.  The current accepted alternative is to use an autologous bone graft 
and similar natural or synthetic alternative to resolve the problem of lack of 
“healing potential”.  
 
2.2.2. Bone Grafts 
There is a driven need to treat orthopaedic diseases, annually, bone 
grafting is a $2.5 billion business [95]. More than 1.5 million musculoskeletal 
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procedures performed in the US annually involve bone grafting with an 
autograft or allograft. Worldwide the figures climb to 2.2 million orthopaedic 
procedures annually [96, 97]. 
 In 1915, autologous bone grafting was introduced as a useful surgical 
technique in the clinical setting and it was not long before its efficacy and 
safety was recognised [95]. An autologous bone graft is bone harvested from 
an alternative site of the same patient. It is not only histocompatible but also 
possesses the structural matrix similar to the original bone structure, with 
hydroxyapatite and collagen within the native bone to serve as an 
osteoconductive framework. It contains stromal, osteoprogenitor cells, 
osteoblasts and endosteal capable of forming new bone. In addition, it also 
contains growth factors to stimulate new bone and vascular development. The 
open porous structure of autologous trabecular bone permits the deposition of 
new bone directly on the trabeculae and are also revascularised rapidly, which 
occurs through the open marrow spaces [98]. Above all, autografts possesses 
the three important traits as identified by Marshall Urist, for bone healing [8, 
9]. (1) Autologous bone is osteoinductive, the ability to induce bone formation 
through release of growth factors and signals which influences cells to 
differentiate for bone repair and formation, such as bone morphogenic proteins 
(BMPs). (2) They are osteoconductive, which interacts favourably and 
chaperons the ingrowth of capillaries and osteoblasts from the host tissue into 
the scaffold structure to form bone. (3) They are osteogenic, as they contain 
cellular elements, such as osteoprogenitor cells, osteoblasts or osteocytes, 
which encourage bone healing. Common autologous bone graft harvesting 
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sites include the pelvis anterior/posterior iliac crest, proximal tibia, femur, and 
distal radius.  
Although autografts are considered the “gold standard” for repairs of 
bone defects and used to engineer fusion, such as in the spine, the main 
inherent drawbacks is the source the bone graft itself. The grafts have to be 
removed from another site in the human body, which limits its supply and 
results in donor-site morbidity which is seen in approximately 20% of all 
procedures [19, 99, 100]. It was reported that the harvest sites (especially large 
ones) were recommended to be reconstructed with autografts, allografts or 
alternative graft materials, such as calcium phosphate bone void fillers to 
minimise associated complications and pain, which would also contribute to 
costs and surgery time [5, 101]. In addition, autologous bone from different 
body location have different  structural and biological properties, bone from 
the distal radius was structurally inferior to and had lower turnover than the 
iliac crest bone graft, so not all autografts are created equal with the optimally 
suitable properties for the defect site. Schnitzler et al. recommended the iliac 
crest bone for grafts which required immediate structural integrity [102, 103]. 
Also cortical autografts could be harvested as a block. However, even 
vascularised grafts and cortico-cancellous bone chips have been reported to 
have shorter healing time compared with a nonvascularised grafts or a massive 
cortico-cancellous bone block [10, 11]. Despite, autografts possessing 
osteoinductivity, osteoconductivity and osteogenicity; the success of bone 
grafting depends on how adequately the graft is incorporated into the defect 
site and host, these are influenced by many factors, such as type of graft 
(chips, block, vascular or avascular), site of transplantation, quality of 
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transplanted bone and host bone, host bed preparation, preservation 
techniques, systemic and local disease, which could significantly affect the 
quality of the autograft, mechanical properties of the graft and rehabilitation of 
patient [12].  
Other concerns and disadvantages include: a second invasive surgical 
procedure is required to harvest the bone, prolonged operation time, 
lengthening of hospital stay, and an increase of the monetary and physical 
costs. Pain is probably the most common complaint after iliac crest bone 
grafting. Over 38% of patients had pain up to 6 months after iliac crest 
harvest, 18% experienced pain up to 2 years postoperatively, while some 
persist chronically. Furthermore, regardless of donor site, although the iliac 
crest is the most common, reported complications related to the harvest of 
autografts include arterial injury, herniation, ureteral injury, nerve injury, 
infection, fracture, pelvic instability, cosmetic defects, hematoma, tumor 
transplantation and chronic pain for years after procedure [5, 13, 104]. 
Fractures due to iliac crest harvestings very often require additional complex 
surgical treatments and could lead to significant disability, which can be 
permanent [105]. Thus, this could result in impairing the patient’s quality of 
life the initial surgery was set out to remedy; consequently the high incidence 
of complications and morbidity during autogenous graft harvest may make the 
acquisition and use of synthetic grafts viable, without the immunological and 
pathological risks associated with allografts and xenografts [12, 13].  
Another possible alternative is the use of allogenic bone, allograft, that 
is bone taken from another human being (same species), usually frozen 
cadaveric bone. However, allografts carry a high risk if disease transmission, a 
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higher resorption rate and a possible immunogenic response. In order to 
minimise these risk of disease transmission, several techniques, including 
tissue freezing, freeze drying and sterilisation with gamma radiation, electron-
beam radiation and ethylene oxide have been used to treat the allografts. These 
result in a bone graft with lower osteogenic capacity (much proteins were 
destroyed), the processes also destroys all osteogenic cells and leaving almost 
no osteoinductive capability; it has also less revascularisation potential [19]. 
The use of allografts has declined over concerns of viral contamination and 
transmission. Xenogenic bone taken from a different species, could be used 
but it is generally not considered, as it elicits an acute antigenic response 
resulting in failure in the majority of cases, along with similar faults associated 
with allografts [106].  
Alternative bone grafts have long been considered for orthopaedic 
applications, especially for the two most frequent procedures requiring bone 
grafts: long bone non-unions and spinal fusions. Furthermore, based on the 
growing number of research and publications over the decade, there is an 
impending need to find a suitable alternative bone grafts [2, 14-19, 29, 107-
109]. 
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2.3. State of the Art in Bone Tissue Engineering  
There is no modern technology yet, that could replicate bone’s natural 
and detailed intricate design and structures. Even, autograft bone may not have 
adequate and suitable properties (vasculature and architecture) which could 
fail due to graft fracture and resorption. However, its chief purpose can be 
seen as to provide an extracellular matrix platform of collagen and calcium 
phosphates, as well as the all important morphogenic factors in the cytokine 
form or as cells; which could be accounted as the “best strategy” to stimulate 
and accelerate natural healing. Furthermore, this strategy is vital to stimulate 
where bone cannot heal or grow on its own, such as in a spine fusion scenario; 
where finally, grafts should be assimilated.  
The main function of bone, once lost to injury or other means, can only 
be regained by restoring skeletal continuity. Briefly discussed in Chapter 1, 
tissue engineering of bone involves providing immediate support through 
implanted scaffolds or matrices and the stimulation of the healing process to 
accelerate and enhance the repair. This stimulation is achieved mainly through 
introduction of cellular elements and/or cytokine protein growth factors, to aid 
in regenerating bone and vascular injury. Currently available alternatives and 
strategies to bone grafts incorporate both synthetic and biological materials. 
Most bone graft substitutes are formed from a composite of one or more 
materials from an extensive list that includes immuno-compatible progenitor 
cells from autologous and allogenic sources, natural and recombinant growth 
factors, and matrices from degradable and nondegradable polymers, calcium 
phosphates and bioactive glass or other bioceramics.  
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2.3.1. Requirements of a Bone Graft Alternative 
In cases of large bone defects with excessive bone loss, there is a need 
for the surgeon to bridge the defect with a graft material; also where the injury 
site suffers from lack of vascularity, the graft should stimulate neo-
vascularisation. Furthermore, as discussed earlier, the measures taken should 
focus on complementing and stimulating the bone regeneration process. Some 
of the basic properties that an ideal graft (natural or synthetic) should possess 
[8, 9, 108, 110, 111]:  
 
a)  Osteoconductive, the bone graft material must be able to interact 
favourably with cells, support the attachment and ingrowth of cells and 
capillaries from the host into the graft or scaffold structure to form bone; 
and thus guides repair in a location where normal healing will not occur if 
left untreated. Hench et al. described osteoconductive bioactivity as the 
property of the material which is able to directly bond to new forming 
bone [112, 113]. 
b)  Osteoinductive, the bone graft should possess the ability to induce bone 
formation through delivery of biosignals which influences stem cells to 
differentiate for bone repair and formation. These factors have been 
identified as mainly bone morphogenic proteins (BMPs).  
c)  Osteogentic, the bone graft should possess the ability to form bone by way 
of its cellular elements, whether through differentiation of mesenchymal, 
osteoprogenitor cells or recruitment of osteoblasts and osteocytes. Hence, 
living cells would be a constituent of the transplanted bone graft or 
alternative.  
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d)  Biocompatible and bioresorbable, the bone graft (material) must be able to 
integrate with the host, without adverse effects throughout implant 
lifetime. After the host tissue has regenerated and healed, the foreign graft 
material should resorb away. The implanted material must not cause an 
inflammatory or toxic response exceeding an acceptable level during the 
resorption phase. For synthetic biomaterial and scaffolds, it would mean an 
adequately selected material with compatible surface chemistry and 
appropriate implant design, in terms of structure, morphology and toxicity 
by-product release [35, 69, 114, 115]. 
e)   Porosity and interconnectivity, is essential for the transport and diffusion 
of nutrients and wastes, to and from the centre and throughout the scaffold. 
This transportation network becomes more vital to prevent metabolic 
inactivity and necrosis, until sufficient angiogenesis [116]. Active support 
for vascularisation and cell proliferation and distribution is also critical for 
tissue regeneration [117]. The introduction of high porosity (and pores) 
reduces the amount of foreign material at the injury site and allows more 
regenerated tissues to mature; however, at the expense of mechanical 
stability, which is inversely related to porosity. 
f)  Adequate pore size, is necessary to optimally coordinate the ingrowth of 
required cells and tissues into the graft, as a part of the regeneration 
process; since different cells and tissue types have specific distinct 
requirements. Although the optimal pore size for bone ingrowth has often 
been reported to be in the range of 150–800µm. Literature has showed that 
the optimum pore size required for neovascularisation is about 5µm, 
osteoid development requires about 40-100µm and for bone regeneration 
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150-800µm [29, 118, 119]. Whang et al. recommended that for non load-
bearing defects (eg. calvarial) polymer scaffolds with pore size less than 
50µm and porosity greater than 90% was optimal compared to larger pore 
size ranges for bone regeneration via early phase hematoma stabilisation 
[118]. The spatial optimal requirement for neovascularisation and 
incursion of osteoprogenitor cells should be less than 20µm, relative to 
their dimensions. However, relative micromotion between the scaffold 
boundaries and surrounding tissue may disrupt vascular ingrowth into the 
small pores. Larger pores, although perhaps not optimal for hematoma 
stabilisation or cell attachment, may allow vascular and host tissue 
ingrowth to occur despite the presence of interface micromotion. 
Definitely, these variables to the equation would change when the defect 
size and load increases. While successful bone repair could be achieved by 
optimising of various critical phases of bone regeneration, still the 
fundamental conclusion is that there is no optimal pore size to facilitate all 
the phases. The relation between pore size, interconnectivity and porosity 
is extremely intricate and affects critically the resultant mechanical 
properties of the scaffold construct [120]. 
g) Mechanically stable, the bone graft must provide a structural matrix to fill 
the defect void and impart mechanical stability to the defect site, which 
should match that of the natural bone tissue at the implantation site. 
Mechanical and stability factors can have both positive and negative 
effects on the in vivo healing response; repeated disruption of vascular 
invasion and fracture of neo-mineralised at the scaffold interface with 
native tissues can result in nonunion. Finally, for load-bearing applications, 
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the bone graft must be able to maintain and transfer this load back to the 
neo-bone tissue as it matures, stress shielding is a nagging problem in bone 
regeneration and remodeling [110]. Constructs possessing insufficient 
strength and fatigue resistance properties are at risk for plastic deformation 
or brittle failure under functional loads, leading to collapse of the internal 
porosity and subsidence of the implant; which is paramount for scaffolds 
being used as a carrier and delivery vehicle for cells or growth factors. 
Martin et al. found that a collagen sponge scaffold with BMP effectively 
induced spine fusion in rabbits, but the same scaffold failed as a delivery 
vehicle in a non-human primate spine fusion model due to mechanical 
collapse [121].  
h) Customisable shape, including flexibility that could be easily trimmed or 
shaped to fit the defect site, within the clinical setting.   
i) Disease and pathogen free, the bone graft material must be sterile and not 
be a carrier for disease transmission. 
j)  Immuno-compatible, the bone graft must not elicit adverse immuno-
response from the host tissue.  
k)  Available and “off the shelf”, the bone graft must be readily and easily 
available for all situations, and be suitable for use with various bone 
defects. They should be customisable and fabricated in an efficiently and 
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2.3.2. Bone Engineering Scaffolds – Role in Tissue Engineering 
Since tissue engineering of bone involves providing immediate support 
and stimulation of the healing process to accelerate and enhance the fracture 
repair; the scaffold play an exceptionally important role, to provide the 
adequate mechanical support, as well as an architecture to stimulate and guide 
bone regeneration and it could be used as a carrier for cell proliferation or 
growth factor delivery. There is a wide range of biomaterials (from synthetic 
polymers and ceramics to natural ones) to choose from and prudent selection 
criteria is essential to ensure the final scaffold is effective and functional, from 
the pre-implantation preparation stages to the final resorption stage after 
complete bone regeneration. Selected biomaterials should direct the growth, 
differentiation, and organisation of cells in the process of forming functional 
tissue by providing physical, chemical, and mechanical cues. Ultimately, all 
the required properties may not be found in just a single material, and a 
combination of materials is necessary to exploit and maximise their potentials, 
such as in composites. Finally, the scaffolds, as well as its fabrication process, 
should be translatable to a commercial situation, especially on meeting 
regulatory criteria. Table 2.2 shows some commercially available bone graft 
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Table 2.2: Commercial bone graft alternatives. 
Products Company Matrix/Scaffold (Material) Uses 
Osteoplug Osteopore www.osteopore.com.sg PCL, PCL/TCP Craniofacial  
Alvelac™ Bio-scaffold www.bio-scaffold.com 
 (PLGA), is a widely-








Vitoss® + Bioglass 
Spine, bone 
voids 
chronOS Synthes www.synthes.com β-TCP Void filler 
NovaBone® NovaBone www.novabone.com 
Calcium phosphor-









InfuseTM  Medtronic www.medtronic.com 
Titanium# + Col-I 










www.stryker.com HA, CaP Void filler 
Conduit®  TCP Void filler 
HEALOS® 
Johnson & Johnson 





β-TCP granules + 




Pro Osteon Coral (HA) 
InterGro 





















β-TCP bone fusion, filler  
Optecure DBM + cortical chips +hydrogel 
OpteMx 
Exactech Inc 













PLGA + cortical bone
defects, 
spine 
(some products have not yet attained FDA approval for clinical use) 
# - non-resorbable. 
PLGA – Poly (lactic co-glycolic) acid 
β-TCP – β-Tricalcium phosphate 
Col-I – Collagen type-I 
rhBMP-2 – Recombinant human bone morphogenetic protein-2 
rhPDGF – Recombinant human platelet derived growth factor 
HA – Hydroxyapatite  
CaP – Calcium Phosphate 
DBM – Demineralised bone matrix 
CMC - Carboxymethylcellulose sodium 
 
 
2.3.2.1. Polymers  
Polymers are a class of materials composed of strings of repeating 
structural units into a large macromolecule, these can be synthesised naturally 
or in the laboratory. Naturally occurring polymers are produced by living 
organisms and can be processed and purified for biomedical applications. 
Since the intent of tissue engineering is to make use of these polymers as 
scaffolds and mimic the extracellular matrix (ECM), intuitively, these natural 
biopolymers could come from natural ECM. Individual components of the 
ECM can be harvested and processed for use as a scaffold, such as starch, 
collagens, gelatins, hyaluronic acids, alginates and chitosan [62, 122-125]. 
Polymers can also be fabricated synthetically, such as polyethylene and 
polyesters. Synthetic polymers resolve issues that could plague natural ones, 
such as shortages of natural polymer sources and cost of purification; natural 
polymers suffer from batch-to-batch variation, cross-contamination (virus or 
disease from plant, animal or human) and sensitivity to processing techniques. 
On the contrary, synthetic polymeric biomaterials can be designed and tailored 
for specific physicochemical and mechanical properties and without 
immunogenicity, such as altering or modifying the molecular weight and 
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function groups. It could also be processed easily with various common 
manufacturing techniques and produced in large quantity with consistency.   
Of these, biocompatible polymers for clinical application can further 
be classified into non-resorbable and resorbable ones. Some non-resorbable 
polymers include polyvinylalcohol, poly(hydroxylethylmethacryalte) 
(PHEMA), poly(N-isopropylacrylamide) and polyetheretherketone (PEEK), 
for membranes, contact lenses and spinal devices [126-128]. Common 
bioresorbable ones mainly include the family of poly(α-hydroxyesters), such 
as polyglycolide (PGA), polylactide (PLA), polycaprolactone (PCL) and their 
copolymers [129-131]. They also include non-polyesters, polyphosphazene, 
polyanhydrides, poly(propylene fumarate), polycyanoacrylate, polydioxanone, 
polyurethanes, etc [132-137].  
Among these two categories, synthetic bioresorbable polymers were 
preferred for tissue engineering applications devices as they possess superior 
strength and processibility. The family of poly(α-hydroxyesters) family (PGA, 
PLA, PCL) is among the few approved for human clinical use by US Food and 
Drug Administration (FDA) and are extensively used or tested as scaffold 
materials. For decades, these polyesters has been used for clinical applications 




Poly(ε-caprolactone) (PCL) is a semi-crystalline linear aliphatic 
polyester, which belongs to the family of poly(ω-hydroxy esters) [138]. PCL 
exhibits several unusual properties not found among the other aliphatic 
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polyesters. These include its exceptionally low glass transition temperature 
(Tg) of ~ -60°C, low melting temperature (Tm) of ~60°C and high thermal 
stability with a decomposition temperatures (Td) of ~350°C, while other 
polyesters decompose at ~250°C [139]. Its molecular structure has a repeating 
molecular unit of five non-polar methylene groups (CH2) and a single 
relatively polar ester group (Figure 2.5). Molecular weight is controlled by 
addition of chain control agents, which usually are water, primary alcohol, 
amines, or some hydrogen active compounds. The mechanical properties of 
solid PCL (Mw = 44000) had been reported to have a tensile strength of 16 
MPa, tensile modulus of 400 MPa and an elongation at break at 80% [139]. 







Figure 2.5. Repeating molecular structure of PCL 
 
Having a low Tg and existing in a rubbery state at room temperature, 
PCL is one of the most flexible and easy to process biomedical polymer. PCL 
also shows relatively high thermal stability compared to PLA and can be 
easily processed without significant molecular weight loss [140]. Even though 
it also has one of the slowest degradation rates, the thermal stability and 
pliability of PCL permits easily tested for many fabrication processes, 
including the study of using the Fused Deposition Modeling (FDM) 
technology. PCL is known to fully degrade from 2-4 years in certain 
conditions, and final products are metabolised through the citric cycle or 
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eliminated via direct renal secretions [141, 142]. PCL is also readily being 
researched as a biodegradable packaging material for commercial uses [129].  
Initially, PCL was known could be degraded by microorganism, which 
led to the evaluation of PCL as a commercial biodegradable packaging 
material [143]. Later, it was discovered that PCL could also be degraded by a 
hydrolytic mechanism. The hydrolytic un-stability was due to the 
susceptibility of its aliphatic ester linkages to hydrolysis, which is an inherent 
characteristic of PCL and its copolymers [141]. However, hydrolysis of PCL 
homopolymer is considerable slower than the other poly(α-hydroxy esters), 
such as PGA and PLA, because of the combination of its crystallinity and high 
olefinic character. On the contrary, copolymerising and blending causes the 
overall crystallinity to decrease and increasing the accessibility of ester 
linkages, thus enhances the rate of hydrolysis. Hence, PCL copolymers and 
blends can be prepared for having a wide range of physical properties and 
degradation rates [130].  
Pitt et al. conducted an in vitro (saline) and in vivo study (rabbit 
model) of PCL for drug-delivery systems. The authors reported that the two 
hydrolytic degradation rates were similar and concluded that physiological 
enzymatic involvement was not a significant factor in the degradation process. 
It was observed that the chain scission of PCL was not accompanied by 
corresponding mass loss of low molecular weight PCL fragments until the 
molecular weight (Mn) had decreased to around 5000 [141]. Similarly, 
Woodward et al. studied the in vivo (Dawley rats) and intracellular 
degradation of PCL and reported that degradation first proceeded with non-
enzymatic bulk hydrolysis and a transient initial inflammatory response 
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occurred only for the first 2 weeks. After 9 months, only when the molecular 
weight had reduced to about 5000, did a loss in mass emerge, and 
subsequently the PCL fragmented. For the study of intracellular degradation, 
low molecular weight PCL (Mn 3000) powders, 53-500 μm, was used. The 
authors reported that the powdered PCL were rapidly degraded and absorbed 
within 13 days inside the phagosomes of macrophage and giant cells. Also that 
the sole metabolite was ε–hydroxy caproic acid (C6H12O2) [144]. It was also 
reported that in rat PCL was metabolised to ε-hydroxy caproic acid, the end 
product of PCL ester hydrolysis in vivo.  The hydroxyl acid was respired and 
broken down to CO2 and H2O when exposed to tissue fluids [145, 146].  
A review of literature has shown that PCL has been extensively 
researched for both medical applications and environmental ones [129]. 
Regarded as a non-toxic and tissue compatible materials, one of the earliest 
commercial usage of PCL is a drug delivery device. Capronor®, a one-year 
implantable subdermal contraceptive device had been approved by the FDA 
[143, 147, 148]. Extensive in vitro and in vivo biocompatibility and efficacy 
studies had also been performed in the research leading to the introduction of 
the Monocryl® monofilament sutures, a copolymer of PGA(75%) and PCL 
(25%) [149]. Recent suture research has led to the development of a P(LA/CL) 
suture, where PCL (20%) was used as a copolymer with PLA (80%) to 
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Table 2.3. Comparison of the properties of the Poly(hydroxy esters) [151, 
152]. 
Polymer / Properties PGA PLLA PDLA PCL 
Tg (ºC) 35 - 40 60 - 65 55 - 60 -65 - -60 
Tm (ºC) 225 - 230 173 - 178 – 58 - 63 
Crystallinity (%) 35 - 75 ~ 35 – 30 - 60 
Degradation Time 
(mths)# 6 - 12 > 24 12 - 16 > 24 
Tensile Str. (MPa) 68 - 140 55 - 84 28 - 41 20 - 35 
Elongation (%) 15 - 20 5 - 10 3 - 10 300 - 500 
Modulus (GPa) 7 2.8 - 4.1 1.4 - 2.8 0.2 - 0.4 
# Time to complete resorption. 
 
Collagen 
Collagen is the most common and abundant naturally occurring ECM 
in the mammalian species which accounts for about 30% of all proteins found 
in the body. Collagen is a highly conserved protein and has inherent common 
amino acid sequences and epitope structures across species, making common 
antigens appear similar and a lack of an adverse immune response even when 
xenogenic collagen (animal source) is implanted as a scaffold material [153, 
154].  Clinically, animal sourced collagen type-I (Col-I), such as bovine and 
porcine, provide readily available sources of scaffold material for numerous 
applications and have proven quite compatible with most human systems, 
products range from tissue and skin fillers, haemostats, wound dressings, heart 
valves, blood vessels, sponges for orthopaedic applications (bone, cartilage, 
meniscus, carriers, etc) and even beauty products.   
Collagen in its native state is structurally sound for cell attachment, 
growth, and differentiation, they also possess inherent activity (functional 
protein motifs) for the stimulation or inhibition of angiogenesis, the promotion 
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of cellular proliferation and differentiation, making it a popular bioactive 
biopolymer for tissue engineering applications [155]. They also serve as 
suitable carriers and delivery vehicles for growth factors [62, 156].  
Commercial collagen for clinical applications is usually stabilised by 
chemical cross-linking methods and sterilised prior to surgical use. This may 
to a certain change the native or original primary structure of the molecule, but 
the overall structure remains relevantly similar, that in vivo bioactivity, 
degradation and resorption is similar to the normal tissue remodeling process 
during wound healing. The resorbable collagen matrix would slowly be 
degraded by cellular and enzymatic actions, where collagenase would be the 
primary enzyme to cleave the fundamental molecule from the C-terminus. 
This causes the whole structure to become unstable, especially at body 
temperature and denatured to random coiled polypeptides, which could be 
degraded by into amino acids and metabolised through natural metabolic 
pathways [153, 157, 158].  
FDA approved collagen-based matrices derived from bovine sources 
consists of sponges, while they were used as osteoconductive bone-graft 
substitutes their low strength only allowed them to be used as a surface-only 
graft rather than for  metaphyseal defects, if not combined with other materials 
such as ceramics [159]. In summary, due to its low immunogenicity and 
bioactivity, it remains a favourable choice as a platform for delivery of cells 
and growth factors in orthopaedic and other clinical applications. Among them 
Apligraf®, a bilayered collagen gel seeded with human fibroblasts and 
keratinocytes from Organogenesis; Infuse® Bone Graft from Medtronic, 
which used collagen sponges as a carrier for rhBMP-2 for spinal fusion 
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applications and Healos® Bone Graft Replacement marketed by DePuy 
Orthopaedics, which is constructed of crosslinked collagen fibers coated with 
hydroxyapatite for spinal fusion [22, 62, 160-164]. 
 
2.3.2.2. Ceramics  
Ceramics are a class inorganic non-metallic material, ranging from 
silicates, metallic oxides, carbides and various refractory hydrides, sulfides, 
and selenides. They may exist in crystalline, semi-crystalline or even 
amorphous (eg. glass). Oxides such as Al2O3, MgO, SiO2, and ZrO2 contain 
metallic and nonmetallic elements and ionic salts. A class of ceramics display 
relative inertness to the body fluids and have been used in the human body has 
come to be known as bioceramics, for direct or indirect applications, such as 
composite or reinforcing fillers. Their microstructural characteristics are prone 
to cracking and propagation, where at a micro-crack tip could lead to stress 
concentration and localised stresses could escalate considerably resulting in 
failure. Thus, their major shortcoming (ceramics in general) is their inherent 
brittleness making them susceptible to micro-cracks with their low tensile but 
impact strength; modern technology and fabrication techniques have managed 
to enhance but not overcome all of these issues [65]. Unlike metals and 
polymers, ceramics are difficult to shear plastically due to the (ionic) nature of 
the bonding and minimum number of slip systems, making them relatively 
non-ductile. 
Bioceramics could be relatively bioinert, bioactive or surface reactive, 
depending on surface chemistry and media it interacts with. They could also 
broadly be classified into non-resorbable and resorbable bioceramics. Non-
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resorbable bioceramics could be used for permanent implants, such as screws, 
plates or as coatings, such as alumina, zirconia, silicone nitrides and carbons. 
Bioresorbable bioceramics could find uses as coatings and filler materials, 
such as certain glass ceramics, calcium phosphates, calcium sulphates and 
calcium aluminates [65, 165]. In the 1970s, certain glass compositions were 
found to be able to bond chemically to bone, a property called bioactivity 
[166]. Other ceramics such as calcium phosphates were observed to be 
bioactive as well and have the ability for good tissue adhesion and integration. 
Usually bioactive ceramics absorb water and form an aqueous sandwich layer 
of ceramic-tissue interface, which enables strong bonds between the ceramic 
and tissue. Calcium phosphate biomaterials, to date, are the most investigated 
bioceramics, they can be use as blocks, granules, powder, injectable pastes or 
putty; although in clinical applications they are mainly limited to non-major 
load-bearing parts of the skeleton because of their inferior mechanical 
brittleness. Interests were also directed toward their use as coatings on metallic 
implant to improve bioactive bonding along with their established history of 
safety and efficacy [167-170]. The two most common and important 
compositions are the β-tri-calcium phosphate (β-TCP) and hydroxyapatite 
(HA) [108, 167, 171, 172]. 
 
Hydroxyapatite 
Apatites are defined by the chemical formula M10(XO4)6Z2 and 
hydroxyapatite (HA) is one of the most common apatite calcium phosphate 
bioceramic used in medicine. Hydroxyapatite has excellent histological 
performance since it is the main mineral constituent of bones. Thus, HA is also 
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relatively insoluble, biocompatible, non-toxic, and capable of bonding directly 
to bone allowing for superior osteointegration [112, 173]. Pure defect free HA 
is monoclinic with columns of calcium ions and oxygen atoms forming 
parallel channels in lattice. This results in a hexagonal crystal structure with 
the network of phosphate ions providing a framework of apatite, giving the 
structure great stability [174]. At temperatures above 1050oC, HA may 
decompose into β-TCP and tetracalcium phosphate (TeCP) by the following 
reaction [175]: 
Ca10(PO4)6(OH)2    2βCa3(PO4)2          +      Ca4(PO4)2O + H2O 
 
At temperatures above 1350oC, β-TCP transforms into α-TCP, which 
is retained upon cooling. It has also been shown that HA is prone to 
substitution by ions such as fluoride, chloride, hydroxyl, carbonate and 
sulphate for phosphate ions, and other divalent metal ions for calcium ions. By 
itself as a bulk structure, HA has poor tensile and shear strength but is 
strongest in compression [112]. HA has a similar mineral fraction compared to 
bone which provides its biochemical inertness as observed, which is not due to 
biological inertness but to the retardation of the reconstructive-resorption 
activity, that is faster in other calcium phosphates [176]. 
 
Tricalcium phosphate  
Tricalcium phosphate (TCP), Ca3(PO4)2, occurs in four polymorphs, α, 
β, γ and super α. The γ polymorph is a high pressure phase and the super α 
polymorph is observed only at temperatures above 1500ºC. Therefore the most 
frequently observed polymorphs are the α- and the β-whitlockite phases. The 
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latter develops at high temperature (>1000oC) in dry air. β-TCP is preferred to 
the other TCP allotropic forms due to its chemical stability, mechanical 
strength, and more predictable and consistent bioresorption rates [177]. 
Natural bone is an apatite consisting of approximately 35% calcium and 15% 
phosphorus; this was closely resembled by β-TCP with a Ca/P ratio of 1.5. 
Submicron sized β-TCP powder can be manufactured from either wet 
chemical methods or by solid-state reaction [177, 178]. Although TCP does 
not exist naturally it has shown to evoke a biologic response similar to that of 
bone. The appeal of these calcium phosphates rests largely with their 
biocompatibility, stability, non-cytotoxic and non-carcinogenic properties, 
inertness, hardness, have good wear properties and are corrosion resistant. 
They are protein free and elicit minimal immunologic and foreign body 
reactions. 
β-tricalcium phosphate has been used in several forms in animals and 
humans to repair different types of defects in bone, and has been found to 
resorb relatively rapidly and by itself, there has been no known reports of any 
adverse reactions in animal or human tissues, and has been used readily in 
orthopedic and dental applications [179-183]. When TCP was immobilised 
next to healthy bone, osteoid is secreted directly onto the surfaces of the 
ceramic. Subsequently, the osteoid mineralises and the resulting new bone 
undergoes remodeling. Differences in chemical composition and 
crystallographic structure of HA and TCP have a major impact on their 
physical characteristics. Due to its lower density and crystalline form, TCP is 
more soluble and resorbs faster than HA, as a result, this allows good bone 
ingrowth and eventual replacement by endogenous bone upon implantation 
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[184]. It reacts rather easily with water to give rise to a substance identical, 
from a crystallographic point of view to HA. Therefore, a close relationship 
exists between TCP and HA. Hydroxyapatite forms on exposed surfaces of 
TCP by the following reaction [185]:  
4Ca3(PO4)2(solid)    +   2H2O             Ca10(PO4)6(OH)(surface)    +   2Ca2+   +    
2HPO42- 
 
The resorption of calcium phosphates also depends on its permeability 
to water and the structure’s porosity that could accelerate dissolution and other 
biologic processes, such as cellular attachment and osteoid deposition, and rate 
of new bone ingrowth into the implant material. Being very low in bulk 
solubility, HA implants are often used in structural augmentations. 
Hydroxyapatite is essentially nondegradable, with resorption rates of only 5%-
15% per year [172, 186-188]. Thus, TCP’s higher resorption rate makes it 
widely acceptable as a bone substitute, especially as a bone filler material in 
non-critical loading regions that require fast resorption. Tricalcium phosphate 
is seldom used as a load-bearing scaffold on its own. The commonly used 
bone graft substitutes made from TCP are approximately 35-50% porous with 
pores ranging from 100-300μm [172]. In 1988, Eggli et al. reported using 
cylinders (∅3mm) of HA and TCP to investigate the degradation for 6 months 
in the femur of 15 rabbits. The implants had a homogeneous pore distribution 
with two pore size ranges, 50-100um and 200-400µm, both with a porosity of 
60%. After 6 months, morphometric analysis revealed up to 85.4% of the TCP 
implant had degraded, while the HA implant only degraded by 5.4%. Within 
the first month bone, tissue ingrowth and implant resorption occurred at a 
higher rate in the TCP cylinder with smaller pore size than larger one. Smaller 
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pore size HA cylinders were infiltrated by bone or bone marrow after 4 
months, whereas no tissue penetration was detected in the larger-pored 
implants for up to 6 months. The group attributed the non-tissue growth in the 
larger-pored implant to the lack of inter-pore connection which were about 
20µm between pores, compared to the smaller-pored scaffold with more 
vascular and tissue ingrowth which facilitated the initial rate of implant 
resorption. The resorption was an active process involving two different cell 
types; acid phosphatase-positive osteoclast-like cells promote active resorption 
by adhering directly to the surface, while clusters of macrophages were found 
in all implanted cylinders playing an active role in the intracellular degradation 
of small-detached ceramic particles [171]. 
These inorganic calcium phosphates certainly are bioactive and possess 
osteoconductive abilities allowing bone to bind with them, they are also 
considered to be “osteoinductive”, with their ability to harness endogenous 
circulating growth factors and proteins, concentrate them on their surface, 
imparting “intrinsic” osteoinductive properties [80, 112, 177, 189]. The 
“intrinsic” osteoinductivity property of CaPs was further demonstrated as a 
result of entrapment of growth factors on CaP surfaces, as this inductivity 
varied in different animal models due to the differences in the amount of 
circulating growth factors in each of the species. It was highly reproducible in 
primates, minimal in dogs and absent in rabbits and rodents. On the other 
hand, the ability of these osteoinductive factors and materials to successfully 
induce new bone formation is also dependent on the microenvironmental 
conditions, especially surface and space - the topography, macro-pore, micro-
pore and porosity [112]. It should be noted that this “intrinsic” 
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osteoinductivity of the CaP materials cannot be compared with osteoinductive 
materials like demineralised bone matrix (DBM), autografts or allografts, 
which originally contains these osteogenic inductive components and factors, 
such as BMPs. The CaP materials, instead acquires, binds and concentrates 
circulating osteogenic factors in the environment onto their surfaces for later 
release of these factors that eventually resulted in bone formation. 
 Most calcium phosphate ceramics have two major disadvantages. 
Firstly, the mechanical properties of calcium phosphate ceramic scaffolds are 
not suited to withstand torsional and tensile forces imposed on the skeleton, 
and their clinical use is usually limited to non load-bearing sites. Secondly, the 
processability of these bioceramics is very limited. Therefore, they were 
commonly used at bone void fillers or usually composite with another 
material, such as collagen and synthetic polymer [180, 182, 190]. TCP was 
mainly used as bone void fillers, such to reconstruct iliac crest defects as a 
result of autologous bone harvest or combined with autologous bone for spinal 
fusion [101, 191]. 
In 2000, the US FDA granted Orthovita Inc marketing clearance of its 
Vitoss scaffold, a synthetic β-TCP cancellous bone void filler product 
(www.orthovita.com). The β-TCP is nanometer-sized (~100nm) and attained 
up to 90% interconnecting porosity as a scaffold. The mechanical properties 
were not reported but Vitoss was recommended for use in non load-bearing 
zones. The scaffold had hydrophilic characteristics, facilitating delivery of 
bone marrow–derived osteoinductive growth factors and osteogenic bone 
precursor cells. The company reported that at 12 weeks, in a canine model 
study the ratio of new to original bone in the Vitoss-filled defect was 1.2 
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compared to the ratio 0.4 of the HA control. Approximately 76% of the 
scaffold was resorbed, by 12 weeks up to 86% was resorbed and at 52 weeks 
all the implants were resorbed through dissolution and cell-mediated processes 
[192].  
 
2.3.2.3. Composites  
Although on their own polymers and ceramics have shown to be 
excellent as scaffolding materials for tissue engineering, there remains 
numerous ways to improve and enhance their mechanical properties and/or 
bioactivity. Since the majority of mammalian cell are anchorage-dependent the 
matrices or scaffolds must provide a conducive platform for maximised cell 
survival, proliferation and delivery with high loading and efficiency to specific 
sites, it should also sustain and modulate signals to maintain or differentiate to 
the required phenotype. There are several methods to improve these properties 
and usually require the addition of another element or material to introduce 
reinforcement or enhance bioactivity. Definition: Composite materials contain 
two or more distinct constituent materials or phases. Examples of natural 
biological composite materials are bone, wood, dentin, cartilage, and skin. 
Thus, preparation of a composite material, such as blending of polymers with 
ceramics or coating of synthetic scaffold with natural bioactive polymer, could 
maximise advantageous properties of each individual elements to overcome its 
own limitation. Thus, the basic and direct approach is to mimic the natural 
ECM, in vivo mechanical properties and structure. The more biocompatible 
biomaterials tend to elicit less of an immune response, reduce inflammatory 
response and improve or accelerate regeneration. Another advantage of 
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preparation of composites would be to regulate the rate of degradation and 
neutralisation of the degradation by-products.  
Polymers are generally weak mechanically and the addition of a 
ceramic component would enhance their strength and stiffness for a more 
functional applications. In 1981, Bonfield et al. mimicked bone itself being an 
organic matrix reinforced with a mineral component, a composite material was 
being created by using hydroxyapatite in the form of a filler in a polymer 
(polyethylene) matrix, it was called HAPEX [193]. It consisted up to 50% 
volume of HA, and stiffness was raised to that of cortical bone, together with 
high toughness and bone bonding characteristics. HAPEX has been used as an 
orbit implant for orbital floor fractures, volume augmentation and middle ear 
implants [194, 195].  
In order to improve biocompatibility and bioactivity, ECM proteins, 
such as collagen and fibronectin, were often coated onto polymer scaffolds to 
enhance cell-scaffold interaction. It was found that collagen coatings on poly 
(DL-lactic-co-glycolic acid) (PLGA) surfaces increased osteoblasts attachment 
and proliferation, but decreased differentiation capability, while chitosan 
coatings had a reversed functional effect. This approach could provide a good 
strategy for modifying microenvironments to increase osteoblast adhesion, 
proliferation, and differentiation on PLGA scaffolds surface. On the contrary, 
when PLGA mesh/collagen composite scaffolds were prepared by introducing 
collagen sponge or gel into the PLGA mesh, this composite scaffold supported 
enhanced cell seeding efficiency and survival. Hybridisation with collagen 
facilitated cell seeding, spatial cell distribution and promoted cell migration 
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and neovascularisation. This demonstrates that mechanical weaker natural 
polymers could be reinforced by the PLGA mesh [196-198].  
PLA/calcium metaphosphate composite scaffolds were also effective 
bone tissue engineering when the calcium metaphosphate particles were 
exposed on the surface and could contact directly with cell/tissues to stimulate 
the cell proliferation and osteogenic differentiation. Also, PLGA/nano-HA 
composite scaffolds fabricated by gas forming and particulate leaching 
allowed for high exposure of bioceramics on the polymer surface. A triple 
hybrid of nano-HA/collagen/PLA composite scaffold was reinforced by chitin 
fiber; its strength was enhanced while positively stimulating cells seeded onto 
the scaffolds [199, 200]. 
As discussed in earlier sections, the structure and molecular formula of 
β-TCP differs from HA, which affects their dissolution rates and susceptibility 
to osteoclasts attach or resorption. PDLLA/TCP composite rods for internal 
fixation had enhanced modulus (from 21 to 47GPa) while reducing the rate of 
degradation of the rods. This was attributed to presence of the CaP filler which 
protected the composite rod from a more rapid degradation by neutralising the 
acidic oligomers that result from the degradation of the polylactide, preventing 
autocatalysis. It was also hypothesised that the TCP formed a protective seal 
between the aqueous environment and the polymer, thus reducing the rate of 
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2.3.3. Scaffold Fabrication Techniques – Role in Tissue Engineering 
As reviewed in the earlier sections, scaffold constructs play an 
important role to provide a conducive and suitable environment for cell 
growth, mechanical support when implanted and allow host tissue 
regeneration (into its pores) as the scaffold resorbs away. Thus, the precise 
control of the scaffold internal pore architecture (pore geometry, size, 
interconnectivity, orientation, and branching) is critical to achieve optimal 
function [29, 125]. Also, the ability to attain and ensure these desired scaffold 
characteristics dictate additional influence over scaffold degradation and 
integrity. Toward achieving these goals, a robust and reproducible fabrication 
method that allows complete management of the independent variation of 
scaffold structural parameters and material is also necessary. Conventional 
scaffold fabricating methods have many limitations, especially on the control 
of scaffold parameters. Hence, there is a need to acquire more control in the 
design and fabrication of the tissue engineering scaffolds, especially for 
structural or load-bearing scaffolds, rather than leaving it up to random 
probability. The novel rapid prototyping (RP) technique provides excellent 
control over scaffold external shape and internal architecture of a computer 
designed product.  
 
2.3.3.1. Conventional Techniques  
The conventional techniques relied mainly on the properties of the 
material (eg. polymer) to shape and mould the scaffolds using either heat or 
solvents. Some of the common techniques include fibre bonding, solvent-
casting and particulate-leaching, and melt-moulding [31, 203-206]. Most of 
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these methods bear restrictions on shape control and could not easily and 
independently control the porosity and pore size, and thus, these methods 
encounter difficulties in creating scaffolds with complex three-dimensional 
shapes and thickness. For example, casting is dependent on the shape of the 
mould and not on being able to easily and independently control the porosity 
and pore size of the scaffolds. These early techniques usually produce spongy 
scaffolds or foams. They are incapable of producing structures with defined 
internal architectures (pores). As a result, the connectivity of these is a random 
does not optimise tissue ingrowth, which compromises on the scaffolds’ 
mechanical properties. Other drawbacks include the extensive use of highly 
toxic organic solvents, long fabrication periods, labour-intensive and time 
consuming processes, incomplete removal of residual particulates in the 
polymer matrix, poor reproducibility, irregularly shaped pores, insufficient 
interconnectivity of pores and thin structures [125, 207, 208].  
 
2.3.3.2. Rapid Prototyping (RP) Techniques  
The quest for industrial productivity, efficiency and competitiveness is 
perpetual. With the advent and rise of the Rapid Prototyping (RP) technology, 
RP machines are able to materialise, at a fraction of tooling and machining 
time, designers’ ideas and perceptions. Solid freeform fabrication involves the 
creation of a solid three-dimensional (3D) object of desired design or shape by 
successively adding raw materials in parts and/or layers, and binding these 
desired regions together to eventually form the intended 3D model. This 
modern technology was capable of reducing the time taken for prototype 
making, depending on the complexity of the design and size, traditional 
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methods ranged from days to weeks while RP models need mere hours 
regardless of the complexity and size, as long as it could be designed on a 
computer. Today, the RP technology has made leaps and bounds, and 
progressed to the numerous advanced RP machines available today, which is 
capable of handling materials from metals, polymers, ceramics and even 
composites. All these advantages greatly reduce the time required to bring new 
products to the marketplace and also provide for the flexible manufacture of 
highly precise products in small quantities [125].  
The main feature and basic concept common to all commercial RP 
processes is the computer-controlled additive-layered approach used to build 
3D objects. Typically, a model is designed on a computer-aided design (CAD) 
program, this digital information of the part is then sectioned into layers of a 
predetermined thickness. This geometric information is transferred to a 
computer-controlled machine, which proceeds to reconstruct the object in a 
layer-by-layer sequence. Depending on the raw material used, it would be 
deposited and constructed the 3D model in layers. As the fabrication is 
accomplished in a computer-controlled environment, any digital information, 
such as a 3D computed-tomography (CT) or magnetic resonance imaging 
(MRI) can be processed and “prototyped”. One of the greatest advantages of 
the RP technology is its ability to create highly reproducible and precise-
controlled architecture. The ability to recreate any complex design gives the 
edge in creating a customised tissue engineering scaffold for any defects. The 
requirements can all be met including the microstructure and porosity of the 
scaffold, and also overall macroscopic geometry and shape of the implants 
could be tailored to fit any defect.  
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Presently, in the market there are numerous commercialised RP 
machines and they include a wide range of materials for their varied 
fabrication techniques. They comprise the stereolithography apparatus (SLA), 
selective laser sintering (SLS), three-dimensional printer (3DP) and the fused 
deposition modeling (FDM) apparatus [36, 37, 125, 209-216]. The 
stereolithography apparatus (SLA) uses an ultra-violet (UV) laser to cure 
designs of models in a bath of photopolymerisable liquid polymer. This 
process is able to attain high resolution, but requires extensive post-processing 
to wash off excess resin and further curing in an UV oven, limited 
bioresorbable photopolymerisable material also restricted its development. 
The selective laser sintering (SLS) technology also creates models by tracing a 
modulated laser beam but across heat fusible powdered materials. Resolution 
and strength (bonding strength of the fused particles) of the final scaffold were 
frequently an issue due to laser power control and the fabrication chamber is 
required to be heated. Post processing would include removing any loose 
material, smoothing the visible surfaces and sometimes post-sintering, thus, 
scaffolds fabricated must always have an outlet for internal powders to exit. 
The 3D printer (3DP) technology uses an “inkjet” printhead to deposit 
a binder solution onto a powder bed which fuses to form the 3D scaffold. 
Strength and resolution of the scaffold remains limited due to the frequent 
weak binding components, and extensive post processing of powder removal 
from pores. If a water soluble binder was used, the scaffold would be water 
soluble as well, or a solvent (toxic) binder could be used with a polymer 
powder. Lam et al. (2002) fabricated scaffolds using the 3DP (Z402) from 
ZCorp with a biomaterial blend of starch, dextran and gelatin. The scaffolds 
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were infiltrated with PLLA-PCL (75:25) copolymer solution, to strengthen 
and prevent the scaffold from dissolving in water [217]. With many more RP 
machines under development, some researchers have also adopted the use of 
the RP machines to manufacture intricate molds for casting the scaffolds, this 
approach is known as indirect RP manufacturing [218].  
The fused deposition modeling (FDM) technique utilises thermoplastic 
polymers by deposition of the melted or molten polymer through a small 
nozzle. The polymer was fed into the liquefier chamber where it was heated, 
melted and forced out the nozzle on the other end as continuous micro-
filament struts. The robotic arm (gantry), which holds the liquefier, translates 
and lays the struts in a pre-designed pattern, layer by layer. Generally, no post-
processing is required and this is the key advantage of the FDM, as the 
solidified and cooled plastic material is sturdy enough for a wide range 
applications. Other than plain polymers, the FDM is also capable of 
fabricating structures with composite materials [36, 37, 216, 219].  
One major limitation of the FDM was in the building of overhanging 
structures, but by using a water soluble sacrificial material during the building 
process for support, it could be removed easily after fabrication. In comparison 
with other RP techniques, the FDM method does not require any solvent and 
offers great ease and flexibility in material handling and processing. The 
resolution of the FDM is limited by the size of the nozzle and position control 
of the “liquefier” movements. Presently, common nozzle diameters are 254 
µm and 406µm, which is capable of attaining 250-965µm in filament width 
and 50-762µm in layer thickness. Although the exit if the nozzle is fixed, the 
flowrate of molten polymer and nozzle translation would also determine the 
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amount of stretching the molten microfilament undergoes. Therefore, the 
operating parameters and conditions for the polymeric material should be 
studied and controlled accurately, and that is usually material specific. 
The FDM technique was evaluated and selected by the author’s group 
for scaffold development as it offered ease of processibility for the raw 
biomaterials, precise control and resolution, and the least post-processing 
requirements. Furthermore, the FDM came as a desktop model which could be 
easily managed. Through the computer design and robotics, mechanically 
stable 3D porous bioresorbable scaffolds with complete interconnectivity 
could be fabricated for bone tissue engineering application [29, 38, 208]. 
Additionally, a biotechnology company was spun off to commercialise the 
FDM scaffolds [220]. 
2.3.4. Cells – Role in Tissue Engineering 
Living cells, the basic building blocks of life, when utilised 
appropriately can aid significantly in regenerating damaged tissues which are 
unable to regenerate themselves. Early cell-based therapies have been 
attempted to resolve a multitude of clinical problems, from structural repair to 
systemic defects, with the greatest challenge being for the implanted cells to 
function as intended [41, 42, 221, 222]. Commercial tissue engineering 
products or therapies based on cells have been FDA approved for clinical 
treatments, such as the cultured autologous epidermal keratinocytes and 
articular chondrocytes, Epicel and Carticel, respectively from Genzyme 
(www.genzyme.com). Their fundamental strategy revolves around isolating 
autologous cells from biopsies, expansion in vitro and re-implanted as 
treatment. However, this is limited by quantity of cells that could be isolated 
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and expanded before quiescence, size of defect and it is currently only two-
dimensional.  
Although differentiated cells, such as osteoblasts and chondrocytes, 
can be used in cell-based therapies, they have numerous limitations in their 
differentiated states. Stem cell therapy is the new frontier for regenerative 
medicine. A stem cell generally lacks certain tissue-specific differentiation 
markers and are capable of proliferation, particularly, with the ability to self-
maintain the population of cells (self-renewal). They produce functional 
daughter cells which some could remain as stem cells or differentiate to the 
required lineage specific cell type to regenerate appropriate tissues after injury. 
Generally, stem cells are classified into two categories - embryonic and adult 
stem cells. Embryonic stem (ES) cells are derived from the inner cell mass of 
developing blastocysts (embryos) and possess the ability to differentiate and 
generate almost any adult cell types. Their almost infinite potential is very 
much recognised but, at present, they are a controversial and ethically 
concerned population of cells. Furthermore, the exact culture conditions 
required to reproducibly induce ES cell differentiation in a controllable 
fashion are extremely challenging and difficult to master and control; making 
any therapies exploiting their use unavailable, in the short-term. Critically, 
undifferentiated ES cells could spontaneously form teratomas, raising another 
important yet unresolved issue of application safety [223].  
The zygote may be the mother of all cells in the human body but 
further down the time-line, when the mesoderm is formed, one of the three 
primary germ cell layers, it contains a pool of adult mesenchymal stem cells 
(MSC). The adult MSC are extremely rare, only 1 in up to 100,000 cells found 
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in nucleated bone marrow cells is an MSC and after the first 4ml, essentially 
no osteoprogenitor cells were found in the aspirate [5]. Adult MSCs hold 
greater potential and promise, than ES cells and differentiated cells, for 
immediate clinical applications as they are primarily responsible for bone 
tissue formation and repair. Under normal conditions, these self-renewable 
adult stem cells would to replace cells lost from normal tissue turnover and 
damage [41, 42]. Adult MSCs are found in a variety of tissues in the human 
body, including bone marrow, blood, skin, muscle and adipose tissue, and 
there lies the potential to ‘regenerate’ cell types specific to these tissues [42-
46, 49, 86, 224, 225].  
Pluripotent adult stem cells from the bone marrow includes the 
hematopoietic stem cells (HSCs) which gives rise to components of the 
immune and blood systems, has already been exploited safely for decades for 
the treatment of immune diseases and leukemia. The bone marrow 
microenvironment also supports the existence of the richest source of MSCs in 
humans. Bone marrow aspiration is a common clinical procedure with 
minimal host morbidity, which could be performed and MSCs easily 
processed for immediate transplantation [46, 47].  
While the osteocyte is the final differentiated cell type for the bone 
lineage, each progenitor cell stage prior to that remains functionally critical for 
the development and regeneration of bone. The development of MSCs to 
osteocytes is marked by a series of specific morphological characteristics and 
biochemical markers during the differentiation phases [81, 86, 224, 226]. The 
MSC would firstly differentiate to the osteoprogenitor cell, which has general 
morphological characteristics of appearing spindle-like (which is fibroblast-
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like) and located adjacent to preosteoblasts at bone sites. The osteoprogenitor 
phase is a highly proliferative period of osteoblast differentiation while most 
common bone markers are not prominently detectable, except for osteopontin 
(OPN) which is evident at the later stages [227].  
Preosteoblasts are a more committed and defined cell type from the 
osteoprogenitor cells. They mark the end of the proliferative phase and 
beginning of the ECM development and maturation phase. Preosteoblasts are 
found near new bone and appear cuboidal in shape. Preosteoblasts produce 
collagen type-I (Col-I), alkaline phosphatase (ALP), and limited quantities of 
OPN. They are a transitional phase of a maturing osteoblast [81]. Osteoblasts 
also appear cuboidal and occupy a slightly more interior position on the 
boundary of newly forming bone. They secrete ECM which eventually 
envelopes them within the new bone.  Osteoblasts produce abundant ALP, 
OPN and bone sialoprotein. Early OCN productions are minute but increases 
as osteoblasts mature [227, 228]. Osteoblasts also produce collagenase at this 
point, marking the beginning of remodeling. Osteoblasts are considered post-
proliferative; they denote the end of the matrix phase and beginning of the 
mineralisation phase. The mature osteoblast is capable of producing Col-I for 
matrix development, proteoglycans, hormones, and growth factors for further 
matrix maturation and mineralisation. Finally, osteoblasts differentiate into 
osteocytes when the bone tissue is ready. The osteocytes are non-proliferative 
and become embedded in the bone matrix they produced earlier as osteoblasts. 
Osteocytes are smaller and have decreased or no ALP production, and are 
considered to be metabolically inactive. However, they continue to produce 
OCN, bone sialoprotein, and OPN [81, 227] 
Chapter 2 Literature Review 
 
66 
There are no proteins exclusive to bone tissue, but specific essential 
sets and combinations of proteins indicative of bone formation activities have 
been identified in research [81, 158, 226]. Col-I is the major extracellular 
matrix (ECM) constituent and the most abundant protein produced by 
preosteoblasts and osteoblasts in bone. They form up to 95% of bone ECM 
where Col-I is the foundation for mineral apposition. Alkaline phosphatase 
(ALP) is one of the earliest osteoprotein markers of osteoblastic development 
and osteogenesis. The ALP enzyme hydrolyses phosphates compounds in the 
surroundings and increases the local concentration of inorganic phosphate. 
This facilitates the mineralisation process by promotion of CaP crystal 
nucleation and formation, ALP could also hydrolyse calcification inhibitors 
like inorganic pyrophosphate. They also act as a transporter for inorganic 
phosphate as well as bind to calcium ions to help stimulate calcium phosphate 
precipitation. 
Osteopontin (OPN) is a multifunctional phosphorylated glycoprotein 
and a member of the sialoprotein family (high sialic acid content). It is 
synthesised by preosteoblasts, osteoblasts, and osteocytes, and secreted into 
the bone ECM, with abundant quantities in areas undergoing mineralisation to 
encourage hydroxyapatite formation. OPN has also been found to promote the 
attachment and spread of osteoblasts and studies indicate that OPN production 
occurs prior to that of OCN. Osteopontin is found also mainly at the borders of 
growth plates in bone, at the borders of defects between old and new bone 
(cement lines), and the border of new bone growth between an implant and 
existing bone; indicative of its involvement in bone growth, healing and 
implant-interface. Contrary to its bone forming influences, it also plays a role 
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in remodeling and resorption. Osteopontin also regulates the differentiation, 
recruitment and attachment of osteoclasts, and has been found in high 
concentrations at sites of bone resorption. It also impacts the inhibition of 
hydroxyapatite formation and growth as it exhibits itself to be a strong 
inhibitor of apatite formation and growth in a dose dependent manner by 
binding to the growing crystal and inhibiting its further growth. The existence 
of OPN at both the sites of crystal formation with osteoblasts and bone 
resorption with osteoclasts reveals OPN’s involvement in mineralisation and a 
promoter of resorption [67, 68, 227, 229]. 
Osteonectin (OSN) which binds to calcium ions, hydroxyapatite and 
collagen is also found in large concentrations in bone. It is synthesised by 
osteoblasts and deposited within the collagenous matrix of bone. Osteonectin-
collagen complexes support plasminogen binding, which plays an important 
role in the degradation and remodeling of bone matrix proteins during 
resorption. Osteonectin is believed also to regulate cellular progression 
through the cell cycle, and may be involved with the binding of growth factors 
to cells [68, 230, 231]. Osteocalcin (OCN), another osteoprotein which is also 
known as bone gla protein, contains several gamma carboxy-glutamic acid 
residues. It is synthesised in bone and dentin, and has a high affinity for 
calcium ions. It is one of the most abundant non-collagenous proteins found in 
bone. Osteocalcin plays a major role in regulation of bone formation by 
encouraging mineralisation, maintenance and remodeling of bone, while also 
with the ability to inhibit mineral crystal growth by osteoclasts recruitment. 
Osteocalcin appears during the later stages of osteoblast differentiation and 
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after the initiation of matrix synthesis, typically after OPN expression, though 
it also forms a complex with OPN [68, 228, 232].  
The multipotent potential of adult MSCs has been extensively reported 
and they could be easily purified and expanded in growth media for at least 
30–40 population doublings [233]. After expansion, they can still differentiate 
to cells of multiple lineages [234]. As MSCs have been shown to give rise to 
adipocytes, osteoblasts, chondrocytes, myoblasts, neurons, and also a mature 
stromal phenotype which supports haematopoietic differentiation, these 
present exciting prospects for stem cell based tissue engineering and 
regeneration [49-53]. The lineage restricted adult stem cells appear non-
tumorigenic and could be used safely for bioengineered products with or 
without prior differentiation. However, the major drawbacks and challenges 
include the quantity of MSCs that could be derived from an individual at each 
instance, also quantities decline over age and for larger or multiple defects, the 
difficulty of obtaining sufficient cells for a significant therapeutic effect [48, 
54].   
Aside from the traditionally lineages, MSCs also aids in regenerating 
myocardial tissue types. When injected into the heart, overall improvement of 
cardiac functions was observed to limiting the infarct size and improves 
ventricular function after myocardial infarction [235]. Transplantation of bone 
marrow and bone-marrow-derived stem cells was reported to activate 
endogenous tissue regeneration, specifically β-cell regeneration in the 
pancreas [236, 237]. Recently, MSC in the form of constructs comprising 
“sheets” of cells, have been used to successfully treat damaged myocardium. 
The adipose-derived MSCs were differentiated into cardiomyocytes and 
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vascular endothelial cells. They were reportedly reverse cardiac wall thinning 
and improved cardiac function in rats with myocardial infarction after cell 
sheet transplantation. It was suggested that some nascent structure may permit 
cell delivery without interfering with beneficial cellular function. The physical 
organisation of cells, whether cell suspension, sheet, or three-dimensional 
construct, remains an important consideration for developing a cell-based 
therapy [238]. Transplant of MSCs have also other benefits such as the 
recruitment of endogenous stem cells, vascularisation of damaged tissue and 
immune transplant tolerance [239-241].  
Cell therapy, using autologous cells, represents the best clinical option, 
as they are immuno-compatible with no risk of disease transfer. However, 
many factors govern what type of cells to use (stem cells or committed cells) 
and its selection (purity). Depending on the therapeutic requirements of the 
situation, if large numbers are needed, autologous cells could require several 
weeks for the isolation and expansion before the final reapplication to the 
patient. This critically makes autologous cell therapy unable to achieve a truly 
“off the shelf” availability for patients. Thus, the availability and potency of 
allogenic cells, especially HSC, are attractive as they have classically been 
used for bone marrow transplantation and immune system therapies. 
Differentiated allogenic cells have also been used to treat the skin, renal 
diseases and diabetes, but pose the risk of eliciting an immunological and 
physiological host response which could be detrimental to the intended 
treatment [242-244].   
A viable allogenic cell source could be mesenchymal stem cells 
(MSC), since they have been reported to be immuno-privileged and 
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immunomodulatory. They express very low levels of co-stimulatory molecules 
and HLA Class I on their cell surface and lack HLA Class II expression, even 
after differentiation. This immunophenotype of MSCs suggested that they may 
play a role in modulating T-cell proliferation and the immune response [245, 
246]. MSCs have been shown to inhibit a mixed lymphocyte reaction (MLR) 
using purified CD3 T-cells and third party dendritic cells as antigen presenting 
cells [48, 247]. It has been postulated that MSCs may suppress T-cell 
proliferation by several mechanisms: secretion of growth factors (such as 
TGF-beta or HGF), suppression of pro-inflammatory (TH-1) cytokines, 
stimulation of anti-inflammatory (TH-2-type) cytokines, and up-regulation of 
pro-apoptotic cell surface molecules [241, 246]. Bone marrow derived MSCs 
have been shown to escape the allogenic immune response and possess 
immunomodulatory activity to block such a response. Intravenously injected 
allogenic MSCs were not rejected in a baboon model due to lack of immune 
recognition. Furthermore, bone marrow transplantation of baboon MSCs into 
MHC mismatched recipients prior to a third party skin graft led to prolonged 
graft survival. Taken together, these data suggest that MSCs not only possess 
immunosuppressive properties that inhibit T-cell proliferation, but they also 
have immunomodulating properties which may enhance graft survival when 
transplanted in vivo, possibly reducing the incidence and severity of graft-
versus-host disease (GVHD) [241, 248, 249]. 
Commercialisation of stem cells and MSCs for the mass market and as 
an “off the shelf” product has many hurdles. Commercial autologous MSC are, 
of course, not “off the shelf” but could be expanded ex vivo in cultures for the 
patients and re-implanted at required sites, at a premium. However, allogenic 
Chapter 2 Literature Review 
 
71 
MSCs are available “off the shelf” and companies offering them typically 
source these cells from “donors” and are guaranteed that these were screened 
for diseases, processed in sterile conditions, compliant to prevailing regulatory 
standards and offered in sterile conditions. Though still under trials, Osiris 
Therapeutics Inc in partnership with Genzyme Corporation has in its pipeline 
to offer allogenic human adult stem cells as Prochymal®, for treatment of 
diabetes, acute myocardial infarction, Crohn's disease, acute graft versus host 
disease, pulmonary disease and acute radiation syndrome for military uses. 
Also Chondrogen® was developed for intra-articular injection following 
meniscectomy in the knee. Also currently under trials, NuVasive Inc would 
offers the product Osteocel® Plus, a mix of mesenchymal stem cells, 
cancellous bone and demineralised cortical bone as filler for spinal fusion 
procedures. 
Still, costs could remain high due to the cost of expansion, disease 
screening, sterility concerns and logistics. Moreover, the batch to batch quality 
or specifically the healing potential cannot be guaranteed or could well be 
reduced due to the preparation and standardisation processes. Fundamentally, 
the main reason that have led scientists away from autologous cells toward 
allogenic ones is that most clinical indications do not require permanent 
survival of the applied cells, but temporary production of a biological stimulus 
or agents that will aid and restore host tissue function. This stimulates interests 
for the use of important key cytokines or growth factors which could precisely 
deliver the inductive effects similar to the transplanted cells. Then altogether, 
the risks and cost of cell preparation could all be avoided.   
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2.3.5. Biomolecules Growth Factors  
Gene and stem cell therapies have shown great potential for 
regenerative medicine but currently still in their infancy with regard to control, 
efficacy and safety [225]. Protein therapy, on the other hand, is more 
downstream and direct in its application and is the most mature technology of 
the three. Growth factors are proteins, which are fundamentally coded 
instructions and the language in which cells communicate with one another to 
achieve the desired functions and are responsible for regulating cellular 
activities. Growth factors and cytokines bind to receptors on cell surfaces, 
stimulating the intracellular environment to respond through a series of events 
expressing or producing other proteins, or directing cell fate. Bone is the only 
tissue that could heal, remodel and regenerate itself without a scar tissue, and 
this involves a complex cascade of signaling factors and morphogens. In bone 
and fracture healing, this cascade of growth factor, or combination, signaling 
is even more elaborate to activate pluripotent progenitor cells (local and 
distant), direct angiogenesis, collagen formation and mineralisation, regulate 
osteoblastic and osteoclastic resorption activities [70, 97, 109].  
The main growth factors found in the extracellular matrix of bone, 
secreted mainly by bone cells include transforming growth factor-β (TGF-β), 
insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), and the bone morphogenetic proteins (BMPs). 
The specific function of these individual factors, their influence and role in 
bone development has been extensively studied. Modern recombinant 
techniques and purification methods has allowed the synthesis, isolation and 
production of these factors in large quantities for administration in a potent 
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and effective concentration to accelerate bone healing and regenerate 
challenging bone defects. Some of these have been approved or under trial to 
entered the market for clinical therapy such as rhBMP-2, OP-1 and PDGF 
[100, 107, 235, 250-253]. 
 
2.3.5.1. Transforming Growth Factor-β (TGF-β) 
Transforming growth factor-β has three structurally and functionally 
related forms, TGF-β1, TGF-β2 and TGF-β3. TGF-β plays an extensive role 
and influences in a variety of tissues and functions, such as skin formation, 
inflammatory fibrotic disease, tumor development, angiogenesis, 
haematopoiesis, mammary gland development, wound healing, cartilage and 
bone activities. TGF-β has been found to be a stimulator of collagen synthesis 
as well as a recruiter of chondrocytes and osteoblasts. While TGF-β could 
stimulate the proliferation of cells that have been committed to the osteoblastic 
lineage, but was not itself sufficient for full differentiation. Generally, TGF-
β increases ALP, Col-I, and OSN production while decreasing OCN synthesis. 
It also has an inhibitory effect on the endogenous production of BMPs in vivo, 
attributing its role upstream of bone induction during bone healing [82, 254-
257]. 
 
2.3.5.2. Insulin-like Growth Factor (IGF) 
Insulin-like growth factor is also expressed in two different forms, I 
and II. Both have been shown to stimulate osteoblast proliferation, Col-I 
expression and involved in bone development activities and repair. One 
suggested stimulation for IGF expression and production is the response to 
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mechanical stresses on bone. One pathway which led to increased osteoblast 
activity and upregulation during the bone formation and remodeling process 
was the stimulation brought about by increased osteoclasts formation in 
response to IGF. Studies revealed that rats administered with higher doses of 
IGF resulted in stronger and more energy-absorbing bones [258, 259]. 
 
2.3.5.3. Platelet-Derived Growth Factor (PDGF) 
Synthesised by platelets, endothelial cells, and macrophages, PDGF 
influences the proliferation of osteoblasts and MSC derived cell types. PDGF 
is released when platelets are activated in response to injury, a number of 
critical events essential for the initiation of musculoskeletal tissue 
repair. Platelet-derived growth factor was also linked to stimulation of protein 
production, both collagenous and non-collagenous where elevated levels of 
PDGF have been detected during bone healing. On its own, it has limited 
potency [107, 260]. BioMimetic Therapeutics Inc is attempting to market 
PDGF to address unmet needs in the repair and treatment  of bone, ligament, 
tendon and cartilage, but currently PDGF products are still under trial and 
targeted only for treatment of diabetic foot ulcers, foot and ankle fusion 
applications.  
 
2.3.5.4. Fibroblast Growth Factor (FGF) 
FGF is mainly involved in angiogenesis, wound healing, and 
embryonic development, and acts on both stem cells and differentiated cells, 
inducing proliferation, regulating differentiation by stimulating and inhibitory 
effects, and cell migration. FGFs are heparin-binding proteins and interactions 
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with cell-surface associated heparan sulfate proteoglycans which are essential 
for FGF signal transduction. The primary FGFs involved in bone are acidic 
and basic FGF, FGF-1 and FGF-2, respectively; which have an inhibitory or 
could accelerate bone repair. FGF-2 is a powerful mitogenic agent for stem 
cell proliferation which also maintains and preserves their pluripotency, 
preventing differentiation [250, 252, 261-264]. 
 
2.3.5.5. Bone Morphogenetic Proteins (BMPs) 
In 1965, Marshall Urist, identified a compound  that was noted to have 
osteoinductive potential, which belonged to the TGF-β peptide growth factor 
superfamily – the bone morphogenic protein (BMP) [34, 56, 57]. Currently, at 
least 20 BMPs were identified from the multifunctional cytokine BMP family 
and the most potent and effective bone inducing BMPs in humans are BMP-2 
and BMP-7 (OP-7). Both have been shown to not only increase the healing of 
bony defects, but also to induce bone formation in ectopic and heterotopic 
sites [19, 57-60].  
BMPs regulate and mediate cell fate by binding to specific membrane 
receptors on different cell types, including mesenchymal stem cells (MSCs), 
osteoblasts, and osteoclasts. BMP-2 has been studied extensively in animal 
models and humans for bone engineering purposes. The homodimeric protein 
has two polypeptide chains of more than 400 amino acids with a region of 
seven cystine amino acids which play a crucial role in the protein function. 
Binding of BMPs to cell receptor complexes leads to activation of the 
intracellular Smad-signalling pathway. Signalling could occur through type-I 
and type-II serine/threonine kinase receptors. BMPs bind to a combination of 
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type-I and II receptors, which accumulates a phosphorylated complex. 
Subsequently, this complex phosphorylates and stimulates receptor-regulated 
Smads (Smad 1, 5, and 8). The Smad pathway is regulated by mediator Smads 
(Smad 4), inhibitory Smads (I-Smads: Smad 6 and 7), Smad binding proteins 
and protein degradation. Whilst the molecular events governing the 
intracellular activities could be extremely complex, their net effects of 
stimulation of bone formation have been consistent in both experimental and 
clinical trials [9, 62, 251, 265-267]. Alternatively, BMPs may provide a 
physiological concentration of free protein in the vicinity of an implant or 
from a wound site which would attract specific cells by chemotaxis [268].  
BMPs are produced endogenously by cells either for autocrine or 
paracrine signaling. In order to exploit it for tissue engineering purposes, 
rhBMPs could be administered directly or via a carrier system. An ideal 
system would deliver the growth factors at the right time, dose and place, 
while preserving its bioactivity and protecting it from degradation. 
Additionally, the carrier system should have suitable mechanical properties 
and adequate pore size that would support the rapid vascularisation and 
ingrowth cells and tissue from the stimulation [269]. Suitable matrices include 
natural and synthetic biopolymers, and bioceramics, such as polyesters, 
collagen, and calcium phosphates (CaP); which also double up as an inorganic 
bone matrix substitute. Growth factors adhere to all of these, particularly CaP, 
which is known to acquire osteoinductive properties from binding of 
endogenous growth factors. RhBMP-2 bone induction has been reported to be 
successfully delivered in these carriers for spinal fusion, ectopic bone 
formation, calvarial and long bone non-union regeneration [59, 61, 62, 112, 
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119, 156, 180, 251, 270-279]. Most of these carriers, release the rhBMPs in an 
initial burst after implantation, yet positive outcomes could be achieved, 
although there is room for tremendous improvement in the pharmacokinetic 
release. Currently, rhBMP-2 has been approved by the FDA for clinical use 
for spinal fusion and non-unions as Infuse Bone Graft (Medtronic) and BMP-7 
as OP-1 (Stryker) with numerous clinical studies demonstrating their efficacy 
[19, 58-60]. 
Since BMPs are proteins and therefore could elicit an immunogenic 
response. Minor antibody responses and some adverse effects have been 
reported, however, the incidence of severe responses remain low, and have no 
correlation to clinical outcome or safety. Nevertheless, the potential 
complications must be considered during application [280-283].  
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2.4. Degradation and Bioresorption 
2.4.1. Calcium Phosphate Bioceramics 
The degradation and bioresorption of bioceramics is affected by three 
factors [189]. Firstly, new surface phases may be formed, such as amorphous 
calcium phosphate. This phenomenon is known as physiochemical dissolution, 
which depends on the solubility product of the material and local pH of the 
environment. The lower the rate of dissolution, or the slower these new 
surfaces are formed on the implant, the greater the rate of resorption. Second, 
is the physical disintegration of the implant material into small particles, 
usually due to preferential chemical attack on the grain boundaries. This 
phenomenon is more pronounced in porous materials. Thirdly, biological 
factors, like phagocytosis and cellular activities (like osteoclast-like cells), 
cause a decrease in local pH concentrations and initiate active resorption. The 
osteoclastic cells produce a pH close to 5.5, which in turn increases the 
dissolution rate of the ceramic material [112].  
Generally, the rates of degradation of the calcium phosphate implants 
also depend on the following factors [189]. 
(i) As surface area of the implant increases, so does the rate of 
degradation. 
(ii) Rate of degradation increases with decreasing crystallinity, crystal 
perfection crystal size and grain size. 
(iii) If there are ionic substitutions for the carbonates, Mg2+ and Sr2+ in the 
calcium phosphate, the rate of degradation increases. 
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(iv) F- substitution in HA, Mg2+ substitution in β-TCP and lower β-TCP to 




The success of a treatment by tissue engineering or regenerative 
medicine pivots about its focus to restore, maintain, or improve tissue or organ 
function [20, 29]; ideally complete regeneration and elimination of any 
consequential foreign materials introduced would be necessary to restore the 
injury to its original and natural state. Therefore, with resorption being key, 
and knowledge and understanding of the degradation and bioresorption 
mechanism of the material of choice is critical for success of the therapy. 
Particularly for orthopaedic applications where the controlled transfer of 
loading or function to the newly regenerated tissue, as the scaffold degrades, is 
essential to understand the mechanism in which the scaffold degrades. 
Additionally, if the material or scaffold was to be employed as a drug delivery 
device, its degradation pathway would influence the drug release profile. 
Eventually to fully exploit and accomplish these benefits, the strategy lies in 
understanding and applying it to the whole regenerative medicine equation. 
This section strives and attempts to clarify the definitions revolving around 
degradation of polymers, and reviews the various mechanisms of degradation 
and more importantly its effects.   
Technically, all polymers, regardless of their chemical structure or 
origin, degrade under appropriate conditions. The term ‘non-degradable 
polymers’ should be taken to indicate polymers that do not degrade during use 
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or very long time after use (decades to centuries), rather than not to degrade at 
all [284]. Also, earlier in 1995, Li et al. defined “biostable” materials as 
materials that have been used for a long time for both permanent and time-
limited applications [285]. While there were many debates over the accurate 
definition of polymer degradation, the term should remain relevant not only to 
tissue engineers and material scientists, but also chemists, physicists, 
environmentalists, etc. Polymer degradation and resorption is a complicated 
process that entails numerous dynamics and is influenced by many elements, 
which ultimately shapes the chemical and physical properties. Degradation of 
a polymer is a chemical reaction which also results in a change in the 
polymer’s properties [286]; as Gopferich defined [284], “polymer degradation 
is defined as the chemical reaction resulting in a cleavage of main-chain bonds 
producing shorter oligomers, monomers, and/or other low molecular weight 
degradation products”. As degradation would entail the production of lower 
molecular weight by-products, the descriptive term, which is closely 
associated with degradation to account for the passage of these low molecular 
weight products, is “erosion”. Gopferich describes the process of erosion as 
the loss of material owing to monomers and oligomers leaving the polymer 
[284].  
Biodegradation is a common term often misunderstood and misplaced. 
Grammatically, “bio” means of relation to a living organism. Hence, 
“biodegradation” would mean degradation mediated or partially mediated by a 
biological system [286, 287]. The organisms commonly include bacteria, 
microorganisms from various sources (eg. garden compost, sewage sludge), as 
in the biodegradation of industrial and commercial waste and packaging 
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material. These organisms are directly responsible for the chemical and 
physical attack on the polymer backbone chains, such as enzymes and acids 
released by a living organism due to interaction. Thus, it is erroneous, 
especially in current circumstances involving clinical synthetic polymers, 
which are chiefly polyesters, implanted or used in animals and humans, to 
conclude that the instrument and mechanism of degradation within the body is 
solely “biodegradation”. In these cases, hydrolysis is the main degradation 
mechanism for polyesters.  
In the biomedical field, the main concern for a tissue engineering 
scaffold material is its eventual “disappearance” or elimination of any foreign 
material in the host. In 1992, a bioabsorbable polymer was defined as a 
polymer that can be assimilated by a biological system and the process of 
elimination of the initial foreign material with no residual side effects [286, 
288]. The action of cells (such as phagocytosis), unlike bacteria and microbial 
action, do not actually participate in the backbone chain breaking of the 
polymers, but rather the assimilation of monomer or oligomers units. In 
conclusion, the concept of bioresorption encompasses the degradation of the 
polymer system and the final elimination or metabolisation of the degraded 
by-products from the body.  
Generally, polymers differ in the rate and mechanism of degradation, 
which is determined by the energy required to break the bond and the location 
of the bond. Polymers with strong covalent bonds in the back-bone (like C-C) 
and with no hydrolysable groups require long times for degradation. The 
agents of degradation could be heat, electromagnetic radiation (visible light, 
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UV, γ-radiation), chemicals (water, oxygen, ozone, halogens) and biological 
agents (enzymes), or any combination of the above.  
Many biopolymers are susceptible to degradation due to the effect of 
water - hydrolysis. These include some naturally occurring polymers, such as 
polysaccharides and proteins, as well as some synthetic polymers, particularly 
condensation polymers with hydrolysable linkages such as amide, ester, urea 
and urethane [285]. Thus, main mechanism of degradation for poly(hydroxy 
esters) such as PGA, PLA and PCL is simply - hydrolysis of the hydrolytically 
unstable backbone [141, 143, 288, 289].  
From the molecular viewpoint, ester hydrolysis is a familiar reaction in 
organic chemistry, as shown below.  
 
 





The by-product of this reaction, RCOOH, is capable of accelerating the 
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The kinetics of the hydrolytic reaction can be expressed by the rate 
[141], as shown below.  
 
d{E}/dt = -d{COOH}/dt  




where {COOH} is the carboxyl end group, {E} is the 





However it should be noted that at the beginning of the polyester 
degradation, the {COOH} component would be equated to 1, as the 
degradation kinetics then is purely uncatalysed hydrolysis, and the rate of 
reaction is only dependent on the ester group and water concentrations. This 
situation persists as long as the {COOH} groups formed are removed from the 
reaction site, in vitro or in vivo. However, only when the uncatalysed 
hydrolysis produces sufficient carboxylic acid that is not removed, then 
{COOH} > 1, in the case of autocatalysis.  
It was widely reported in literature that the hydrolytic degradation of 
poly(α-hydroxy esters) could proceed via the surface or bulk degradation 
pathways, and fundamentally it was the diffusion-reaction phenomenon which 
determines the mechanism which degradation takes place. Diffusion as 
understood is a transportation phenomenon and a function of distance and 
resistance to the diffusion; hence the size, dimensions and chemistry of the 
material could affect the diffusion “passage” and in turn play a major role in 
the balance of this diffusion-reaction phenomenon [284, 290, 291]. In the 
surface degradation mechanism, polymer degradation and erosion involves the 
hydrolytic cleavage of the polymer backbone at the surface only [284, 292]. 
This occurs when rate of hydrolytic chain scission and production of 
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oligomers and monomers, which diffuses into the surrounding, is faster than 
the rate of water diffusion and intrusion into the polymer bulk. Typically, this 
result in thinning of the polymer device over time without affecting the 
molecular weight of the internal bulk of the polymer, and molecular weight of 
the remaining bulk material would usually remain unchanged over the 
degradation period. Polyanhydrides and polyorthoesters are classical examples 
of polymers that undergo this type of erosion. The advantage of surface 
eroding polymers is the predictability of the erosion process [293]. This 
system of erosion is desirable for drug delivery devices as the release of drugs 
can be related to the rate of erosion.   
Bulk degradation occurs when water is able to diffuse and enter the 
whole polymer bulk and result in hydrolysis throughout the entire polymer 
matrix. Random hydrolytic chain scission would take place and produce an 
overall reduction in molecular weight for the polymeric device. Equilibrium, if 
reached for the diffusion-reaction phenomenon, water is able to diffuse into 
the polymer, hydrolyse the chains and the cleaved oligomers and monomers 
are able to diffuse out rapidly, then erosion would occur gradually as the low 
molecular chains are lost from the polymer body. This equilibrium requires the 
diffusion of low molecular weight particles swiftly out of the polymer bulk as 
the degradation reaction proceeds at a steady pace, any offset in either would 
tip the equilibrium.  
When this diffusion-reaction balance is tipped, the degradation 
mechanism could lead to internal autocatalysis [285]. A single chemical 
reaction is said to have undergone autocatalysis if the reaction product is itself 
the catalyst for that reaction. In this case for biodegradable polyesters, the 
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hydrolysis by-products are carboxyl and hydroxyl end groups, and the buildup 
of these acidic groups, especially carboxylic acid, could result in catalysis of 
the ongoing degradation reaction. The resistance to diffusion depends mainly 
on the chemistry of the polymer and the thickness, both fundamental factors 
influencing the diffusion-reaction equilibrium. Chemistry of the polymer or 
co-polymers may generate selective acidic end groups which would enable 
autocatalysis, such as faster degrading lactic and glycolic groups [289, 294]. 
Imbalance of the degradation reaction due to non-random and preferential 
chain-end scission would generate carboxyl end groups more rapidly, such as 
for (D,L-lactide) [295]. Morphological-structure factors, such as crystalline 
and amorphous structures resulting from the fabrication processes, was also a 
contributor to tipping the diffusion-reaction balance [296]. Size of fabricated 
device was also an influential aspect directing the diffusion-reaction imbalance 
[291].  
For internal autocatalysis to occur, the oligomers and carboxyl end 
groups at the surface of the polymeric device can easily diffuse into the 
surroundings as compared to the by-products at the centre. Thus, new carboxyl 
end groups would form as each ester bond is cleaved, building up the 
concentration of carboxylic acid inside the device; the reaction accelerates due 
to autocatalysis and a gradient of acidic groups would form. These acidic 
groups would further autocatalyse the degradation reaction and more 
oligomers and larger molecular weight chains would be cleaved at an 
enhanced rate, these larger chains would add to the resistance to diffusion of 
the monomers and carboxylic acids as they clog up the passage to the surface, 
augmenting faster internally degradation. Eventually, an outer layer of less 
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degraded barrier of macromolecules is formed which would control the 
swelling and osmotic exchanges. As degradation advances and supplemented 
by internal autocatalysis two distinct masses would be created, a higher 
molecular weight skin layer and a degraded lower molecular weight interior. 
At this stage, the degradation mechanism could be characterised by a bimodal 
molecular weight distribution. When the pressure swells up internally, the 
polymeric device could burst and the sudden release of internal acidic products 
could occur; alternatively  should the inner oligomers become small enough 
they would all diffuse out rapidly through the barrier layer into the 
surroundings as well, an onset of weight loss and a decrease in the rate of 
chain scission would result [284, 289]. Once either occurs, this rapid release of 
these oligomers and carboxylic acid could result in adverse tissue reactions 
and inflammation in vivo [297-299]. In the end, a higher molecular weight 
hollowed-out structure would remain.  
This faster autocatalytic degradation is a general and common 
phenomenon  in polymeric devices [285, 300]. However, since polymer chain 
degradation and scission is a dynamic process, and a continued rebalancing 
and re-equilibrating of constants process, it is difficult to generalise 
degradation mechanisms based on material nor dimension and size alone. In 
the case of some semi-crystalline polymers, no hollow structures were 
obtained due to the recrystallisation capabilities of the degradation by-
products. The two populations of different molecular weight chains however, 
remain the key characteristic [301].  
The human body is a very hostile environment for a foreign material. 
Depending on the implant’s function, whether long-term (a pacemaker’s 
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casing) or short-term (suture), the control of the rate and extent of 
degradability of these polymeric biomaterial is critical for its assigned 
function. Especially for orthopaedic scenarios, where loadings and stresses are 
critical for bone healing and regeneration, the support and transfer of loads to 
the healing bone must be timely or detrimental results would arise.  
While the mechanism of degradation may be relatively specific to the 
chemical configuration of the polymer (eg. hydrolysis), yet there are still many 
factors, both inherent and external that would affect the rate of degradation. 
Also, as the polymer degrades, the changing polymer chemistry and structure 
also result in contributory dynamics influencing degradation. Some of these 
factors are presented accordingly: 
 
2.4.2.1. Chemistry and structure  
The chemical composition of the polymer is one of the main factors 
influencing degradation, after all degradation is the chemical breakdown of 
these chains. Aside from the reactivity of the components in the polymer, such 
as the ester group, how the whole structure of these esters and carbon-based 
groups are put together also contribute considerably to degradation [284]. It 
was established earlier that the rate of degradation of the most common 
synthetic bioresorbable polymers proceed in this order: PGA > PDLA > PLLA 
> PCL. Chemically and structurally, the GA unit, a single methylene group 
(CH2), configured linearly is easily breached as compared to the DLA or LLA 
unit, which has a more complicated methyl pendant group (CH3), besides the 
alkyl group hinders the attack of water. Functional groups also have the effect 
of altering steric and electronic properties [284].  Finally, the CL unit, which is 
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composed of five methylene units, makes it the hardest to breach among the 
three.  
The structuring of the chains has a potent effect on the polymer 
morphology, as in the case of the PDLA and PLLA polyesters; influence of 
morphology would be discussed in the following paragraphs. Accordingly, the 
chemical structure, reactivity and resulting chemistry also can be reinforced or 
disrupted by processes such as co-polymerisation and blending.  
 
2.4.2.2. Molecular weight and distribution 
Molecular weight and molecular weight distribution are important 
factors; after all, it is often used as a measure of degradation. A polymer 
synthesised to compose of shorter chains or longer chains would result in low 
and high molecular weight. This difference in molecular weight has 
pronounced effect on its chemical properties and physical properties. 
Typically, higher molecular weight polymers were observed to degrade slower 
than lower molecular weight ones [289, 302]. Pitt et al. (1981) reported in vivo 
PLA films of Mn 14000 and 49000 being resorbed at 28 week and 60 weeks, 
respectively [303]. Also, Li and co-workers (1995) reported that the presence 
of low molecular weight components within a higher molecular weight 
polymer would accelerate its degradation. They also concluded that the lower 
the molecular weight, the faster the degradation rate [285]. 
 
2.4.2.3. Morphology 
Morphology of the polymer structure: crystallinity (polymer’s chain 
orientation and arrangement), microstructures, residual stresses; plays a 
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critical role not only in its mechanical properties but also its degradation rate. 
Semi-crystalline (glassy) polymers generally have superior mechanical 
properties compared to its amorphous (rubbery) counterparts in terms of 
resistance to deformation, due to their highly ordered crystalline structure. 
This highly organised configuration is also more resistant to chemical attacks 
and liquid penetration, rendering it tougher to degrade as compared to the 
amorphous regions. Li et al. (1995) describes the degradation of semi-
crystalline polymers in two stages. The first stage starts with water diffusion 
into the amorphous zones and random hydrolytic scission. The second stage 
starts when most of the amorphous regions are degraded and the degradation 
proceeds to the crystalline domains [285].  This preferential attack of 
amorphous regions was also concurred by numerous researchers [284, 289, 
302]. Even in biotic degradation, the enzymes and biological agents attack the 
amorphous first [304, 305].  
The element of crystallisation or recrystallisation may arise even for 
totally amorphous polymers. As polymers degrade, the long chains are 
cleaved, the resultant shorter chains acquire more mobility than before, and 
this shift in energy level means a swing in the inherent properties such as 
crystallinity and Tg. The rate of degradation would decrease significantly when 
these shorter chains order themselves into crystal lamellas [289, 302]. Hence, 
polymer morphology and morphological changes can be pre-dominant factors 
governing degradation.  
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2.4.2.4. Shape and Size 
Polymeric scaffolds and medical devices come in various designs and 
porosities, the issue of shape and size relates to the surface area to mass ratio 
of the polymeric device. Essentially, it determines the rate of water diffusion 
and thus hydrolysis. Grizzi et al. (1995) found that degradation of films, 
powder and microspheres was much slower compared to that of large-sized 
specimens. They concluded that the smaller the sample’s size, the slower the 
degradation. Additionally, bulk degrading polymers could easily suffer from 
faster autocatalysed interior, as its size increase.  
 
2.4.2.5. Hydrophobicity 
As we have understood that the hydrolysis of polyesters is a “water-
based” reaction. Naturally, the other main reactant is water. Thus, the 
concentration and availability of the reactants play a vital role in establishing 
the rate of reaction or degradation. The speed and amount of water capable of 
diffusing throughout the polymer crucially dictates the hydrolytic reaction 
rate. Accordingly, when the polymer or components are polar-repulsive and 
restrict the interaction with water (surface energy and/or chemistry), 
degradation would slow drastically [129, 131].  
 
2.4.2.6. Processing Conditions 
The complications of fabrication conditions of the medical device 
could have a significant result in altering their original properties. After 
processing the molecular weight, crystallinity and other morphological aspects 
may be altered due to polymer degradation, moisture, processing temperatures 
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or use and inclusion of chemicals [152]. For example, Middleton et al. (2000) 
reported the need to reduce PGA moisture to 0.003% while processing or it 
may degrade over 50%. Chain orientation (morphology) also influences the 
preferential assault of chemical degradation on polymers. Chain orientation 
along the fibre axis renders the fibre material less susceptible to water 
penetration and more resistant to hydrolysis [306, 307]. Ginde et al. (1987) 
reported that the degradation rate was faster for PGA pellets than fibres, 
despite the pellets having higher crystallinity. They attribute this difference to 
the presence of long-range order in fibres, which resulted from the fibre 
fabrication process [292].  
 
2.4.2.7. pH 
Degradation of hydrolytically unstable polyesters has been reported 
also to be affected by a fluctuation in the pH. PGA is more sensitive to an 
alkaline medium than physiological or acidic media [306, 307], in the case of 
another polyester, PLA, the findings were similar [308]. Accelerated 
degradation of PCL polymers, was also studied with alkaline media [37]. The 
effects of pH were interpreted in terms of electric potential distribution at the 
polymer-solution interface. Generally, alkaline and acidic media accelerate 
polymer degradation [150, 285]. 
 
2.4.2.8. Temperature 
Temperature is another critical factor in chemistry and an important 
role in polymer degradation where the rate increases with temperature. Reed et 
al. (1981) noted that for PGA (Tg = 37ºC), when the polymer enters the glassy 
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state, it is protected from the hydrolytic attack as all short-term chain motions 
are frozen [309]. However, above the Tg, water diffusion and hydrolysis 
accelerates. In contrast, paradoxically, a rising temperature would impart 
sufficient energy for immobile chains to continue crystallisation, and invoking 
an annealing process, as well. 
 
2.4.2.9. Implant Site 
The eventual application and function of the polymeric device would 
be at the implant site. Depending on the site, the device would be imparted 
external factors influencing degradation, such as pH and temperature, which 
has been discussed. Yet another major factor would be the mechanical forces 
the device is subjected, compression, tensile, shear or even torsion, this impact 
on the physical endurance of the polymer. Generally, wear and fatigue would 
enhance the rate of degradation tremendously [141, 300].  
Bioresorbable biomaterials have been used as medical devices, such as 
sutures, fixation pins and screws, as well as drug release systems and tissue 
engineering scaffolds. These devices, regardless of application, when properly 
evaluated and obtained regulatory approval proves to be nontoxic locally and 
systemically. There have been reports of inflammation, foreign body response, 
and cell lysis although normally these are within acceptable risks and limits 
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2.5. Spinal Fusion   
2.5.1. Biology and Function of the Spine  
The spinal column or vertebral column is one of the earliest features 
and structures to be formed during embryogenesis, even before organogenesis, 
and its function has remained key as a structural support platform for the 
organism as well as origin/pathway for signaling factors and communication 
to be channeled. In the beginning, after to creation of the single cell zygote, 
there was embryogenesis, mitotic cell division occurs and cells start to 
differentiate and acquire specialised functions to form the distinctive three 
germs layers (ectoderm, mesoderm and endoderm) during gastrulation. 
Subsequently, the notochord forms and would play an important role signaling 
the successive developments. The next significant event is the formation of the 
neural tube at the stage of neurulation, the start of organogenesis, where 
organs start to form. The notochord and neural tube eventually develop or 
leads to development of the vertebral column (through somites and the 
sclerotome) and the central nervous system (consisting of the spinal cord and 
brain), respectively. Eventually, the other bone structures would also ‘bud’ 
from this central structure.    
The anatomy of the spine and vertebrae is uniquely designed to protect 
the spinal cord and provides the central support for the skeletal system 
facilitating locomotion and physical movements. In humans, the spinal column 
consists of 33 vertebrae, from superior to inferior, 24 individual vertebral 
bodies, each separated by an intervertebral disc which makes up the cervical 
(C1-C7), thoracic (T1-T12) and lumbar (L1-L5) regions; and 9 fused sections 
which form the sacral (S1-S5) and coccyx (4) regions (Figure 2.6).  




    
 
Figure 2.6. Above: Schematic of the human vertebral column showing the different 
regions. Below: Schematic of the cross-section of a lumbar vertebra.  
 
2.5.2. Lower Back Pain and Spine Pathologies  
Low back pain a common disorder, particular at the lumbar region and 
represent more than half of the musculoskeletal impairments reported in the 
USA. Conservative treatment for back pain may include rest, anti-
inflammatory medications and physical therapy. However, when these 
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treatments fail, surgical intervention, such as a spinal arthrodesis or fusion 
procedure, may be the final solution. Spinal fusion is one of the most 
commonly performed procedures for degenerative disorders of the lumbar 
spine, with over 300,000 procedures performed annually in the USA [272, 
310-312].  
Some other ailments may also warrant spinal fusion as a treatment 
option. These may include spine deformative disorders and abnormal spine 
curvatures, such scoliosis and kyphosis. Pain caused by pressure on spinal 
nerves due to abnormal protrusion of the intervertebral disc is known as 
herniated disk. Spinal stenosis caused by organ hypertrophy of the facet joints 
or osteoarthritis, spondylolisthesis, diffuse idiopathic skeletal hyperostosis 
(DISH) or degenerative disc disease. Tumors and infection or trauma and 
injury of the spine may require spinal fusion [312-314].  
 
2.5.3. Spinal Fusion Technique: Anterior Lumbar Interbody Fusion (ALIF) 
The option of spinal fusion is usually the final option, after failed 
conservative medical attempts, as it is a permanent procedure. This procedure 
would surgically fuse the different segments of the spine together 
permanently. Thus, the adjacent vertebrae of the affected region would be 
immobilised and fused together. This allows for correction to spinal curvature, 
prevents abnormal movement and alleviates pain. Spinal fusion is an effective 
treatment option for several spinal pathologies described above. A common 
technique for the surgeon to access and fuse the vertebrae is the anterior 
lumbar interbody fusion (ALIF) technique, which approaches from the front of 
the patient and expose the vertebral bodies to perform arthrodesis, other 
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techniques could also be used, such as the posterior approach (PLIF). The 
ALIF procedure would entail an incision at the patient’s abdomen to expose 
and allow access through the layers of muscle to the vertebrae. The surgeon 
would then perform a diskectomy, excision of the ruptured intervertebral disc 
to create space for a bone graft to be inserted. Then the neighbouring superior 
and inferior vertebral endplates would be removed to expose the underlining 
bone. An autologous bone graft would be taken from a non loaded and non-
detrimental site in the patient, usually the iliac crest. The autologous bone 
graft comprising of structure (cortical and cancellous regions) and 
osteoinductivity (blood, bone marrow, progenitor cells and growth factors) is 
placed in the intervertebral body space; this would induce bone regeneration 
and healing to fuse the spine together. As the approach is from the anterior 
while the spinal cord is in the posterior, the procedure is carried out away from 
the spinal cord regions. Recently, interbody spinal fusion could also be 
achieved using laparoscopic surgery or minimally invasive surgery (MIS) 
techniques [180, 270, 278, 315].  
Autografts are ideal bone grafts and remains the gold standard to be 
used. They are usually taken from patient’s iliac crest and placed in the 
removed spinal disc space to stimulate fusion of the adjacent vertebrae bodies. 
This procedure would commonly be associated with donor site morbidity, 
chronic pain and secondary scarring. Arthrodesis would be achieved usually 
within three months. When unavailable due to age, disease, scarcity, quantity 
or quality, surgeons can opt to use nonresorbable metallic (titanium) or 
polymer (PEEK) cages, with autografts or clinical approved recombinant 
human bone morphogenetic protein-2 (rhBMP-2) as bone graft substitutes to 
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promote bone formation. However, these have several drawbacks of stress 
shielding and tissue-implant mismatched implications, in the long term. Tissue 
engineering could offer strategies to create the “ideal” alternative bone graft 
substitute, which would “engineer” bone at the implant site with the final end 
product being regenerated native bone integrated and fused between the 
vertebrae bodies, after bioresorption of the biocage. This alternative tissue 
engineering graft scaffold system should encompass the advantages of an 
autograft (osteoinductive capability and mechanical stability) without its 
limitations, with the ultimate potential of being commercialised as an “off the 
shelf” bone graft alternative for spinal fusion and could possibly be extended 









3. CHARACTERISATION OF COMPOSITE PCL/TCP SCAFFOLDS 
FOR BONE ENGINEERING  
 
Bioresorbable composite (PCL/TCP) scaffolds with enhanced 
mechanical properties over PCL scaffolds would be fabricated and 
characterised. Primary porcine bone marrow stromal cells (BMSCs) would be 
cultured on the scaffolds to assess compatibility and scaffold’s capability to 
support growth and differentiation of pBMSCs.  
Thermoplastic PCL blended with bioactive TCP are suitable for the 
design and fabrication of bone engineering scaffolds owing to its significant 
track record for regulatory approval, and their minimum provocation of 
inflammatory and immunological response, as such they had already been 
made into a number of medical devices. Above all, its low softening 
temperature enables it to be easily fabricated into 3D scaffolds with desired 
geometry and controlled porosity with interconnectivity using modern 
computer-based solid freeform fabrication.  
 
3.1. Experimental Setup: Materials and Methods  
3.1.1. Fabrication of PCL/TCP scaffolds  
PCL was used as received for the fabrication of PCL scaffolds. 
PCL/TCP was prepared by blending PCL and TCP (20%wt) in a twin screw 
blender, resulting in a uniformly distributed composite material of TCP 
embedded in a PCL matrix. Material sources are presented in Table 3.1. 
Scaffolds were fabricated via the fused deposition modeling technique (FDM). 




The working principle of the FDM is described in Chapter 2 and reported in 
literature [36, 37]. Basically, the FDM rapid prototyping technique melts the 
polymer in a liquefier chamber and the molten PCL material is pressurised 
through a nozzle (~350µm) and extruded as micro-diameter struts (Figure 3.1). 
These struts were laid in a pre-determined pattern and stacked layer by layer 
building up a porous structure, such as the 3-angle design, scaffold struts were 
deposited at 0°, 60° and 120° orientation.  
 
Table 3.1. List of materials used for fabrication of mPCL-based and 
PCL-based scaffolds. 
Materials Abbrev Source 
Research Grade Polycaprolactone 
(440744) PCL 
Sigma Aldrich Chemical 
Company Inc 
Medical Polycaprolactone 
(B6003-2) mPCL DURECT Corporation 
β-Tricalcium Phosphate (~10µm) TCP Progentix 
 
3.1.2. In Vitro Cell Culture Experiment  
Porcine bone marrow progenitor cells were isolated by plating in 
tissue culture flasks bone marrow aspirates from 6 month old Yorkshire pigs 
(~50kg). The adherent pBMSCs were expanded in T150 culture flasks in 
growth media (Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal 
bovine serum (FBS) and 1 % Penicillin-Streptomycin. They were either use 
directly or frozen for storage, only BMSCs passages 4 and below were used 
for experiments. 
3-angle scaffolds (0-60-120°) prepared into 5×5×4mm3 cuboids for 
in vitro cell culture. They were treated with sodium hydroxide (5M NaOH) 
for 3 hours and sterilised. Approximately 50,000 cells were seeded onto each 
scaffold, and cultured up to 28 days in osteogenic media (0.1mM ascorbic 




acid 2-phosphate, 10mM β-glycerophosphate, 100nM dexamethasone). 
Media was replaced every 3-4 days. 
 
 The following evaluation methods were used to characterise the 
composite PCL/TCP scaffolds and the cell culture study using composite 
PCL/TCP scaffolds: 
 
3.1.3. Scanning Electron Microscope (SEM)  
Scaffold morphology, pore size and cell attachment onto the scaffolds 
were studied using the SEM. Scaffold surfaces were gold-sputtered and 
observed using 15kV accelerating voltage under vacuum conditions (Phillips 
XL30 FEG).  
 
3.1.4. Compressive Mechanical Tests  
Mechanical compression tests were conducted on the scaffolds using 
an Instron 4302 Material Testing System operated by Series IX Automated 
Materials Tester v. 7.43 system software with a 1-kN load cell; in accordance 
with the ASTM D695-96 guidelines. The specimens were compressed at a rate 
of 1mm/min up to a strain level of 0.6. 
The stress-strain (σ - ε) curves were obtained to evaluate the 
compressive stiffness (modulus) and compressive yield stress for the scaffolds. 
The stiffness was calculated from the stress–strain curve as the slope of the 
initial linear portion of the curve, with any toe region due to the initial settling 
of the specimen neglected. The compressive yield stress was taken at the yield 
point (if any) or at the end of the linear region.  




3.1.5. Phase Contrast Imaging and Tomography (PCIT) 
The distribution of TCP was visualised assessed using the Phase 
Contrast Imaging and Tomography (PCIT) beamline at the Singapore 
Synchrotron Light Source (SSLS). The key strength and importance of 
synchrotron imaging arises from the unique properties of the x-ray beam. The 
synchrotron source emits highly accelerated photons from a wide energy 
spectrum (<1eV to 100keV) at high flux densities. Highly collimated and 
polarised x-rays can be selected using optical arrays which would result in 
excellent imaging with reduced x-ray scatter. Lastly, the use of 
monochromatic x-rays resolves the problem of beam hardening which is 
commonly encountered with conventional x-ray sources, excellent for defining 
low-contrast details. It also gives excellent spatial resolution brilliant for 
visualising fine particle sizes [317, 318]. The datasets (image slices) acquired 
from the synchrotron facility were then reconstructed and visualised by an in-
house build software algorithm from the Australian National University 
(ANU) [319, 320], which was excellent and specific in visualising spatial and 
contrast details such as the TCP distribution within the PCL.  
 
3.1.6. Nano-computed tomography (nano-CT) 
The SkyScan-2011 nano-CT with a spatial resolution of 400nm was 
used to determine and visualise the TCP distribution within the PCL. The 
commercial nano-CT was one of the most advanced and modern piece of 
technology, at the point of usage for this project. Prior to this, other imaging 
techniques were not able to achieve the details of spatial resolution and 
contrast compared to one from a synchrotron facility. The author was 




interested to attempt a direct comparison. The scanned datasets were 
reconstructed and visualised using SkyScan’s CT-analyser software. 
 
3.1.7. DNA Quantification  
Picogreen assay using a fluorescent probe that binds proportionally to 
double strand DNA (dsDNA) was used to quantify the amount of dsDNA 
present, thus indicating proportional cell number. Cell scaffold constructs were 
removed at specified time points and placed in deionised water (500µl) and 
stored at -80°C. At the final time point, all samples were subjected to 3 cycles 
of freezing-thaw cycles of 15 minutes each and vortexed for 3 minutes. The 
scaffold was removed leaving the released DNA behind and the amount of 
DNA quantified with picogreen according to the manufacturer’s instructions. 
Briefly, samples were incubated with 1ml of picogreen reagent (dilution 
1:200) for 5 minutes at room temperature along with the provided dsDNA 
standard. The fluorescence was measured at excitation 485nm and emission 
535nm.  
 
3.1.8. Alkaline Phosphatase (ALP) Assay 
ALP is a membrane bound enzyme used as a marker for osteogenic 
differentiation as it is actively produced by osteoblasts as they deposit bone 
matrix. Cell-scaffold constructs were rinsed with tris buffered saline (TBS) 
and ice cold RIPA lysis buffer (100µl) was added and vortexed for 30s. The 
supernatant was then stored at -80°C until assay. 50µl of each sample was 
mixed with 150µl of para-nitrophenol phosphate (pNPP – Sigma) in 




triplicates, and incubated at 37oC for 30 minutes and the absorbance was 
measured at 405nm immediately with a microplate reader. 
 
3.1.9. Confocal Laser Microscopy (CLM)  
The cell attachment and viability on the PCL/TCP scaffolds were 
observed on a CLM using green fluorescent fluorescein diacetate stain (FDA) 
for live cells and red propidium iodide (PI) for necrotic cells. The fluorescence 
CLM (Olympus) observations were done using an excitation wavelength of 
488nm (green) and 543nm (red).   
 
3.2. Results and Discussions  
The fabricated scaffold structure were highly consistent in architecture 
and design, all struts were laid down with computer precision. An overview of 
the FDM principle is shown in Figure 3.1 and overall architecture, structure 
and SEM observations of FDM fabricated scaffolds shown in Figure 3.2.  
 





Figure 3.1. Schematic showing how the FDM liquefier head 
works. Scaffold material (PCL or PCL/TCP) is fed into the 
liquefier head and melted by the heaters. The molten material is 
extruded from the nozzle and laid down to form specific patterns 
by the robotic manipulation (x-y-z axes) of the whole liquefier 
unit as the struts are extruded. 
 
 





Figure 3.2. Gross overview of a 3 angle (0º-60º-120º) scaffold 
block. Inset: SEM micrographs of side and top view. 
 
There are two common mechanical tests to evaluate the properties of a 
material or construct. First, is the modulus of elasticity (E) which is a measure 
of the stiffness/elastic properties of an isotropic elastic material, specifically, a 
ratio of how fast the material deforms, relative to its original dimensions 
(mm/mm), under an applied force (N). After normalising by the area, 
compressive modulus is expressed as MPa (N/m2). Form the compressive 
modulus, the construct’s elastic/stiffness behaviour could be determined. Next, 
the yield strength of a material is an adequate indicator of the material's 
mechanical strength, more specifically the parameter that predicts the point of 
plastic deformation in the material, beyond which the material would not 
recover to its original state.  
Mechanical tests revealed that composite PCL/TCP scaffolds were 
about 2.5× stiffer than the PCL scaffolds, due to the TCP bioceramic 




reinforcement. Although, the average yield strength was slightly higher, it was 
not significant. This was anticipated as the overall bulk material within the 
struts were stiffen by the inclusion of TCP but majority of the matrix material 
was still the weaker PCL (80%wt); which yielded within the same order of 
magnitude of applied force. Besides, the TCP was blended in particles, which 




















Figure 3.3. Comparison of improvement in mechanical properties 
– compressive stiffness for the PCL/TCP over PCL scaffolds (p < 
0.05). 
 



















Figure 3.4. Comparison of improvement in mechanical properties 
– yield strength for the PCL/TCP over PCL scaffolds (not 
statistically significant). 
 
The PCIT and nano-CT analyses revealed the internal structure of the 
PCL matrix with the TCP reinforcements, as presented by the various analysis 
techniques in Figure 3.5 and Figure 3.6. While, both are X-ray based 
techniques, the purpose was not to compare the two methods, but to maximise 
on their strengths to analyse the composite material and structure at a micron 
or almost nano level. The TCP particles were uniformly distributed. 
Surprisingly, inherent “defects” of voids or air pockets were also found within 
the matrix, possible due to the mixing process, where sub-micron air voids 
were churned up and entrapped. These voids would likely reduce the 
compressive stiffness of the material as well as increase its rate of degradation. 
Based on estimations from probability density functions plotted from the data, 
TCP particles were estimated to be averaged ~10.7µm while voids averaged 




~8.5µm. However, due to the current mixing and fabrication process, there 
was not simple solution to eliminate this issue. Two possible methods to 
remove or reduce void formation would be to prepare all materials in a 
vacuum or use a solvent process to blend the composite; this however, would 
produce smaller nanopores, due to the solvent evaporation process and 
possible detriment of TCP settling at the bottom of the blend resulting in non-
homogeneous TCP distribution. Nevertheless, the current composite scaffold 
still meets the mechanical requirement as a load-bearing implant. Inherent, 
micropores could enhance the rate of degradation and resorption of the 
scaffold system as well. Strategies, to improve the composite’s integrity has 
been underway and achieved significant success, through not within the scope 
of this project. 
 
 
Figure 3.5. PCIT scanned composite PCL/TCP, visualised by 
software developed at ANU. Observations of well distributed 




TCP (red) within the PCL (yellow) matrix. Voids (blue) also 
distributed within the composite. Cube width is 175µm, each grid 
is 35µm (50voxels). 
 
 
Figure 3.6. Nano-CT visualised composite PCL/TCP, indicating 
TCP (white) and voids (hollow) distribution within the PCL 
matrix. Results concurring with the PCIT imaging.  
 
 
Figure 3.7. Probability density function of particle size 
dimensions of TCP particles and voids detected within the PCL 
matrix in the PCL/TCP composite material. 
 




pBMSCs were observed to proliferate and differentiate well in the 
composite PCL/TCP scaffold system. Microscopic observations, using phase 
contrast shows bridging of cells from strut to struts as they start to spread and 
migrate over the scaffold surfaces by day 7, while some pores were filled with 
cell and cell-sheets by day 14 (Figure 3.8). Confocal laser microscopy showed 
cells attached prominently on the strut surfaces over the entire cylindrical 
surface by day 7, they proliferate and fill some pores by day 14 (Figure 3.9). 
Scanning electron microscopy shows similar extent of cell proliferation and 
carpet-like spreading of cells and ECM over the scaffold surfaces at 7 and 14 
days (Figure 3.10). DNA quantification also showed healthy cell growth and 
proliferation, with increasing DNA production (Figure 3.11). ALP assay also 
indicated increased osteogenic activity (Figure 3.12).  Taken together, the 
scaffold system supports bone tissue regeneration via osteoprogenitor 
colonisation and differentiation.  
 
 
Figure 3.8. Phase contrast of pBMSC proliferating in the PCL/TCP scaffolds at 7 
days (left) and 14 days (right). Cells were observed to bridge the struts.  
 
 




Figure 3.9. Confocal microscopy of pBMSC proliferating in the PCL/TCP scaffolds at 7 
days (left) and 14 days (right); live cells stained green and apoptotic cells red.  
 
 
Figure 3.10. SEM images of pBMSC proliferating in the PCL/TCP scaffolds at 7 
days (above) and 14 days (below).   
 
 





















Figure 3.11. DNA quantification by picogreen assay of cell-
scaffold constructs over 28 days. Increasing DNA quantity 



















Figure 3.12. Alkaline phosphatase activity of uninduced and 
induced cell-scaffold constructs up to 28 days. 




A critical factor for scaffolds used for tissue engineering, apart from its 
mechanical stability and biological compatibility, is the porosity and more 
importantly structure of the interconnected pore size. Depending on the 
materials and fabrication process, porosity and pore size could be random or 
controlled. While traditionally, most scaffolds aim for high porosity, this is but 
a one dimensional perception and misconception. Many early sponge and 
foam scaffolds are >90% porous but have non-interconnected and closed 
pores, resulting in the inability to support uniform cell proliferation and tissue 
defelopement. Base on definitions, porosity is a scalar property; it is simply 
the fraction of void space within a defined closed system. Thus, an empty box 
could have a porosity of up to 99%, but meaningless as a scaffold. Trabecular 
bone has a porosity of 30-90%, while that supports a wide array of cell types, 
it is importantly composed of an irregular latticework of trabeculae forming an 
interconnected network of pores for marrow and cells to reside. Therefore, it is 
how the internal structure of this void space is interconnected and formed by 
its pores that would allow efficient proliferation and regeneration of cells and 
tissues, as well as support for their functions such as transport and diffusion of 
nutrients and wastes.  
The current PCL/TCP scaffold with a porosity of 65-70% and pore 
sizes of between 400 – 800µm clearly supports BMSC proliferation and 
differentiation. This range of pore size is vital for transportation and metabolic 
activities, as well as for the ingrowth of blood vessels, host and neo-bone 
tissue, to penetrate and anchor to the implant. Reported optimal pore size for 
bone ingrowth is about 150–800µm [29, 116-119]. With the optimal pore size 




to facilitate the primary function, for tissue ingrowth and survival, a high 
porosity also reduces the amount of foreign material implanted.  
Further, when the porous scaffold system is implanted in a bone defect, 
the pores would become filled first with blood clot, and then with recruitment 
of osteoprogenitor mesenchymal cells to the defect site, would these cells 
(host bone) penetrate the osteoconductive platform. The efficiency of bony 
ingrowth repair depends on the degree of mechanical stability in the early 
stages of healing, apart from osteoinductive factors. When the neo-bone 
ingrown becomes stabilised and matures, the higher the porosity and optimally 
interconnected the pores, the better the neo-bone integrates and anchors itself 
to the implant, occupying and recovering up to 70% of the scaffold system, 
playing a significant role in re-establishing its load-bearing role. Thus, the 
critical and conflicting relationship between mechanical properties and 
porosity (pore size) should be customised accordingly. 
 
3.3. Conclusions  
The fabricated composite PCL/TCP scaffolds have enhanced 
mechanical properties over the PCL scaffolds, in a static setting. They also 
proved to be biocompatible and supported primary pBMSC proliferation and 
differentiation. The open pore architecture allowed cell and tissue to infiltrate 
the entire porous and interconnected scaffold. Thus, these scaffold fabricated 
from FDA approved materials, shows promise to be useful as practical bone 
engineering scaffolds in the near future. In the next chapter, the degradation 




4. SCAFFOLD DEGRADATION: LONG-TERM IN VITRO & IN VIVO 
 Degradation and resorption are the key characteristics for the 
bioresorbable scaffold systems, yet this is an extremely dynamic process 
interplayed by many equilibrium states, as the intrinsic and extrinsic properties 
evolve in a very complex manner. It should degrade and be resorbed in a 
practical and complementing manner to tissue regeneration, transfer of load in 
a timely manner and not release toxic by-products beyond threshold limits. 
Thus, it is paramount to study and understand the realistic behaviour (chemical 
and mechanical aspects) over the lifetime of the scaffold implant, and envisage 
how such a scaffold system could be maximised. The key objectives are to 
understand, approximate and assess that the scaffold (from design, fabrication 
to usage) is able to meet the requirements to serve as a bone engineering 
scaffold pertaining to strength, stability and safety of the implant until full 
resorption. 
 
4.1. Experimental Setup: Materials and Methods  
As established in Chapter 2, the degradation of PCL proceeds mainly 
via hydrolysis. A series of in vitro and in vivo experiments were designed to 
investigate degradation and resorption of the PCL and PCL/TCP scaffolds, the 
crux of the study would trace the physical and chemical changes over the 
degradation period. Additionally, since the scaffold was designed to function 
and provide mechanical support to the defect site, mechanical stability over 
the period was also examined critically.   
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4.1.1. Long-term In Vitro Degradation Study  
The in vitro degradation experiment was set up to investigate the 
degradation of the scaffolds in a controlled environment, also specifically to 
look at chemical, physical and mechanical changes which would be extremely 
difficult and complex to scrutinise in vivo; such as mass loss, mechanical 
studies, etc. For the in vitro degradation experiment, mPCL and mPCL/TCP 
scaffolds were pretreated with sodium hydroxide (5M NaOH) for 12 and 3 
hours, respectively, this resulted in a similar surface texture and roughness for 
both scaffold groups. Details of experimental parameters are summarised in 
Table 4.1. The scaffolds were submerged in individual tubes with 10ml of 
phosphate buffered saline (PBS) at pH 7.4, with screw-caps tightened, 
maintained at 37°C and PBS refreshed monthly. At selected time-points, the 
scaffolds were removed and rinsed thoroughly with deionised water. The 
scaffolds were dried and placed in an oven at 35°C for 12 hours. 
Typically, polymeric scaffolds with less hydrophilic surface 
chemistries would be pre-treated (3-24 hours) to render the surface more 
hydrophilic and more corrugated for cell attachment [321]. In a preliminary 
study, it was determined that after 1 hour of NaOH treatment the quantity of 
carboxylic groups (-COOH) on the scaffold surface has already reached a 
saturation. Further etching would likely only to enhance the surface roughness 
and increase surface area, or a strategy to create a more spongy and porous 
scaffold [37]. Although, the NaOH treatment was primarily a superficial effect 
and enhances surface erosion, the effect due to the NaOH treatment on long-
term degradation was also studied to understand how this common chemical 
modification procedure would affect the scaffold degradation. In a 
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supplementary experiment, two groups of scaffolds were prepared, absolutely 
untreated and extensively treated up to 72 hours. The critical results revealed 
that this superficial treatment did not significantly affect the degradation 
(molecular weight reduction) of the scaffolds, except for a small spike in the 
initial mass loss due to degraded polymer chains and oligomers on the surface 
[217, 322].  
An initial short-term in vivo degradation experiments was conducted to 
investigate the degradation of the scaffolds in an immunocompetent animal 
model, 3 sets of scaffolds were prepared: PCL scaffolds (NaOH treated for 12 
hours), pre-degraded PCL scaffolds (PD-PCL, NaOH treated for 7 days) and 
untreated mPCL/TCP scaffolds. The rational of the pre-degradation (up to 1 
week pre-degradation in NaOH), was to understand its biocompatibility and 
feasibility, should a strategy of pre-treatment be used along with its indications 
and limitations, to etch PCL material away, to achieve an implant scaffold 
which was more porous but weaker. The scaffolds were implanted at 2 sites in 
a rabbit model (New Zealand White rabbits ~ 4kg each), subcutaneous (SC) 
and intramuscular (IM). At specific time points after 3 and 6 months, there 
rabbits were euthanised and scaffolds explanted. Results of this experiment 
indicated that these scaffolds do not elicit toxic nor inflammatory responses 
over 6 months, and there was little or no degradation of the polymer (even pre-
degraded ones) and composite scaffolds. This corroborates earlier findings that 
polyester degradation occurs mainly via hydrolysis in vivo [141]. It also 
revealed details of what happens during the dynamic polymer degradation and 
insights during the short-term degradation [217, 322].  
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4.1.2. Long-term In Vivo Degradation Study  
The long-term 2-year in vivo degradation evaluation was studied in a 
calvarial reconstruction procedure with critical-sized calvarial defects 
(∅15mm) in a rabbit model (New Zealand White rabbits ~ 4kg each). mPCL 
scaffolds disc (NaOH treated for 12 hours) were used.   Two rabbits with a 
total of 4 defects, 2 in each calvarium, were created and reconstructed with the 
scaffolds. Details are summarised in Table 4.1. After 2 years, the rabbits were 
euthanised and scaffolds explanted.  
All animal experiments were conducted with close adherence to the 
standard animal care protocols and regulations (eg. IACUC).   
Table 4.1. Scaffold groups and specifications for in vitro and in vivo 
degradation studies. 
 Composition Dimensions  n Time Site Remarks 
PCL 6.5×6.5×13.5mm3 6 Treated 72hrs 





mPCL/TCP(20%) 4×4×4mm3 5 
Up to 5 






mPCL ∅15×5 mm3 4 2 years Calvarium Treated 12hrs 
 
The following evaluation methods were used to study the degradation 
of the scaffolds and histological analysis: 
 
4.1.3. Mass Loss  
Before the start of the in vitro and in vivo degradation experiment, each 
individual scaffold was weighed using an electronic balance with a resolution 
of 0.1mg. Subsequently, when each scaffold was retrieved at the end of the 
Chapter 4 Scaffold Degradation: Long-term in vitro & in vivo 
 119 
experiment it was dried scaffold was again gravimetrically determined and 
mass loss determined. Mass loss is represented as a percentage, as follows. 
% Mass Loss = 100×−
Mi
MfMi     
where  Mf is the final mass 
Mi is the initial mass 
 
Tissue removal 
A method was devised for the removal of the tissue which filled the in 
vivo explanted scaffolds so the mass of the remaining scaffold material only 
could be accurately measured. Initial trials using enzymes proved to be 
inadequate and expensive. An oxidising agent was subsequently used and this 
method proved to be effective and efficient. The scaffolds were treated in 
10ml of undiluted Clorox® solution (5.25% solution of sodium hypochlorite, 
NaOCl) for 30minutes. An initial trial of soaking PCL scaffolds in Cholox® 
for 30 minutes and up to 72 hours was conducted, and it was observed that it 
had no apparent effect on the PCL material, in terms of the physical surface 
and texture, the mass, crystallinity and chemically (molecular weight). Whilst, 
20–30 minutes in Clorox® was sufficient for the removal of the integrated 
tissue. 
 
4.1.4. Scanning Electron Microscopy (SEM)  
Scaffold morphology and pore size were studied using scanning 
electron microscopy (SEM). Scaffold surfaces were gold-sputtered and 
observed using 15kV accelerating voltage (Phillips XL30 FEG). 
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4.1.5. Porosity 
Scaffold porosity is measured as a ratio of the true volume to the 
apparent volume. The true volume is the actual volume of material that makes 
up the scaffold, and there are several methods to measure or estimate this 
value. The apparent volume is the overall geometry volume. Thus, porosity is 
a scalar value that gives an estimated relationship of the volume of the scaffold 
or object. Porosity of the scaffolds, represented as a percentage, was calculated 
by the general formula. 
% Porosity, P = 
Va
VtVa )( −        
where Va = apparent volume 
          Vt = true volume 
 
A gas pycnometer (Accupyc 1330, Micromeritics Instrument Corp.) 
was used at 25°C in pure helium to determine the polymeric scaffold volume, 
Vt. The machine works by having the scaffold in a fixed volume chamber and 
fills it with helium (He), the equipment then calculates the volume of the 
scaffold through a series of gas purges and equilibriums. The apparent volume, 
Va, was calculated by the physical dimensions measured (eg. rectangular 
block). Five measurements were taken for each specimen and the mean used 
for porosity calculations. 
 
4.1.6. Mechanical Tests  
Mechanical compression tests were conducted on the in vitro scaffolds 
using an Instron 4302 Material Testing System operated by Series IX 
Automated Materials Tester v. 7.43 system software with a 1-kN load cell; in 
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accordance with the ASTM D695-96 guidelines. The specimens were 
compressed at a rate of 1mm/min up to a strain level of 0.6. 
For the in vivo scaffolds (6-months) an Instron 5548 Uni-axial Testing 
System (Micro Tester INSTRON 5848) with a 50N load cell was used. A 
sample size of n = 6, was tested for each group, along with non-implanted 
controls. The specimens were compressed at a rate of 1mm/min. Only non-
destructive micro-compression was carried out for the scaffolds.  
The stress-strain (σ - ε) curves were obtained to evaluate the 
compressive modulus (stiffness) and compressive yield stress (strength) for the 
in vitro scaffolds. Due to the small size, only compressive modulus was 
determined for the in vivo scaffolds. The compressive modulus was calculated 
from the stress–strain curve as the slope of the initial linear portion of the 
curve, with any toe region due to the initial settling of the specimen neglected. 
The compressive yield stress was taken at the yield point (if any) or at the end 
of the linear region.  
 
4.1.7. Differential Scanning Calorimetry (DSC)  
Thermal analyses, utilising differential scanning calorimetry (DSC), 
were conducted to study the thermal response of the materials and to 
determine the fractional crystallinity of the polymer. The heat-flux Pyris 6 
DSC from Perkin-Elmer was used with sample of 8-12mg held in standard 
aluminum pans and covers. The specimens were scanned from 20 to 80°C at a 
ramp rate of 5°C/min, using nitrogen as purge gas. The crystallinity fractions 
calculated were based on an enthalpy of fusion value of 139.5 J/g for 100% 
crystalline PCL [141].  
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4.1.8. Gel Permeation Chromatography (GPC)  
The average molecular weight of the PCL was determined by high 
performance liquid chromatography utilising a gel permeation 
chromatography (GPC) apparatus. Sections of the PCL scaffolds were cut and 
dissolved in tetrahydrofuran (THF) at a concentration of ≤0.1% (≤1mg/ml) 
and filtered through 0.2μm inorganic membrane filters. The polymer 
molecular weight distribution was determined using GPC equipped with a 
differential refractor (Waters 410) and an absorbance detector refractor 
(Waters 2690). The samples were eluted in a series of configurations through a 
Styragel column refractor at a flow rate of 1ml/min, using THF as the mobile 
phase. Polystyrene standards (Polysciences) were used to obtain a calibration 
curve. Both the weight average molecular weight (Mw) and number average 
molecular weight (Mn) were evaluated.  
 
4.1.9. Micro-computed tomography (μCT) 
Micro-computed tomography (SMX-100CT μCT scanner, Shimadzu, 
Japan) was used to analyse the scaffold-reconstructed calvaria retrieved. The 
calvaria were also scanned and analysed on a custom built µCT at the 
Australian National University [319, 320].  
 
4.1.10. Histological analysis 
The calvarial scaffolds (2-year) were fixed in 3.5% neutral buffered 
formaldehyde (Merck). Specimens were embedded in resin (PMMA) after 
dehydration in ascending concentrations of ethanol and xylene. They were 
then sectioned, prepared and stained using Macneal’s tetrachrome with von 
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kossa as a counter stain to detect mineralised bone. Using bright field 
microscopy, the sections were examined for cell type, morphology and tissue 
inflammation. Details of tissue formation and integration of tissue into the 
scaffold from the neighbouring tissue were also examined.  
 
4.1.11. Statistics 
Statistical analysis was performed on all the quantitative results using 
the Student’s t-test for comparing means from 2 independent sample groups. A 
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4.2. Results and Discussions  
4.2.1. In vitro Degradation Study  
The in vitro hydrolytic degradation of PCL, mPCL and mPCL/TCP 
scaffolds in PBS at 37°C was conducted for a long-term period of up to 60 
months. Though the PCL and mPCL-based scaffold dimensions were 
different, the degradation mechanism would essentially be the same   as the 
architecture and strut sizes remain the same.  
After up to 60 months in vitro degradation, the overall gross 
morphology of all the PCL and mPCL scaffolds, respectively, showed no 
visual differences compared to the day the experiment started. Upon closer 
examination of the physical surface characteristics (up to 12 months), the 
scaffold strut surface remained coarse due to the NaOH treatment but appeared 
defect free. However, at 26 and 41 months, the surface was slightly coarser 
and numerous micro-cracks had appeared (Figure 4.1). The micro-cracks 
observed on the mPCL and PCL scaffolds were not obvious due to the already 
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Figure 4.1. Gross morphology of in vitro degraded mPCL and PCL scaffolds 
observed by SEM. All samples degraded in PBS up to 41 months appeared 
visually no different from 0 months. (a) mPCL scaffold at start (×55; 0-
mths); (b and c) mPCL scaffolds after 26 months of degradation (×30 and 
×500, respectively); (d and f) PCL scaffolds at start (×64 and ×500, 
respectively; 0-mths); (e and g) PCL scaffolds after 41 months of 
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After 26 months and up to 45 months, the overall gross morphology of 
the mPCL/TCP scaffolds remained similar to the morphology at start. As the 
scaffolds were also NaOH treated, no obvious micro-cracks were observed on 
the surface (Figure 4.2c and e). However, numerous pits were observed on the 
strut surface, which were likely due to dissolution or erosion of the TCP 
particles (Figure 4.2c and e). At the fractured surfaces, large pits averaging 
100μm in size were observed in the scaffold struts which were likely due to 
the increased hydrolytic attacks at TCP sites. As water invades the polymer 
matrix it encounters the TCP particles dispersed within and this increases the 
interfacial surface area for hydrolysis, eventually the TCP would dissolve into 
solution. As a result, the hydrolytic attack of mPCL/TCP was considered to 
take place over a much larger surface area and volume with the presence of 
hydrophilic TCP. Although the regions of attack were possibly increased 
compared to a homopolymer PCL scaffold, nevertheless after all the TCP was 
uniformly distributed and eventually not interconnected, hence the separated 
pittings and caverns were observed (Figure 4.2d and f). As hypothesised, the 
TCP particles accelerated water diffusion into the polymer by physically 
acting as “conductors” and channels for water diffusion which enhances 
hydrolysis through its hydrophilic nature. The regions around the TCP would 
likely to be more amorphous, as TCP particles could obstruct crystallisation 
and resulted in smaller or thinner regions of crystalline lamellae more 
















Figure 4.2. Gross morphology of mPCL/TCP scaffold degraded in PBS 
observed by SEM. (a) mPCL/TCP scaffold at start (×55); (b & c) scaffolds 
after 26 months (×30 and ×200, respectively); (e and f) scaffolds after 45 
months (×100 and ×500, respectively). Scaffolds analysed beyond the 26 
months period revealed pores and pits formed on the strut surface, likely due 
to TCP dissolution and degradation, fusion joints remain intact; fractured 
surface of mPCL/TCP scaffold strut, as a result of handling the brittle 
scaffold, showed enhanced eroded (pitted) and degraded interior apparently 
result of susceptible polymer matrix due to TCP particle inclusions; but no 
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Good fusion of the struts at the surface was observed before the 
degradation commenced and throughout the degradation period. Closer 
examination of Figure 4.2 and Figure 4.3 (b and d) revealed the detachment of 
scaffolds parts was neither localised nor specific to the expected joints and 
stress concentration regions, such as the strut joints and layer interfaces. 
Indeed, from the SEM micrographs, it was observed that the breaking off 
regions and interface encompassed the whole fusion region with no distinction 
between struts of different layers. This demonstrates excellent union between 
the struts and layers from the fabrication process, which produced the scaffold 
like it was made out of one bulk material. Our previous reported results also 
showed that the well fused and integrated scaffold strut network would hold, 
through thinning and shrinking of the struts through aggressive surface 





























Figure 4.3. Excellent fusion of scaffold struts from the FDM fabrication 
process, broken struts and broken off scaffolds parts with an intact cross-
section even up to 60 months of in vitro PBS degradation. All fractured 
cross-section surfaces show no hollowed out struts and intact polymer 
matrix, indication bulk degradation mechanism with no autocatalysis. (a) 
PCL scaffold with excellent fusion between the layer interface (×200, 60-
mths); (b) scaffold periphery broken off but breaking off regions non-
specific to joint areas (×100, 41-mths); (c and d) PCL scaffolds with struts 
damaged or broken off during handling due to low molecular weight 
brittleness (×200, 41-mths). 
 
The averaged starting molecular weight of the fabricated scaffold were 
different, due to the different sources of commercial or medical grade 
materials used and the process and fabrication methods employed, with PCL ≈ 
80,000 (Mn); mPCL and mPCL/TCP ≈ 55,000 (Mn). The molecular weight of 
the mPCL, as received was analysed (GPC) to be about 70,000 (Mn), meaning 
the medical grade PCL material was more sensitive to the fabrication process 
than the research grade PCL material. However, the overall molecular weight 
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scaffolds (Figure 4.4). There was no bi-modal molecular weight distribution 
chromatogram detected indicating a bulk degradation mechanism. The average 
molecular weights of the PCL scaffolds fell to about 94% (Mw) and 93% (Mn) 
after 12 months. By 41 months, they were only about 13% (Mw) and 7% (Mn) 
of the initial molecular weights. It was observed both molecular weights 
decreased gradually in unison. The average molecular weights of the mPCL 
scaffolds were observed to decrease gradually to 40% (Mw) and 28% (Mn) 
after 26 months, while the mPCL/TCP scaffolds decreased to about 22% (Mw) 
and 15% (Mn). The graphical profiles of all the three scaffolds were similar, 
with the composite mPCL/TCP scaffold displaying the fastest rate of 
degradation. This indicates a slightly advanced degradation system for the 
composite scaffold. All the scaffolds retrieved after 26 months we observed to 
be more brittle when handled (compared to at the start of the experiment) 
which resulted in the some breaking off of the scaffold bits at the periphery. 
This extreme brittle outcome of the scaffolds can be explained by the drastic 
reduction of its molecular weights.  
 










































































Figure 4.4. Molecular weight (Mw and Mn) profile of in vitro PBS 
degraded PCL, mPCL and mPCL/TCP scaffolds over time. 
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The overall rate of mass loss (erosion) was extremely slow (Figure 
4.5), mPCL scaffolds have lost an average of 12.2% after 45 months while the 
PCL scaffolds lost about 18.4% at 60 months. The composite mPCL/TCP 
scaffolds also exhibited an extremely slow mass loss rate; it lost about 12% of 
mass after 45 months. Its mass loss trend mimicked that of the treated PCL 
scaffolds closely. The mass loss profile of the mPCL group (and the untreated 
PCL scaffolds in an earlier study, [217, 322]) proceeded gradually, whereas 
the treated PCL group and composite mPCL/TCP group exhibited mass loss 
spike from 0 to 3 months, then a similar gradual behaviour thereafter (Figure 
4.5). The spike could possibly be due to the intense NaOH treatment (up to 72 
hours), increased the surface area and producing a large amount cleaved 
polymer chains and exposed oligomers on the surface which was easily and 
quickly hydrolysed and eroded during the early 3 months, while similar could 
have occurred with the composite mPCL/TCP group, in addition dissolution of 
TCP could also have contributed to the mass loss.  
With TCP in the polymer matrix, the hydrophilic bioceramic allowed 
the PBS to infuse and hydrolyse the polymer matrix much faster initially. The 
region around the TCP would likely to be more amorphous as TCP particles 
could obstruct crystallisation and result in smaller or thinner regions of 
crystalline lamellae. Although throughout the degradation period the melting 
temperature of mPCL/TCP was constant around 62°C, it was slightly lower 
than PCL (65°C), this could indicate less “perfect” crystallisation [37]. At later 
time points, numerous pittings were observed on the mPCL/TCP composite 
scaffolds only, which were likely due to these more amorphous regions 
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brought about by incorporation of TCP (Figure 4.2). Additionally, the 
disintegration of TCP could escalate the initial mass loss as well. 
After removal of those susceptible chains or TCP particles, the rate of 
mass loss was the similar thereafter for both groups. Although treated 
differently (varied NaOH treatment times) and with the incorporation of 
20%wt TCP, the overall mass loss profile of all the scaffold groups proceeded 
very closely, since bulk of the matrix material, PCL, remains firmly integrated. 
A more intense pre-treatment regime or inclusion of a hydrophilic bioceramic 
means does not significantly influence the other physical and chemical 
attributes.  
All the scaffolds groups exhibited an initial gradual mass loss and an 
increased rate after about 40 months, one possible reason is due to the loss of 
fragments of the brittle scaffold falling off observed for all the samples.  
 



































Figure 4.5. Mass loss profile of in vitro PBS degraded PCL, mPCL and 
mPCL/TCP scaffolds over time. 
 
 
As discussed in Chapter 2, polymer degradation is a chemical reaction 
which entails the reduction of molecular weight. For bulk degrading polymers, 
if the diffusion-reaction equilibrium was tipped, internal autocatalysis may 
result, leading to a catastrophic rapid production and release of low molecular 
weight acidic by-products [284, 285, 289, 291, 294]. Once either occurs, 
adverse tissue reactions and inflammation in vivo could result [297-299]. In 
the end, a higher molecular weight hollowed-out structure would remain.  
From this study, the molecular weights of the PCL-based scaffolds 
were observed to decline gradually by up to 93% (Mn) of the original 
molecular weights, while mass loss was only less than 19%. This clearly 
indicates bulk degrading kinetics for the PCL-based scaffolds. Although, the 
PCL scaffolds degraded via the bulk degradation pathway there were no 
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obvious evidence of internal autocatalysis. This was evident from the mono-
modal GPC chromatograms observed and tabulated into molecular weight 
results (Figure 4.4) and the resulting intact cross-section of the scaffold struts 
(Figure 4.3), no hollowed out structure was detected throughout the long-term 
degradation period. This is well attributed to the dimensions and chemistry of 
the PCL-based scaffolds. Having thin structures, about 500µm in contrast to 
devices with millimetre dimensions, the diffusion mechanisms were not 
hindered, also PCL has a relatively hydrophobic chemical structure making it 
very slow to hydrolyse, slow to produce acidic by-products [130, 291]. Thus, 
generally they are endured very well in vivo or in the clinics in the long run 
[38, 39].  
Shih (1995) found that the hydrolysis of poly (D,L-lactide) (PDLLA) 
was not random under acidic conditions, rather the rate of chain-end scission 
was 10-fold faster than the rate of random scission of the internal chain bonds, 
while PCL samples instead, just underwent random hydrolytic scission. 
Enhancing the rate of reaction (degradation) would also tip the diffusion-
reaction equilibrium and autocatalytic hydrolysis is likely to result and 
develop when ester hydrolysis occurring at the chain-ends (one or both) is 
faster than the internal random ester bonds [295]. The main culprit for 
autocatalytic hydrolysis is the carboxylic acid end group and exponentially 
multiplies if chain scission was selective of the chain-ends. This difference 
between the PDLLA and PCL results were likely attributed the distance 
between functional groups, such that the distance of the carbonyl and alkoxyl 
was shorter in PDLLA than the functional groups of PCL. Therefore with 
generation of the hydroxyl groups and especially the acid groups from the first 
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degradation steps were enhanced which accelerates the later hydrolysis 
reactions.  
The starting compressive modulus of the PCL scaffolds was 2.5MPa 
and yield strength stress was 0.8MPa. While the mPCL and mPCL/TCP had a 
compressive modulus of 28MPa and 190MPa, respectively; and yield stress of 
6.9PMa and 5.1MPa, respectively. The compressive modulus of the medical 
grade mPCL and mPCL/TCP scaffolds decreased over time to about 12MPa 
and 60MPa after 45 months, respectively. The modulus of the PCL scaffolds 
was observed have increased and peak at about 6MPa (250% increase) after 41 
months and decline to 5MPa after 60 months. Again, this shows behaviour of 
the different source materials of the PCL; in terms of scaffold and material 
strength, determined by the strength of the material molecules, behaves very 
similarly. The yield stress (strength) of mPCL and mPCL/TCP scaffolds was 
maintained initially and after 6 months starts to decline to about 10% 
(0.7MPa) and 50% (2.7MPa) of the initial strength after 26 months, 
respectively; and reaching 2% (0.1MPa) and 20% (1.0MPa), respectively at 
the end of 45 months. The yield stress of the PCL scaffolds was observed to 
increase slightly to 136% (1.1MPa) over the initial periods of 12 months but 
decrease thereafter to 13% (0.1MPa), after 5 years. 
The mean compressive modulus (stiffness) and yield stress (yield 
strength) of the scaffolds are presented in Figure 4.6 and Figure 4.7. 
 


































Figure 4.6. Compressive modulus profile of PCL, mPCL and mPCL/TCP 



































Figure 4.7. Yield stress profile of PCL, mPCL and mPCL/TCP scaffolds 
throughout the in vitro PBS degradation period. 
 
The scaffold fabrication process did not alter much of the polymer’s 
chemical and physical properties, the PCL scaffolds at the start of the 
experiment sturdy were robust constructs while still retaining certain rigidity 
combined with elasticity. However, after 26 months, the whole scaffold 
structure was brittle as revealed from the stress-strain profile during the 
compressive loadings and handling for SEM observations, the scaffolds 
crumbled easily into fragments once a small force was applied.  
There is not specific written definition for “brittleness”. It is a relative 
behaviour and characteristic as opposed to ductility (elasticity) when 
compared to similar classes of materials or materials for similar applications, 
much like “hot and cold”. However, classical and universal understanding of 
brittle materials, like ceramics and glasses, does not experience any plastic 
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deformation and will fracture under relatively low stress. Generally, brittle 
materials and phases are composed short molecules and small grain sizes, 
which being reason the molecules are unable to absorb minimal loads (energy) 
and fail through brittle fracture (including rupture as the result of crack 
propagation). 
This resultant brittleness after about 2 years, could be attributed to the 
random hydrolysis which reduced the entire molecular weight of the polymer, 
thus the polymer matrix is only composed of short chain fragments [141]. Low 
molecular weight polymers are usually more brittle than high molecular 
weight polymers, as the longer and elastic polymer chains can easily stretch 
and slide over one another to allow the polymer to deform and stretch under 
load therefore possessing better plasticity/ductility, absorbing much of the 
deformation loads. Short chains simple deform under the applied loads and are 
like multiple defects which are susceptible to failure by brittle-fracture, they 
break or crumble due to their inability to support and interlock adequately with 
each and fail when the material is loaded. The brittleness of the scaffold was 
also experienced during the handling of the scaffold while drying and 
preparing for the SEM viewing. Some of the scaffold struts at the periphery 
were broken off during handling and manipulation of the samples during 
preparation for SEM examinations (Figure 4.2f and Figure 4.3).  
The different scaffolds groups, due to their different material sources 
and processing conditions, started with slightly different crystallinity 
measurements; PCL group about 66%, mPCL group about 70% and 
mPCL/TCP lowest at about 61%.  The mean crystallinity of mPCL and 
mPCL/TCP scaffolds were observed to decrease gradually from the start but 
Chapter 4 Scaffold Degradation: Long-term in vitro & in vivo 
 140 
increases approximately after 26 months peaking at about 37 (95%) and 45 
(87%) months, respectively. the crystallinity of mPCL and mPCL/TCP 
scaffolds whereas the PCL scaffolds were observed to increase slightly after 3 
months then decreasing slightly after 41 months before increasing to about 
96% after 60 months (Figure 4.8). There seemed to be a critical molecular 
weight reached after 26 months which enabled the remaining polymer to 
recrystallise more rapidly, that is estimated to be about 35, 000 – 50, 000 
(Mw), from this study.   
The micro-sized TCP particles was know to obstruct crystallisation of 
the polymer chains and thus with TCP distributed within the composite 
scaffold has the lowest starting crystallinity. Throughout the degradation 
period the melting temperature of mPCL/TCP was constant around 62°C, it 
was slightly lower than PCL (65°C), this could indicate less “perfect” 
crystallisation [37]. The region around the TCP would likely to be more 
amorphous and resulted in smaller or thinner regions of crystalline lamellae. 
Perhaps these thinner regions of crystalline lamellae were also preferentially 
hydrolysed together with amorphous regions resulting in a more rapid 
decrease in crystallinity for the composite scaffold, up to 6 months. After 
which, the overall crystallinity appeared to increase, possibly after the initial 
amorphous regions were eliminated and certain hydrolysed polymer chains 
start to recrystallise. This fluctuation demonstrates the dynamics of a 
polymeric material (chains) property over time.  
As the polymer chains strive for a lowered thermodynamic energy 
balance, environment temperature (of 37°C) was sufficient to enabled the 
chain mobility to achieve a lower energy level [217]. Continued hydrolysis of 
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polymer chains further increased its chances of crystallisation by reducing the 
length of each chain and therefore increasing their mobility. The PCL and 
mPCL groups, which were hydrolysed slower also, exhibited a slower 
crystalline increase. The slow degrading kinetics of PCL is primarily due to its 
chemical function groups, crystallinity and molecular weight. It is recognised 
that hydrolysis of PCL is considerable slower than the polyesters (eg. PGA 
and PLA) because of its crystallinity and high olefinic character; particularly 
its chemical structure of five methylene groups which confers a hydrophobic 



































Figure 4.8. Crystallinity behaviour of PCL, mPCL and mPCL/TCP scaffolds 
throughout the in vitro degradation period.  
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In conclusion, based on the in vitro degradation studies, the 
degradation and molecular weight reduction profile of the mPCL and 
composite mPCL/TCP scaffolds were almost parallel; the notable difference 
with the mPCL/TCP was the enhanced the rate of hydrolysis by about 10-20% 
(based on Mw and Mn). Generally, on the sub-micro and micro scale, the 
20%wt TCP incorporation resulted in a “weaker”, less intact, less crystalline 
and more hydrophilic material matrix which resulted in enhanced water 
absorption and mass loss, faster reduction in crystalline phases and creation of 
caverns within the polymer matrix. On the functional and macro scale, the 
composite scaffold did exhibit enhanced mechanical properties initially and 
maintained superior yield strength and a higher compressive modulus 
compared to the mPCL scaffolds even after 45 months; despite the enhanced 
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4.2.2. In vivo Degradation Studies in a Calvarial Defect (2 years) 
The long-term influence and effects of in vivo degradation were 
studied with mPCL scaffolds of ∅15×5mm implanted into critical sized 
defects in the rabbit calvarial. After 2 years the rabbits were sacrificed and the 
scaffolds retrieved. The calvaria were trimmed to size and scanned on a 
custom built µCT [319, 320].  
Upon explantation, the mPCL scaffolds were observed to be still in 
place and intact after 2 years, similar to findings from the in vitro PBS study. 
No fibrous encapsulation was observed in all the samples. Closer examination 
revealed that neo-calcified regions had replaced some regions of the mPCL 
scaffold from the both top and the scaffold (Figure 4.9a). Imaging analysis 
using the µCT proved to reveal more valuable information compared to 
histology. It was observed that the mineralised regions were of high density 
similar to the surround bone. The calcified regions in the scaffold not only 
invaded the scaffold pore spaces, viewed as the complementary architecture of 
the scaffolds but some regions completely replaced the scaffold struts (Figure 
4.9b). Figure 4.10 shows the µCT scan and reconstruction of the same defect 
as Figure 4.9b, top orientation of the left calvaria. Both have similar details 
and defined resolution, however, the customised algorithm enabled us a finer 
resolution and differentiation the soft tissue regions.  
For this specimen (Figure 4.9), it could clearly be observed that 
calcification occurred mainly from the bottom on the right defect site and 
calcified from the bottom on the left defect site. Histology section only reveal 
limited information as it is dependent on how and location where the sections 
were derived. However, it concurred with µCT results indicating presence of 
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new mineralised tissue within the scaffolds (Figure 4.11). These preliminary 
results confirm the efficiency and efficacy of the PCL scaffold to regenerate 
critical size defects of the skull. 
Degradation analysis of mPCL scaffolds (2 years) revealed moderate 
molecular weight loss supporting slow degradation of the mPCL material and 
late molecular weight decrease. At 2 years, molecular weight had decreased by 
63% (Mw) and 74% (Mn). These in vivo degradation results match molecular 
weight loss profiles of the earlier two sections, reinforcing the reality that in 
vivo degradation of PCL scaffolds (or devices) proceeds chiefly via bulk 
hydrolysis, and biological aspects (cells and micro-organisms) played a 
minimal role.  The crystallinity decreased about 4%.  
It was observed that PCL scaffolds degraded in vitro in PBS had a 
similar mass loss rate with the in vivo PCL. This suggests that the biological 
environment and cells could have minimal or no effect. Literature has 
suggested in vitro and in vivo study of PCL for drug-delivery systems, had two 
similar degradation rates and concluded that physiological enzymatic 
involvement was not a significant factor [141, 325]. It was observed that the 
chain scission of PCL was not accompanied by the loss of low molecular 
weight PCL fragments until the molecular weight (Mn) had decreased to 
around 5000. Similarly, in vivo studies with rats reported that PCL degradation 
first proceeded with non-enzymatic bulk hydrolysis and a transient initial 
inflammatory response occurred only for the first 2 weeks. After 9 months, 
only when the molecular weight had reduced to about 5000, did a loss in mass 
emerge, and subsequently the PCL fragmented. Concurrent intracellular 
degradation of low molecular weight PCL (Mn 3000) powders of 53-500 μm, 
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reported rapid degradation and absorption within 13 days inside the 
phagosomes of macrophage and giant cells. The sole metabolite was ε–
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         Soft tissue / PCL scaffold           ●           Bone within defect region 
 
Figure 4.9. Gross overview and µCT analysis of the same rabbit calvarial 
explanted after 2 years in a calvarial defect. (a) Gross overview of explanted rabbit 
calvarial. Implanted scaffolds observed to be intact with portions being replaced 
by calcified matrix. (b) Micro-CT images of rabbit calvarial with scaffolds in the 
defect. Some calcified (high density) regions had taken up the complementary 
architecture of the scaffolds while some regions of the scaffold were completely 
replaced by the calcified matrix. From this specimen, calcification invaded mainly 
from the bottom of the right defect and from the top of the left defect. 
 
   
Figure 4.10. Images from 
the Shimadzu µCT, left 
calvarial.  
Figure 4.11. Resin embedded histological section 
of rabbit calvaria. Magnified images show the left 
calvaria defect, structure of new ingrown bone 
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In conclusion, the long-term in vivo degradation study, degradation of 
PCL-based scaffolds occurred primarily via hydrolysis. After losing more than 
60% of the initial molecular weight, there was not adverse tissue pathology 
observed from the implant site after 2 years. Also, bone was able to be 
conducted and repaired the defect partially, while the scaffold provides 
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4.2.3. Conclusions  
The main advantage of using bioresorbable scaffold systems is their 
bioresorbability, the eventual elimination of implanted foreign material. This 
chapter has highlighted, that as the material is degrading and being resorbed 
away, the polymeric degradation is a “dynamic” process which polymer chains 
are being cleaved and re-organised simultaneously, this is critical, as stability 
of support will hinge on this as the polymer degrades and micro structure 
changes; just as the remodeling of bone occurs – mineralisation and resorption 
of bone. Degradation entails a complex process than just ‘elimination’, 
crystallinity and molecular weight changes are “dynamic” which will affect 
the eventual rate of degradation, discharge of acidic by-products, stiffness 
changes and participation of intracellular degradation, the eventual metabolism 
of the polymer. Also, critical design considerations would prevent catastrophic 
autocatalysis which accelerates the release of acidic by-products. It has been 
demonstrated that the scaffold system is stable, mechanically adaptive, capable 
and safe of being used at a bone engineering scaffold in a minimal load-
bearing system. The degradation mechanisms and profile of the PCL and PCL-
based scaffolds, thus far, can be predicted reliably in a “low load” 
environment. However, the scaffold system alone is no osteoinductive and is 
only nominally osteoconductive; making the strategy of using the scaffold 
alone for large and complex defects a major challenge; despite having found 
success with “simple” defects [38, 39]. 
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CHAPTER 5 
5. PERFORMANCE OF MPCL/TCP SCAFFOLD SYSTEM IN A 
SMALL ANIMAL MODEL  
 
The proof of concept, for the effective scaffold system delivery of 
rhBMP-2, for the bone engineering approach would be evaluated via the 
calvarial reconstruction of a critical-sized rat cranial defect, with and without 
growth factors (rhBMP-2). The key objectives are to assess its feasibility and 
performance when incorporated as a part of a tissue engineering strategy. The 
calvarial defect is an uncomplicated low load-bearing defect suitable for 
evaluating bone engineering scaffolds [39, 41]. As appreciated from Chapter 
4, the mPCL/TCP alone has limited osteoconductive capabilities, and would 
be necessary to incorporate cells or growth factors to enhance its osteogenic 
potential, in order to repair a bone defect within an optimum time. The 
performance of the mPCL/TCP scaffolds used on its own would be tested 
alongside rhBMP-2 loaded ones. RhBMP-2 was selected as it is already a 
commercially available FDA approved growth factor in clinical bone 
regeneration and for its potency in osteoinduction [34, 58, 62].  
 
5.1. Experimental Setup: Materials and Methods   
5.1.1. In Vivo Calvarial Defect  
Experiments were designed to investigate the efficacy of using the 
mPCL/TCP scaffold system for bone regeneration and repair in a small animal 
model. mPCL/TCP scaffold sheets of 1mm thick were purchased from 
Osteopore International (0-90° lay-down pattern and 70% porosity). Details of 
the fabrication of the rapid prototyped scaffold were described in principle in 
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Chapter 2 and prior reports [36, 37, 162]. ∅5×1mm scaffold discs were 
punched from the sheets using a biopsy punch, they were then pre-treated with 
5M NaOH for 3h, rinsed with sterile PBS and sterilised in 70% ethanol for 1h, 
then dried for storage. Collagen type I (rat-tail; 5 mg/ml, Sigma) was 
lyophilised onto the scaffold discs, and further sterilised with UV for 20min. 
Five micrograms of rhBMP-2 (R&D Systems) was loaded onto each collagen-
lyophilised disc prior to surgery (Figure 5.1). Sterile saline (5µg), as control, 
was loaded onto the control collagen-lyophilised mPCL/TCP scaffolds instead 
(Figure 5.2). 
Two bilateral trephinated critical-sized calvarial defects were created in 
a total of 45 Wistar rats (~12wk old, 250–300g), without irrigation permitting 
for heat damage to the neighbouring bone but without damaging the dura. 
Defects were randomly implanted with the rhBMP-2 loaded scaffolds, control 
scaffolds or left empty (Figure 5.2). At specified time points (4 and 15 weeks), 
the rats were euthanised and calvaria retrieved for evaluations. 
All animal experiments were conducted with adherence to the standard 
animal care protocols and regulations (eg. IACUC). The following methods 
were used to evaluate the performance of the calvarial reconstruction:  
 
5.1.2. Micro-computed tomography (μCT) 
Micro-computed tomography (Skyscan 1076) was used to analyse the 
scaffold-reconstructed calvaria retrieved. The scan image slices were and 
visualised as a three-dimensional (3D) model and calculation base on density 
(Hounsfield) were performed in Mimics (Materialize). Total bone volume 
regenerated was quantified from the calvarial defects (n=5) for each group at 
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both 4 and 15 weeks. The quantification method was performed by optimising 
a threshold value for the bone (neo-bone and older host bone) to be optimally 
presented with definitive structural sharpness and minimal artifacts and noise, 
it would exclude the scaffold material, which from experience is close to soft 
tissue. Next, a circular disc-shaped mask of ∅5 was created; this was fitted to 
µCT scan data of the rat calvaria and acquired the bone volume from the top of 
the cranium to the bottom, calculating the total bone volume through each 
pixel layer.  
 
5.1.3. Mechanical Tests  
Immediately after euthanasia, the rat calvaria were retrieved, wrapped 
in wet gauze and stored at -20°C until tests. Upon thawing, the calvaria were 
potted in a petri dish using the Meliodent Rapid Repair 
polymethylmethacrylate (Heraeus Kulzer) to enable stabilisation for 
mechanical testing (Figure 5.4). Non-destructive micro-compression was 
performed with a micro-fabricated indenter probe of ∅0.5mm using the 
Micro-Tester 5848 and a 10-N load cell (Instron). Micro-compressions of up 
to 50% strain were conducted at an average of eight different locations (n=8) 
on each defect site. The resistance to the probe force (stiffness) and depth 
deformed was calculated as the compression modulus of the neo-tissue. The 
probe locations were identified to be the pore spaces (between the scaffold 
struts) of the constructs so as to measure the modulus of regenerated tissue 
rather than scaffold material (Figure 5.5).  
After the micro-compression tests, push-out tests were conducted to 
evaluate the functional integration of the tissue-engineered constructs into the 
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host calvaria, and were performed on the Micro-Tester 5848 (Instron) with a 
1-kN load cell [41, 326, 327]. An indenter probe of ∅4.5mm was used and the 
specimens were tested to failure - defined when fracture was detected or when 
the scaffold “pop” out of the defect site (Figure 5.6). Four to eight specimens 
were used for each group at each time point, while intact rat calvaria were 
used as controls. 
Statistical analysis was performed on all the quantitative results using 
the Student’s t-test for comparing means from 2 independent sample groups. A 
confidence level of 95% was used with results considered significant at p < 
0.05. 
 
5.1.4. Histological analysis   
The calvaria were fixed in 3.5% neutral buffered formaldehyde and 
decalcified in 15% EDTA for 3 weeks. After dehydration, the calvaria were 
embedded in paraffin and histological sections were prepared by haematoxylin 
and eosin (H&E) staining. Using bright field microscopy, the sections were 
examined for regenerated tissue morphology and inflammation. Details of 
tissue formation and integration of tissue into the scaffold from the 
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5.2. Results and Discussions  
The efficacy of the composite mPCL/TCP scaffold system in 
conjunction with and without rhBMP-2, to enhance and accelerate effective 
bone regeneration was evaluated over 15 weeks in a rat calvarial model. This 
current scaffold system adopted a cell-free approach, which essentially utilises 
a combination of two commercially, off the shelf and readily available 
products.   
Upon explantation, neither fibrous encapsulation nor any signs of 
inflammation was detected at the reconstructed site. Closer gross examination 
revealed neo-calcified regions at the site of rhBMP-2 repaired defects while 
the scaffold alone and empty defects were observed to be covered only with 





















Figure 5.1. mPCL/TCP scaffold disc 
(∅5×1mm) before and after 
lyophilisation with collagen. 
 
 
 Figure 5.2. mPCL/TCP scaffolds 





Figure 5.3.  Rat calvarial after 15 
weeks, empty defect (left) and 
scaffold loaded rhBMP-2 defect 
(right). Doted circle indicate possible 




Figure 5.4 Rat calvaria (4 weeks) 
potted in polymethylmethacrylate 





Figure 5.5. Rat calvarial undergoing 
micro-compression tests with a 
∅0.5mm probe. 
Figure 5.6 Rat calvarial undergoing 
push-out tests with a ∅4.5mm 
indenter. 
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The rat calvaria were then radiologically analysed and visualised on 
Mimics, where 3D models could be created from the µCT data and 
quantification made base on density values (Hounsfield). 3D visualisation 
showed the healing of the calvaria defect over the experiment period. Empty 
defects and the scaffold group remain unclosed with minor bone ingrowth 
from the periphery, bone mineralisation and regeneration was more 
pronounced in the scaffold group; while the rh-BMP-2 group had greatest 
bone apposition and most defects were closed by 15 weeks (Figure 5.7).  The 
regenerated bone volume within the defect was quantified by µCT and 
revealed that at both 4 and 15 weeks, the rhBMP-2 loaded scaffolds 
encouraged more (statistically significant) bone mineralisation (16 and 
24mm3) as compared to scaffolds alone (11 and 17mm3) or empty defects (7 
and 12mm3), respectively (Figure 5.8). Based on this quantitation method, its 
seems treating the defects with scaffold system loaded with rhBMP-2 
produced double the volume of bone compared to untreated defects, 
effectively closing the defect after 15 weeks. While, it also produced about 1.5 
times more bone volume when treated with the scaffold system with “limited 
osteoconductivity” alone.  
Based on the bone-inducing capabilities of rhBMP-2, one would 
expect the potency of rhBMP-2 to induce more bone formation. However, the 
formation of neo-bone should not be in an uncontrolled and overwhelming 
manner. Examination of the amount of bone formed relative to the scaffold 
volume (disc-shaped volume, ~20mm3), revealed that the rhBMP-2 has 
formed about 81% after 4 weeks and about 125% after 15 weeks (Figure 5.9). 
Taken together with the gross overview of the explanted calvarial and 
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histological sections (Figure 5.10), the rhBMP-2 stimulated bone formation 
beyond the theoretical boundaries of the scaffold system; but not in an 
uncontrolled manner; rather it was guided by the structure of the scaffold 
system and had taken up all available interconnected pore spaces.  
 






























Figure 5.7. Reconstructed 3D models of the rat calvaria visualised in 
Mimics. Empty: Defect site with some bone ingrowth at the ream at 15 
weeks. Scaffold: Evidence of some bone ingrowth at 4 weeks and more 
significant bone ingrowth into the implanted scaffold and repair of the 
defect site at 15 weeks. rhBMP-2: Strong manifestation of bone 
regeneration at 4 weeks, while some samples showed complete closure 
of the defect sire at 15 weeks. 




























Figure 5.8. Bone volume quantification within scaffold by µCT using Mimics. 
The rhBMP-2 treatment showed greatest (* p<0.05) bone volume than the other 
2 treatment methods at both time points; while between time points, only the 



























Figure 5.9. Bone volume within defect site, expressed in percentage relative to 
scaffold volume. The empty defect only filled 61% of the relative scaffold 
volume, while the scaffold group 86%, after 15 weeks. The relative bone 
volume of the rhBMP-2 group filled 125%, beyond the scaffold volume.  
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Histological sections revealed bridging of rhBMP-2 treated defect at 4 
weeks by dense woven mineralised bone and near closure at 15 weeks by 
lamellar-like bone structures (Figure 5.10). For the scaffold alone group, only 
marginal bone infiltration at the periphery and minimal or no bone 
regeneration from the empty defect, both were mainly filled with membranous 
and fibrous tissue. The neo-tissue, whether it is fibrous (scaffold) or newly 
regenerated bone (rhBMP-2), was formed directly adjacent to the scaffold 
struts indicating excellent tissue and osteo-integration with the composite 
scaffold system. This also demonstrates the bioactivity of the mPCL/TCP 
material which was allowed bone to bone directly with it [112]. The empty 
defects remained primarily empty throughout the study, demonstrating they 
were of critical size (within the time frame of the study). No inflammatory 
cells or tissue were detected. The histological quantitation data concur with 
µCT findings, indicating µCT as a useful and powerful tool for evaluating 
mineralised bone. Many reports have also found µCT analysis to be 
indispensible, being able to analyse 3D spatial distributions in a non-
destructive manner with easier and more accurate quantification methods, 
along with minimised background noises, when compared to the use of stains 
to mark mineralised regions [180, 273, 328].  
The scaffold structure and struts were clearly observed at both time 
points, as anticipated of the degradation profile of the scaffold system. 
However, at 15 weeks in the rhBMP-2 repaired defect, more pronounced and 
“aggressive” bone regeneration took place, the scaffold struts were observed to 
be distorted and fragmented. This could well be the compelling dynamics of 
the vigorous bone remodeling process. It was also the only group which had a 
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more matured tissue phenotype of lamellar bone structure, as a result of 
rhBMP-2 induction which was concurred by others [273].    
 























Figure 5.10. Histological sections (H&E stained) of rat calvaria at 4 and 15 
weeks. Empty: The empty defect remained unclosed and was full of fibrous 
tissue at both time points, only some bone ingrowth at the reams were 
observed. Scaffold: The scaffold reconstructed defect shows presence of the 
scaffold and was mainly filled with fibrous tissue. At both time points, 
defects remained unabridged. rhBMP-2: Dense woven bone tissue was 
detected to fill the scaffold at 4 weeks, more intense (denser) lamellar-like 
tissue was observed in the defect site at 15 weeks. Scaffold struts and 
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The tissue, particularly mineralised tissue, within the reconstructed 
calvaria was tested by a micro-compression protocol for its mechanical 
response (compressive modulus) and the effective calvarial reconstruction was 
tested by push-out tests to evaluate the integration of the scaffold system to the 
host tissue. Un-operated rat calvaria were used as controls. The micro-
compressions would reveal much of how tissue was formed and strengthened 
within the scaffold pores (Figure 5.11). The data has to be interpreted 
carefully, as the micro-compression protocol only probe the surface (~500µm 
into the scaffold) of the neo-tissue, and any response would mean a well 
anchored tissue (mineralised or otherwise) that is able to impart significant 
resistance to the deformation force by the probe. Thus, an effective 
interpretation would be “functional support” at the surface that the neo-tissues 
possess while being integrated to the scaffold (or host bone). Probed values of 
the native bone on the calvaria, scaffold struts (mPCL/TCP material) and soft 
tissues were also included for reference and comparison.  
Empty defects without scaffold repair showed the lowest stiffness at 4 
weeks and moderate stiffness (with high standard deviation) of about 20MPa 
at 15 weeks. The scaffold group exhibited similar mean compressive modulus 
at both time points at about 30MPa. The rhBMP-2 group demonstrated the 
highest mean modulus at both time points, at about 38MPa and 77MPa, for 4 
and 15 weeks, respectively.  From the results, we observe that at 4 weeks, 
there was no difference in neo-tissue resistance, in terms of compressive 
modulus values, between scaffold and rhBMP-2 groups. However, at 15 
weeks, the rhBMP-2 group (77MPa) was significantly stiffer (stiffer neo-tissue 
structure with good integration) than scaffold group which remained around 
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30MPa, but still not as stiff as native bone. The tested compressive modulus 
(stiffness) of normal bone (positive control), stiffness of the struts and soft 
tissue were also incorporated in the graph for comparison.  
The push-out test would determine how well attached and integrated 
the implanted scaffold system is to the host bone. The test was conducted, with 
a ∅4.5mm indenter probe placed directed on the scaffold construct, until 
fracture of bone (sudden drop in load from the applied indenter); this would 
signify that the weakest portion of the calvaria or bone-scaffold construct has 
given way, and the force measurements recorded (Figure 5.12). Usually, this 
would be the host bone-scaffold interface, but in the rhBMP-2 group, some 
instances bone was also broken off from the host bone as well. At 4 weeks, 
integration strength of scaffold alone group was similar to the resistance from 
the periphery bony ingrowth of the empty defects. In contrast, the rhBMP-2 
group has displayed, at this early time point, firm integration resistance similar 
to native bone (no significant difference). At 15 weeks, the 2 groups repaired 
with the scaffold system without and with rhBMP-2 were comparable to host 
bone (no significant difference). This indicates adequate repair of the calvarial 
by the scaffold system without rhBMP-2, although histologically, minimal 
osseous tissue reside within (Figure 5.10) and the neo-tissue probably lack 
functional attachment and integration to the scaffold struts, results concurred 
by µCT analyses (Figure 5.7). Both the scaffold system truly achieved 
excellent integration with the host bone, but clearly only one group achieved 
closure of the defect site within 15 weeks with mature bone (Figure 5.7).  
 
 


































Figure 5.11. Micro-compression analysis reveals the neo-tissue resistance to 
external deformation and also the integration to the surrounding anchorage 
points, such as the scaffold struts and host bone. The limitation of the 
experiment was that it only tested the tissues at the surface level (~500µm) 
within the pore of the scaffold. Empty defects without scaffold repair showed 
the lowest stiffness at 4 weeks and moderate stiffness (with high standard 
deviation) of about 20MPa at 15 weeks. The scaffold group exhibited similar 
mean compressive modulus at both time points at about 30MPa. The rhBMP-2 
group demonstrated the highest mean modulus at both time points, at about 
38MPa and 77MPa, for 4 and 15 weeks, respectively. The tested compressive 
modulus (stiffness) of normal bone (positive material control, stiffness of the 
struts and soft tissue were also incorporated in the graph for comparison. 







































Figure 5.12. Push-out test conducted to determine the force required to fracture 
or “push-out” the host-scaffold construct. At 4 weeks, the rhBMP-2 and native 
bone were significantly more resistant than scaffold and empty defect (# p < 
0.05). While after 15 weeks, the 2 groups repaired with the scaffold system 
without and with rhBMP-2 show no difference compared to the native bone (*p 
< 0.05). 
 
Orthopaedic and bone defects, including craniofacial defects, may exist 
as complex three-dimensional (3D) anatomic defects for bone grafts or 
alternatives to fill. Thus, in order to fabricate a bone tissue engineering 
scaffold system to fit and fill such a defect, the present state of art is to exploit 
modern technologies, such as medical scan information (MRI or CT) to 
acquire the anatomical features for processing, a design software to devise the 
design and a fabrication system able to construct the required scaffold system 
with the appropriate biomaterials [30, 41, 329]. Computer controlled design 
and fabrication techniques using the rapid prototyping technology not only 
enables complex geometries to be fabricated but also the interior scaffold 
Chapter 5 Performance of mPCL/TCP Scaffold System in a Small Animal Model 
 
 163 
architecture and pore-size to be accurately produced. In this experiment, the 
design of the scaffold was built for high porosity and low load-bearing 
requirements. Despite the fact that, for a scaffold system, the mechanical 
strength and compressive modulus is inversely related to its porosity and pore-
size, the design can be optimised toward the application. A high 
interconnected porosity and large pore-size to enable optimised quantities of 
growth factors to be carried and delivered, and maximal pore space to 
facilitate neo-tissue ingrowth with sufficient tissue-guiding ability. 
Additionally, minimising the quantity of foreign biomaterial required to be 
implanted in vivo and resorbed. Altogether, the scaffold system should also 
possess the adequate mechanical support for the calvarial defect; by 
preventing collapse of muscle, soft tissue and skin, and maintaining the form 
and aesthetics of the patient [29, 38].  
Traditional preferred clinical bone grafts used were autografts and 
allografts (especially demineralised bone matrix (DBM)), these materials were 
excellent bone grafts as they possess the all important osteogenic factors, 
particularly BMP-2, to stimulate bone repair and regeneration. A shift in trend 
was introduced, to use alternative bone grafts made from natural or synthetic 
materials, due to the various limitation and complications associated with 
autografts and allografts, as reviewed in Chapter 2. However, these 
biomaterials when used alone, even the osteoconductive and “osteoinductive” 
calcium phosphate materials, performed averagely in terms of bone forming 
and regenerative capabilities; as they were very reliant on the native tissue 
regenerative capabilities and endogenous growth factors present [112]. 
Therefore, the challenge is to accelerate and expedite the bone forming and 
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regeneration process, and the current prudent strategy is to incorporate and 
deliver osteogenic growth factors, especially BMP-2 to achieve an improved 
medical outcome [62, 330].   
The calvarial defect is well established for studying bone regeneration, 
induction and integration capabilities of grafts, due to its simplistic and well 
defined defect region. Ruhe et al. reported using calcium phosphate (CaP) 
cement implants, with averaged 100µm pore size and 75% porosity (but only 
about 36% was > 1µm), to repair calvarial defects in New Zealand white 
rabbits. The scaffolds were loaded with rhBMP-2 (10µg) and an absorbable 
collagen sponge (ACS) group was used as control. It was reported that at 2 
weeks, all the rhBMP-2 groups had some healing, including the ACS group, 
where the ACS was observed to be fully resorbed. However, more bone was 
detected outside the CaP scaffold than inside. At 10 weeks, it was reported that 
the CaP scaffold group had 75% coverage of the defect diameter, but the 
authors provided no clear quantification of the new bone regenerated. In 
reviewing the results, it was observed from the histology sections that new 
bone formation was significantly low and sparse. This was likely due to the 
architecture of the scaffolds, which seemed unfriendly to new bone ingrowth, 
which had the minimum adequate pore-size (~100µm) but low macroporosity 
of 36%, which accounted for the lack of space for new tissue ingrowth, blood 
clot, neovascularisation, cell migration and extracellular matrix (ECM) 
development. For the ACS group, the authors reported newly deposited bone 
did not form according the original skull contour and lacked the final required 
shape, it was concluded to be due to the flaccid aspect of the ACS. No 
mechanical tests were conducted to evaluate the calvarial reconstruction [331]. 
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Despite the excellent osteoinductive properties, this lack of shape and structure 
maintenance is a major drawback of the rhBMP-2 loaded ACS as a scaffold 
system for bone engineering. What the study highlighted, was the need for a 
mechanically stable scaffold with adequate pore-size and porosity to guide 
tissue ingrowth and support neo-tissue development from within the scaffold, 
and although potent, rhBMP-2 needs to be appropriately partnered for clinical 
success.  
In another reported study for treating rat calvarial defects, porous 
PLGA scaffolds fabricated from particulate leaching method was used, with 
pore sizes 200-300µm and porosity of 90%. A range of 0.6µg to 5.7µg of 
rhBMP-2 was loaded onto the scaffold to repair ∅5mm defects, up to 12 
weeks.  It was reported that at “low dose” of 2.3µg (half the maximum dose), 
more osteoids, immature and woven bone than mature bone was formed at the 
defect while the maximum dose of 5.7µg resulted more mature and highly 
mineralised bone but restricted to the exocranial surface, at 12 weeks. µCT 
analysis revealed that only 65% of the original defect volume was mineralised 
bone, while histologically the defect was bridged. It was also reported that 
there was a reduced thickness of the bony bridge in samples which received 
the maximum amount of BMP-2 (5.7µg) which was concluded to be due to the 
rapid bone formation which may have restricted the release of rhBMP-2 to 
host cells and thereby reduced the overall size of the resulting bone. 
Interestingly, the study designed a 500µm thick PLGA scaffold to deliver 
rhBMP-2 and repair an averaged 1mm defect thickness. While, lower doses 
could restore the full thickness of the defect at a slower pace of bone 
maturation (as reported) which was likely in allowing more cell-host 
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communication and interactions for a progressive but moderately accelerated 
physiological targeted repair and remodeling to the needs of defect site. 
Delivering a higher dose resulted in accelerated healing and tissue maturation 
but without full thickness restoration, which could be detrimental if not 
controlled or guided adequately. No mechanical tests were conducted to 
evaluate the calvarial reconstruction. The study highlights again the need for 
an appropriate scaffold delivery system for the delivery of precious potent 
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5.3. Conclusions   
From the in vivo results, µCT visualisation and semi-quantitation, 
histology and mechanical analyses we have observed that the collagen-
mPCL/TCP scaffold system with rhBMP-2 produced excellent regeneration 
results, in terms of time for healing, amount of mineralisation deposited, 
extensive closing of the defect site and most importantly repairing the calvarial 
defect and restoration of function. Although other tissue engineering 
strategies, such as reconstruction with the scaffold system alone or scaffold 
system with cells, may very well produce similar results, but possibly with a 
longer healing duration; the medical grade materials used here are safe and off 
the shelf products available (almost) to the mass market. Also, the important 
role a well-designed scaffold system plays, for a specific defect, in delivery of 
growth factors, guiding and complementing the bone regeneration dynamics 
cannot be undermined. Thus, we have demonstrated the performance of the 
optimised scaffold system combined with the delivery of rhBMP-2 could lead 








6. Performance of Scaffold System in a Clinical Relevant 
Spinal Fusion Model  
 
The bone scaffold system would be used, as a bone graft alternative, in 
a large animal load-bearing site for lumbar spinal fusion using the anterior 
lumbar interbody fusion (ALIF) technique. The key objective of this study is 
to ascertain its performance in a clinically relevant spinal fusion situation 
when compared to control groups. Importantly, the overall performance would 
be examined and assessed critically based on clinical feasibility and effective 
fusion.  
The spinal fusion procedure is a significant challenge for any bone 
engineering scaffold system as there is no original “defect” to repair, rather 
“real” living bone needed to be engineered in the interbody space where the 
vertebral disc was (annulus fibrosus and nucleus pulposus), without excessive 
outgrowth of bone which could lead to adverse pathologies (eg. encroachment 
into the spinal canal). It is paramount that this neo-bone is functional as it 
needs not only simply fill the gap but more critically fuse the two adjacent 
vertebrae firmly together and eliminate motion, as well as undertake the 
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6.1. Experimental Setup: Materials and Methods   
6.1.1. Resorbable Biocages for Spinal Fusion  
Bioresorbable biocages - mPCL/TCP scaffolds (15×12×4mm3) (Figure 
6.1) produced by the FDM technique were purchased from Osteopore 
International [36]. The designed biocages had a 0-90° lay down pattern with 
pore size of 350–500µm and a porosity of 65%. Clinical grade rhBMP-2 was 
purchased in the form of Infuse® Bone Graft kit from Medtronic. All 
mPCL/TCP scaffolds were NaOH treated for 3 hours and lyophilised with 
bovine collagen type-I (Symatese, France) to enhance biocompatibility and to 
create a mesh/sponge structure within the pores which would enhance cell 
seeding efficiency as well as to improve rhBMP-2 delivery.   
 
6.1.2. Compressive Mechanical Tests  
Mechanical compression tests were conducted on the biocage scaffold 
systems using an Instron 4302 Material Testing System operated by Series IX 
Automated Materials Tester v. 7.43 system software with a 1-kN load cell; in 
accordance with the ASTM D695-96 guidelines. The biocages (n = 5) were 
either tested in dry state or wet state simulating physiological conditions (PBS 
at 37°C), which were pre-conditioned up to 1 hour before the tests. The 
specimens were compressed at a rate of 1mm/min up to a strain level of 0.6. 
The stress-strain (σ - ε) curves were obtained to evaluate the load to failure 
(N) (taken at compressive yield strength), compressive modulus (stiffness) and 
compressive yield stress for the scaffolds. The compressive modulus was 
calculated from the stress–strain curve as the slope of the initial linear portion 
of the curve, with any toe region due to the initial settling of the specimen 
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neglected. The compressive yield stress was taken at the yield point (if any) or 
at the end of the linear region.  
 
6.1.3. Cumulative rhBMP-2 Release Study 
The cumulative release of rhBMP-2 from the collagen-biocage was 
assessed in an in vitro study, 30µg of rhBMP-2 was loaded into collagen-
biocages and biocage alone, placed in a 1.7ml microcentrifuge tube containing 
1ml of PBS and subsequently incubated at 37°C up to 3 days. The release of 
rhBMP-2 was examined at selected time points, at each time interval, 100µl of 
supernatant was removed and replaced with an equal amount of PBS. The 
amount of rhBMP-2 released was quantified by an enzyme-linked 
immunosorbent assay (BMP-2 Quantikine ELISA kit, R&D Systems) 
according to the manufacturer’s instructions, and expressed as percentage of 
cumulative release. 
 
6.1.4. Lumbar Interbody Spinal Fusion with Biocages 
Thirty-six male SPF Yorkshire pigs (~6 months old, ~ 50 kg) were 
used for the ALIF in vivo study with 4 treatment groups, autograft, biocages 
alone, biocages with cells and biocages with rhBMP-2, up to three time points 
of 3, 6 and 9 months (Table 6.1). Two level interbody fusion (at two disc space 
per pig, non-adjacent) was performed under strict aseptic conditions and a 
total of two autografts or biocages (n=2) were used per pig. After exposing the 
spine via an anterior approach the disc levels of interest was identified, the two 
intervertebral discs to be fused were separated by an intact disc. Then, the two 
intervertebral discs were carefully removed (discectomy) and the adjacent 
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endplates were decorticated, autografts or biocage implants were inserted after 
disc space distraction (Figure 6.2 and Figure 6.3). Titanium screw-rod was 
used to immobilise the adjacent vertebrae (Figure 6.3d).   
 
Autograft – Autogenous bone grafts of appropriate size (n=2 each) 
were harvested during surgery from the iliac crest of the pig, via a second 
incision (Figure 6.3a). 
 Biocage alone – The collagen lyophilised scaffold systems were stored 
at -20°C until surgery. Upon implantation, the spongy lyophilised collagen 
absorbed blood and fluids from the wound site (Figure 6.3b).  
Biocage with BMSC – Two months prior to surgery, up to a total of 
100ml of bone marrow was aspirate from the pigs selected for the (Biocage 
with BMSC group). BMSCs were isolated and expanded as described earlier 
in Chapter 3. The autogenous cells were expanded for 5-6 weeks using growth 
media and subsequently induced using osteogenic media for another 2-3 
weeks. Approximately, a total of 4 million cells were used for each biocage, 1 
million individual cells and 3 million cells (cell sheet) were seeded and 
wrapped around the biocage, respectively. The individual cells were 
trypsinised and seeded into the scaffold while cell-sheets from confluent petri 
dishes were lifted as cells sheets for the wrapping procedure [332]. They were 
statically cultured a further 2-5 days prior to implantation (Figure 6.3c). 
 Biocage with rhBMP-2 – The rhBMP-2 from the Infuse® kit was 
reconstituted, as per manufacturer’s instructions, it was aliquoted into 600µg 
of rhBMP-2 in 200µl, and stored at -80°C for not more than 6 months prior to 
use. During surgery, prior to biocage implantation, 600µg of rhBMP-2 in 
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200µl was thawed and loaded completely onto the collagen-biocage system 
(Figure 6.3b). Clinical ranges for spinal fusion vary from site and approach 
(eg. ALIF), generally a total dose of 4.2–12 mg of rhBMP-2 at 1.5 mg/ml is 
recommended, which was estimated to be about 10mg per fusion level for 
lumbar fusions [333, 334]. The 600µg dosage (~16-fold lower) was selected 
based on reported literature, which had a positive fusion outcome for a porcine 
model using the same rhBMP-2 source at this lower than clinical dose [335].  
 
Table 6.1. Experimental group for the ALIF procedure, (n) = 2 levels per 
pig. 
Groups Pigs Sample size, n 
Autograft 6 12 
Biocage only 12 24 
Biocage with BMSC 12 24 
Biocage with rhBMP-2 6 12 
 
At designated time points, animals were euthanised and the spine 
segments of interest harvested, cleaned of soft tissue and stored at -80°C until 
analysis. All animal experiments were conducted with adherence to the 















Figure 6.1. Biocage 
(mPCL/TCP) used for 
spinal fusion. 
Figure 6.2. Surgically prepared disc space ready for 
implantation. Up to three levels of intervertebral disc 
was exposed for two levels to be removed and 









Figure 6.3. Overview of bone graft groups. (A) Autograft being retrieved from a 
secondary surgical site. (B) Biocages before implantation. For biocage alone 
group, it was used as is. For rhBMP-2 group, the 600µg of rhBMP-2 was 
loaded onto the biocages prior top implantation. (C) Biocages with BMSC 
seeded into and wrapped around. (D) Biocage implanted (arrow) into the 
created defect site, with screw fixation system.  
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 The following methods were used to evaluate the performance of the 
spinal fusion:  
 
6.1.5. Micro-computed tomography (μCT) 
µCT (Shimadzu, SMX-100 CT) was used to evaluate the 
microstructural morphology the segments as well as semi-quantify amount of 
bone engineered. The quantity of bone measured was based on the volume of 
“mineralised bone” at the defect site and used pre-determined threshold value 
of “mature” bone from the surrounding in Mimics software (Materialize). The 
scan image slices were and visualised as a three-dimensional (3D) model and 
calculation base on density (Hounsfield) were performed. Quantification of 
total bone volume regenerated within the scaffold system was quantified from 
all groups at all time points, 3 - 9 months. The quantification method was 
performed by optimising a threshold value for the bone (neo-bone and older 
host bone) to be optimally presented with definitive structural sharpness and 
minimal artifacts and noise, it would exclude the scaffold material, which from 
experience is close to soft tissue. Next, rectangular-shaped mask, measuring 
15×12mm2 was created, replicating the dimension (length and width) of the 
biocage (Figure 6.4). This was fitted to µCT scan data of the region of interest 
(intervertebral space) and acquired the bone volume in the cranial to caudal 
direction (along the spinal axis), guided by the biocage and its rectangular 
outline which was easily identified due to its regular pattern (0-90°), then 
calculating the total bone volume through each pixel layer to acquire the 3D 
volume. Due to the irregular volume of the defect site, this method of 
quantification only measured the repaired and regenerated mineralised tissue 
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within the scaffold volume but not outside of it, even in reality, the defect site 
created (discectomy and decortications) usually produced a larger volume and 




Figure 6.4. Screen capture of bone volume measurement in Mimics. 
Volume data was acquired within the rectangular dimensions of a biocage 
and within an optimised threshold for “developed” bone. Biocage 
threshold shown in red, while “developed” bone threshold shown purple.  
 
6.1.6. Histological analysis 
Up to two representative implanted segments or functional spine units 
(FSU) were selected from each time point and group for histological analysis, 
based on gross and µCT evaluations. Segments were processed for hard tissue 
histology by dehydration in graded ethanol and embedment in acrylic resin 
(Technovit; Kulzer), longitudinal sections were prepared high-speed precision 
saw (EXAKT 300 CP Band System). Sections were stained with basic fuchsin 
and methylene blue to differentiate connective tissues (eg. bone, fibrous 
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tissue) as well as scaffold strut filaments. Using bright field microscopy, the 
sections were examined for regenerated tissue morphology and inflammation. 
Details of tissue formation and integration of tissue into the scaffold from the 
neighbouring tissue were also examined. 
 
6.1.7. Mechanical Tests  
Harvested motion segments were subjected to non-destructive 
mechanical test to determine the global range of motion [336, 337]. Briefly, 
each functional spine unit (FSU – adjacent vertebrae bodies with disc space or 
fused region) were potted in acrylic cement and tested in flexion, extension, 
right and left lateral bending and axial rotation at a constant loading rate 
(1.0°/s) using a servo-hydraulic materials-testing system (MTS MiniBionix 
858), up to a maximum torque of 5Nm (determined during preliminary test) 
without any compressive preloads. The moments and angular displacements of 
the free end of each motion segment were recorded. This test would 
effectively compare functionally the stiffness and resistance to motion that the 
newly fused FSU possessed. A total of 3 to 6 samples were used for each 
group and time point.  
 
6.1.8. Degradation Analysis  
After the non-destructive mechanical tests, up to two biocages two 
from each group and time point were retrieved from the fused vertebrae by 
sawing out the scaffold blocks, then the retrieved biocage with tissue within 
was treated in 50ml of undiluted Clorox® solution (5.25% solution of sodium 
hypochlorite, NaOCl) for up to 24 hours to remove any soft tissue, as 
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describes in Chapter 4. Next, the polymer retrieved was washed and dried. The 
molecular weight of the biocage was measured using GPC as described in 
Chapter 4.  
 
6.2. Results and Discussions  
The biocages were mechanically tested under uniaxial compression to 
understand how much load, rate of deformation (modulus) and stress the 
designed constructs could take. Due to its porous design the biocages 
displayed mechanical properties at the lower ranges of cancellous bone, yield 
strength of 2-5MPa with compressive modulus above 9MPa, but when tested 
under wet physiological conditions, the properties decreased by about 50% 
[74]. Compressive modulus fell from 51MPa to 26MPa, a 50% decrease 
(Figure 6.5). Yield strength decreased by 65%, from 6.5MPa to 2.3 MPa 
(Figure 6.6). Load at failure, which is the absolute maximum load which the 
biocage yields (deforms into the plastic region of the stress-strain curve) also 
decreased from 1162N to 493N, a 58% decrease (Figure 6.7).  
Typical stress-strain graph of a compressive test is shown in Figure 
6.8. The elastic region is where the material undergoes elastic deformation, 
where modulus (elastic/compressive) is measured. Within this region, the 
material obeys Hooke’s law, and when the deformation force is released, the 
material (scaffold) would return to its original state without damage. Yield 
strength is the point (intersect) between the elastic and plastic region; it is also 
where failure load is measured. Beyond the yield point the material enters the 
plastic deformation region, where even if the deformation force is released, the 
material would not return to its original state due to molecular damage and 
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disruption. For this composite scaffold system, there is no evident ultimate 
yield point or failure point, the appropriate failure usually defined in bone 
biomechanics studies, such as those listed in Table 6.2, is when the bone 
fractures and a catastrophic crack occurs in the bone, after which it cannot 
(should not) be loaded. Thus, due to the difference in the definition of 
“failure” the results should not be taken at the superficial values.  
Polymeric and most polymeric-ceramic scaffolds, when compressed 
beyond the yield point would undergo a densification process when the struts 
start to buckle and collapse, material becomes compacted and crushed, and the 
stress/load increases exponentially – the densification process [35]. Thus, 
without a proper failure point for the scaffold system, it would be a complex 
matter in theory to determine when it would “fail”. Since there is no 
catastrophic failure, like the fracturing of bones, the “failure” could be 
assumed when the pores become crushed. Hypothetically, if failure was 
defined as the point where the scaffold is deformed till half its original height, 
the corresponding load to failure would be approximated at 2500N, a 
physiologically relevant figure. In a normal spinal column system, the facet 
joints could load-share up to 12% of the compressive loads. In the current 
clinical setting, when titanium screw-rod fixation systems are used, the pedicle 
system could take up to 70% and facet joints about 4%; resulting in about 25% 
of the load to be borne by the bone graft or alternative [338]. Embracing the 
strategy of using bioresorbable implant devices, the possibility is open for a 
complete set of fully bioresorbable implant devices, including fixation devices 
available for orthopaedic therapies [339]. Progressively, technology would be 
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able to create stronger bioresorbable devices with minimal adverse effects 
from its by-products [340].  
Taken together, the resorbable biocage should be able to share some of 
the load until adequate regeneration or fusion (3-6 months), as the load-
sharing mechanics is slowly transferred to the neo-mineralised bone, which is 
also necessary for dynamic and micro-mechanical stimulation. Besides, in 
reality to resolve the issue of material-strength mismatch and effects of stress-
shielding, the implant should not undertake all the loads, especially in the long 
term. Further, the physiological load after surgery should be gradually 








































Figure 6.5. Compressive modulus of biocages tested in dry 
and wet conditions. The dry scaffold exhibited a compressive 
modulus of 51MPa; while, after conditioning to physiological 























Figure 6.6. Compressive yield strength of biocages tested in 
dry and wet conditions. The dry scaffold exhibited a yield 
strength of 6.5MPa; while, after conditioning to physiological 
conditions, the modulus decreased by 65% to 2.3MPa 





















Figure 6.7. Load to failure of biocages tested in dry and wet 
conditions. The dry scaffold exhibited a failure load of 
1162N; while, after conditioning to physiological conditions, 





















Figure 6.8. Typical compressive stress-strain graph of a scaffold. Within the 
elastic region, the material would return to its original state when load is 
removed. Yield strength is the point between the elastic and plastic region; 
where scaffold “failure” is measured. For this typical composite scaffold 
system, there is no evident ultimate yield point, scaffold struts would collapse 
and the densification process would occur, when stress increases exponentially.  
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Table 6.2. Tabulation of compression mechanical properties of vertebrae 
samples, mPCL/TCP scaffolds and other anatomical bone regions. A vast 
range of compressive mechanical requirements can be observed from different 
regions.  
Normalised Vertebrae Sample 
Units Modulus (MPa) Yield (MPa) Reference 
Porcine cancellous vertebrae 229 13 [341] 
Human cancellous vertebrae 316 - 1057 2.02 [342-344] 
Biocage (mPCL/TCP) -Wet 26 2.3 This study 
Human cancellous femoral neck 3230 17.45 [342] 
Human cancellous mandible  0.22 to 10.44 [345] 
Human iliac crest wedges 102.18 18.26 [346] 
Human cancellous bone 90 - 400 2 - 5 
Human cortical bone   175 
PMMA for VP  80 
CPC for VP  100 
[74, 347] 
    
Vertebrae Samples Failure Load (N) Reference 
Biocage (mPCL/TCP) - Wet 493 This study 
Human single lumbar vertebrae 2047 [348] 
Human vertebrae (T9)  2405 - 2888 
Human spinal column (T10-L2) 1501 - 1775 
[347] 
Human vertebrae (L1-L5)  1248 - 2200 [349] 
Human iliac crest wedges 2966 [346] 
*VP – vertebroplasty; PMMA – polymethylmethacrylate; CPC – calcium phosphate 
cement. 
 
The in vitro rhBMP-2 release study indicated that majority (~90%) of 
the rhBMP-2 was released within the first 12 hours from the scaffold system, 
regardless with or without the lyophilised collagen mesh. However, within this 
12 hours release, the collagen-scaffold system was slightly slower and delayed 
(Figure 6.9). This was typical of most adsorbed scaffold systems including 
collagen sponges.  While timing of the growth factor release is important, the 
dynamic nature of the healing zone and other clinical factors play a major role 
in regeneration as well. 
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Collagen which is recognised and approved for its biomimetic 
properties and low immunogenicity, is a favourable and functional choice for 
the clinical delivery of cells and growth factors. Collagen possesses a higher 
number of negatively charged residues which is excellent for protein-protein 
interactions. A comprehensive characterisation conducted by Friess et al. 
estimates the minimum robust binding and retention of rhBMP-2 when soaked 
on to collagen sponges was 20%. Differently treated (chemical modification) 
collagen may incorporate different levels of rhBMP-2, non-crosslinked 
material may incorporated up to 100% of the rhBMP-2 while crosslinking 
modifications, would reduced swelling and enhance stronger interaction 
between the collagen structures but result in less surface area and reduction of 
binding sites. On the other hand, non-crosslinked material experiences higher 
rhBMP-2 loss rate for being more susceptible to collagenase degradation. All 
these challenging and conflicting factors make the efficient delivery of 
bioactive rhBMP-2 for a positive clinical outcome extremely complex [156].  
Reports on the delivery of rhBMP-2 on collagen carriers, polymeric 
matrices and calcium phosphate scaffolds for spinal fusion applications, 
osteotomy, oral and maxillofacial defects have continued to be impressive and 
convincing. It was reported that less than 5% of the rhBMP-2 dose remains at 
the application site whereas combinations of the proteins with gelatin foam or 
collagen could increase retention ranging from 15 to 55% [350]. The ambition 
is to have an intelligent delivery system to deliver or release the precise 
effective dose at the right time in prefect synchrony with the healing regime. 
Therefore, a deeper understanding and knowledge about effective rhBMP-2 
dosage, time-course, release dynamics and carrier systems need to be 
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addressed. The current release profile only tells one particular side of the 
story, although it has been reliable and successful clinically [274, 282, 351-
354]. Essentially, rhBMP-2 has a local effect for inducing progenitor cells to 
activate bone healing processes and it could diffuse and recruit stem cells 
(chemotactic effect) or stimulate other healing processes, such as 
vascularisation [251]. The latter two functions could very well require a totally 
release profile than the idealised local release profiles, suggested to be in the 
picograms to nanograms range (based on physiological concentrations). Most 
studies use rhBMP-2 at supra-physiologic concentrations though reports on the 
issue of safety have been varied [16, 85, 107, 160, 281, 282, 315, 333]. 
Debates on release pharmacokinetic profiles, excessive dosages, carrier 
systems and animal models are ongoing but would come full circle to the need 
for an effective scaffold system to complement the defect void and facilitate 
biological repair by the cellular elements, which the rhBMP-2 is suppose to 
induce and recruit. Thus, the formidable synergistic effect of a functional 
stable and bioactive scaffold system platform with optimal architecture for cell 
and tissue infiltration could be successful even with a low-dose rhBMP-2 to 
achieve effective and successful fusion in a large animal model.   


























Figure 6.9. Cumulative release of rhBMP-2. Up to 90% release 
within the first 12 hours. Biocage-collagen system observed to 
retain rhBMP-2 slightly longer.  
 
At the earliest specified time point of 3 months, the fused spine 
segments were explanted and retrieved for examination. Minimal fibrous 
tissue reaction was observed at the wound site and overall neither excessive 
fibrous tissue nor inflammation were detected. A solid bony fusion at the 
surface between the two adjacent vertebrae was observed in majority of the 
samples, independent of treatment groups. Bone outgrowth beyond the defect 
site, covering part of the pedicle screws and rods was observed in defects pre-
dominantly treated with rhBMP-2 systems as early as 3 months (Figure 6.10). 
A similar gross visual overview was observed at 6 and 9 months.  
A thorough internal assessment was required to reveal the actual 
quantity and quality of bone tissue regenerated and engineered. After the non-
destructive biomechanical tests, selected fused segments, were sectioned and 
sawed through the implantation site for gross examination (Figure 6.11). All 
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the treatment groups showed excellent bridging and contact between graft with 
host bone (adjacent vertebrae), including neo-tissues at all time points. All the 
fused segments sectioned, including autograft and rhBMP-2 groups, showed 
some remnants of the annulus fibrous which remain present within the bony 
structure, which were not entirely resected due to surgical difficulties. 
Nevertheless, it reinforces the importance and requirements for adequate 
design and plan to have a successful engineered tissue or clinical outcome. 
The autograft group showed uniform bone trabeculae observed at the defect 
cross-section but with some fibrous tissue and irregular non-mineralised tissue 
regions (Figure 6.11a). This could affect tissue regeneration and increase the 
risk of leading to pseudoarthrosis, a disastrous result due to lack of adequate 
mineralisation and sustained micro-motions.  
The spinal fusion treatment with biocage alone revealed that it was 
well integrated into the surrounding trabecular bone body but soft and non-
mineralised tissues were observed to fill the scaffold pores, instead of the 
required bone (Figure 6.11b). mPCL/PCL had been shown to integrate and 
bond well with surrounding host bone but osteoconduction into the porous 
scaffold depended immensely on the osteogenic factors and possess limited 
osteoconductivity in a large defect [41]. Thus, in order to improve the 
osteoconductivity and osteogenic potential, osteoinductive factors were used 
in combination with the scaffold system. The biocage with BMSCs appeared 
to be well integrated into the surrounding trabecular bone body but soft and 
non-mineralised tissues were observed to fill the scaffold pores. In a few 
instances, bony intrusions and possible bridges could be observed (Figure 
6.11c). Accordingly, the incorporation of autologous BMSCs seemed capable 
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of improving the osteoinductivity to a certain extent. When the biocage was 
loaded with rhBMP-2, the gross overview displayed excellent integration into 
the surrounding trabecular bone body with regions of dense cortical-like 
tissue, it could be distinguished from the normal trabecular structure as it was 
likely to possess a denser mineralised phase and lesser marrow space, thus a 
lighter colour possibly due to lack of vasculature (Figure 6.11d). Bone 
induction and development seemed to proceed in a swift manner, possibly 
through the direct ossification pathway. The production of mineralised tissue 
was so aggressive that two outcomes were observed: mineralised tissue 
infiltrated the scaffold pores after only 3 months and also portions of the 
scaffold appeared to be “crushed” by de novo bone formation, growth and 
penetration. In all the biocage groups, bone was again observed to bond 
directly with the biocage demonstrating their bioactivity [112]. 
At 6 and 9 months, base on clinical radiographic assessment and µCT 
analysis, only the autograft and rhBMP-2 groups were deemed “fused” where 
radio opaque bone were observed in the disc space. Normal trabecular bone 
was observed to fill this defect in the rhBMP-2 group with seamless scaffold 
integration into host bone bed (as early as 3 months, Figure 6.12). Defects 
from the autograft group showed graft retention, there was minimal evidence 
of graft integration into host bone bed at 3 months (Figure 6.12). The other 
groups, biocage and BMSC groups showed minimal mineralisation within the 
scaffold system but defect space was maintained by the biocages. Some bony 
ingrowth was detected infiltrating into the scaffold in the longitudinal 
direction in the BMSC group, but no bridging was observed. Overall, all the 
biocage groups maintained their mechanical integrity and functionally 
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maintained the disc space, although only the rhBMP-2 group successfully 
supported new bone regeneration within its porous space. 
 
 
Figure 6.10. Spinal segment treated with rhBMP-2 
loaded biocage, no inflammation and minimal fibrous 
tissue were detected. Bone growth observed on the 



















Figure 6.11. After the non-destructive biomechanical tests, selected fused segments, 
were sectioned and sawed through the implantation site for gross examination and 
biocage material retrieval. Image shows all sample groups at 6 months. (A) Autograft: 
uniform bone trabeculae observed at the defect cross section but with some fibrous 
tissue and irregular non-mineralised tissue regions, indicative of possible graft 
resorption which could lead to pseudoarthrosis due to lack of adequate fusion. (B) 
Biocage alone: scaffold system well integrated into the surrounding trabecular bone 
body but soft and non-mineralised tissues were observed to fill the scaffold pores. (C) 
Biocage with BMSC: scaffold system well integrated into the surrounding trabecular 
bone body but soft and non-mineralised tissues were observed to fill the scaffold 
pores. In a few instances, bony intrusions and possible bridges could be observed 
(arrow). (D) Biocage with rhBMP-2: scaffold system appeared well integrated into 
the surrounding trabecular bone body with regions of dense cortical-like tissue 
(lighter colour – lack of vasculature). Bony tissue infiltrated the scaffold pores but 
toward the posterior region, the scaffold appeared to be “crushed” by neo-bone 
growth instead. The (a) and (p) in each picture indicates the general orientation of the 
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Figure 6.12. µCT images of defect site from 3 to 9 months. As early as 3 months, 
base on this radiographic assessment, only the autograft and rhBMP-2 groups were 
deemed “fused” where radio-opaque bone was observed in the disc space. Normal 
trabecular bone was observed to fill this defect in the rhBMP-2 group with seamless 
scaffold integration into host bone bed. The biocage and BMSC groups showed 
minimal mineralisation within the scaffold system but the defect space was 
maintained by the biocages. Some bony ingrowth was detected infiltrating into the 
scaffold in the longitudinal direction in the BMSC group, but no bridging was 
observed.  
 
Quantification of bone volume at defect regions at all time points 
showed significantly higher bone ingrowth volume into the biocage in the 
rhBMP-2 groups, compared to other treatment groups (Figure 6.13). The 
autograft group exhibited an average about 70% bone volume, indicating 
minimal resorption and a balances remodeling process. The osteoconductive 
biocage group saw bone ingrowth maintain at about 22%. The BMSC group 
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saw bone formation increase from 10% to 15% and finally to 37%, after 3, 6 
and 9 months, respectively. The most significant bone mineralisation increase 
came from the rhBMP-2 group, which increased from 64% (3-mth), to 82% 
(6-mth) and 98% (9mth), which was reconstructed the full thickness of the 
biocage.  
Histological evaluation at 3, 6 and 9 months shows that woven bone 
had colonised the scaffold and bridged all defect gaps in the rhBMP-2 treated 
group concurring with µCT findings. New bone formation was observed to be 
by direct ossification rather than via the endochondral ossification mechanism. 
Columns of bony trabeculae (vertical trabeculae) were observed in this group 
traversing the longitudinal length of the disc space. These new mineralised 
tissues were found to be in direct contact with scaffold struts, indicating osteo-
compatibility. These bony columns that normally act to reinforce transverse 
(horizontal) trabeculae indicates load-bearing/sharing function for the newly 
formed bone. Autograft group showed substantial bone growth and integration 
at the defect site as well. However, some cases of graft fractures were detected 
at 3 months. At 6 and 9 months, both autograft and rhBMP-2 groups showed 
increasing trabecular remodeling and maturation. For the biocage only and 
BMSC groups, minimal bony tissue ingrowth or mineralisation was observed 
but defect space was preserved. There was no evidence of scaffold rejection or 
foreign body reaction such as biocage or foreign material encapsulation, 
infection or scaffold strut fractures at all time points. 
The biomechanical testing determines the effective limitation to range 
of motion (ROM) which indicated the ability of the fused interbody joints in 
resisting motion – functional outcome of spinal fusion (Figure 6.15). The 
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intact spinal unit (control), normal functional intervertebral disc which is not 
operated showed the widest range of motion at both time points and least 
stiffness, at both time points. All the treatment groups showed increased 
average stiffness from 3 to 9 months, most notable increase in the autograft 
and rhBMP-2 groups. At both time points, both autograft and rhBMP-2 
performed functionally well by allowing the narrowest range of motion and 
highest stiffness. The BMSC group showed marginal lower range of motion 
and higher average stiffness compared to the biocage alone group, this may 




























Figure 6.13. Quantity of bone base on defect volume semi-quantified by µCT 
using Mimics. Bone measurements for autograft average about 70%, similarly 
the biocage alone and BMSC groups also averaged 22% and 20%, respectively, 
over the 9 months. Only the rhBMP-2 group exhibited significant difference in 
bone volume compared to the biocage and BMSC groups at all time points, 















































Figure 6.14. Histological section of spinal segment showing implanted autograft or 
biocages, stained with basic fuchsin-methylene blue stain. The general anatomical 
orientation for the spine segments are posterior to anterior (where grafts were inserted), 
from left to right, respectively. All groups with biocages displayed good integration 
with upper and lower vertebrae and direct contact with bone, no fibrous tissue was 
detected. Based solely on histology sections, the biocage only and biocage with BMSC 
treatment showed no or minimal bone ingrowth into the porous scaffold system, only at 
6 months for the BMSC group and at 9 months for both groups were some bony 
infiltration detected. Based solely on histology sections, the better performing treatment 
groups were the autograft and biocage with rhBMP-2, dense bony trabecular tissue was 
detected (integrated into the scaffold pores) as early at 3 months. As implant time 
increases, a denser cortical-like region at the anterior surface (bridging of defect 
aperture) of mainly the autograft and rhBMP-2 group was observed; this could possibly 
be due to neo-tissue mimicking the neighbouring host tissue (the adjacent vertebrae) of 
the same structural configuration, this could also suggest an adequate biomechanical 
stimulation, support and response. In some samples from the biocage only and BMSC 
group, the anterior defect aperture (both gross and histological examination) was only 
closed with soft tissue or membrane.  
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Figure 6.15. Mechanical test for the range of motion for the spinal 
segments from 3 to 9 months. Flexion-extension (top), right-left lateral 
bending (middle) and axial rotation (bottom). 
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The degradation profile of the mPCL/TCP biocages were analysed up 
to 9 months (Figure 6.16). The molecular weight distribution of biocages 
implanted in the lumbar spine showed a decreasing trend similar to the in vitro 
results in Chapter 4. The Mw profiles of the biocages alone and with BMSC 
followed the in vitro profile closely, in term of the rate of molecular weight 
loss. The Mn instead decreased at a faster rate initially up to 3 months before 
following a similar rate of decline thereafter. The rhBMP-2 biocage group, 
showed similar profiles within the first 3 months, before displaying a drastic 
reduction in rate of degradation after, this could be due to massive quantities 
of mineralisation produced and regenerated around the composite structure 
thereby significantly reducing the amount of fluids (water as reactants) for 
hydrolysis. As observed, biocages without rhBMP-2 had loss about 50% of its 
molecular weight after 9 months, but only about 22% when loaded with 
rhBMP-2. Faster degrading polyesters, such as polylactide-based devices 
(such as poly-L-lactide-co-D,L-lactide cages) risk early loss of cage support, 
leading to subsidence, and possible onset of osteolysis [355]. Osteolysis 
arising from degradation by-products is a major concern and could bring about 
failure of the treatment and undesirable tissue reactions. As described in 
Chapter 4; implant design could reduce chances of acidic by-product 
accumulation. At the current 9 month time point, no adverse inflammation nor 
tissue reaction were observed.  
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Figure 6.16. Molecular weight distribution of biocages implanted in the 
lumbar spine up to 9 months, both Mw and Mn were plotted on the graph. 
(Dark brown lines broken and unbroken, represents the trend for the 
mPCL/TCP scaffolds from the in vitro study.) A decrease in the molecular 
weight of the biocages (PCL/TCP scaffolds) was observed, similar to the in 
vitro study, the Mn decreased at a faster rate. Only the biocages from the 
rhBMP-2 group showed a reduction in rate of degradation after 3 months, 
this could be due to massive quantities of bone produced and regenerated 
around the composite structure thereby significantly reducing the amount of 
fluids (water as reactants) for hydrolysis.  
 
Although the BMSC cell-sheet group did not achieve clinical fusion, it 
remains an innovative method of transplanting in vitro cultured cells along 
with its in vitro cultured extracellular matrix (ECM). The ECM is a highly 
organised meshwork of molecules and structural components including 
collagens, glycoproteins, proteoglycans, laminin, heparan sulfate 
proteoglycans and osteoproteins in bone ECM. The ECM provides cells with a 
scaffold microenvironment that they can attach to and move about. It also 
plays a protective role buffering and insulating the tissues, impedes cell 
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migration and regulates diffusion and the spreading of physiological and non-
physiological stimuli. These passive but supportive functions serve as a 
dynamic cellular microenvironment that can mediate information to and from 
the cells and store and protect essential regulatory factors produced by the 
cells. The ECM is also an essential communication relay between cells and 
ECM, and cell to other cells through the multitude of growth factors and other 
signaling molecules stored or secreted [356, 357]. The advantages and 
applications of cell-sheet technology have been explored and recognised [25, 
238].  
Several growth factors bind or interact to ECM either directly or via 
specific binding proteins. The largest group of ECM associated growth factors 
binds to heparin sulfate proteoglycans (HSPG) or heparin, such as fibroblast 
growth factors (FGF), platelet derived growth factors (PDGF), hepatocyte 
growth factors (HGF), vascular endothelial growth factors (VEGF), epidermal 
growth factors (EGF), bone morphogenic proteins (BMP), certain 
hematopoietic cytokines (IL-3) and granulocyte macrophage growth factors 
(GM-CSF) [250, 358-366]. Certain growth factors (eg. FGF) are known to 
protect by HSPGs from proteolytic degradation, inactivation by heat and 
extreme pH conditions, preserving their potency (Saksela et al., 1988). Thus, 
these growth factors could be stored and modulated for the generation of rapid 
and highly localised signals in situations like tissue damage and microbial 
invasion [250, 277, 367, 368].  
Besides structural and biochemical features of the scaffold, the 
presence of a viable population of osteogenic cells has been identified to play 
a crucial role in this current study. With the efficient and successful bone 
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forming potency of rhBMP-2, the role of cell-sheet based tissue-engineered 
constructs appeared somewhat limited. However, evident differences could be 
drawn to substantiate the subtle potential it held when compared to the 
scaffold alone group. Even in literature, though the contribution of in vitro 
seeded cells is well established, the functional results have been described as 
variable [369, 370]. Qian et al. reported enhancement of bone regeneration and 
spine fusion in an ovine interbody fusion model when autologous bone 
marrow cells were seeded on natural bone collagen scaffold [371]. The 
incorporation of partially differentiated pBMSC into the mPCL/TCP scaffold 
system clearly enhanced bone regeneration and biomechanical stability of the 
lumbar spinal segment compared to non-cell scaffold systems. Newly formed 
bone was observed to grow into and around the implants from both the 
cephalic and caudal vertebral bone beds forming bony projections that were 
visible as early as 3 months. The observed bone ingrowth indicates smooth 
osteointegration with surrounding bone, a vital factor in functionality of the 
newly form bone tissue. The continued challenges for the use of cell-based 
constructs remain are the size of the defect site which directly affects the 
potency of the osteoinductive cues, survival and viability of the progenitor cell 
populations, vascularity of the defect site and nutrient availability [370, 372].  
Clinical and effective fusion was achieved in a large animal model 
with ALIF using the mPCL/TCP biocages and at a low dose of 600µg per 
level. Biologics, which includes, vaccines, blood, cells, gene therapy, tissues, 
and recombinant therapeutic proteins, are considered as medicinal products 
created by the biological processes, as opposed to synthetic drugs, which are 
developed by chemistry. Nonetheless, they also possess the capacity to 
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stimulate, activate or inactivate specific biochemical processes and functions 
when delivered in vivo. Thus, growth factors could also have its side effects 
and adverse outcomes. There are mainly two reported adverse effects, 
immunogenicity and heterotopic bone formation. All recombinant human 
proteins, including rhBMPs could induce immune (antibody) responses, which 
could be particularly severe in a select group of patients. Hwang et al. found 
that there were no serious adverse effects resulting from the incidence of 
antibody formation, which was slightly higher in rhOP-1 than in rhBMP-2 
trials. They concluded that the immune responses against rhBMPs have no 
correlation with any clinical outcome or safety, and that clinicians must be 
aware of the potential complications caused by the immunogenicity of BMPs 
[280].  
BMPs are currently being used in supra-physiologic concentrations and 
expensive dosages in the milligram range) estimates up to 12mg per fusion 
lumbar fusion level. Which are occasionally linked to adverse reactions and 
outcomes, like soft tissue edema, erythema, local inflammation, heterotopic 
ossification and immune responses. Osteoclastic activation has been noted in 
some cases, resulting in undesired bone resorption occurred. [283, 315, 334, 
373]. The osteoinductive properties of rhBMP-2 were observed to be enhanced 
in combination heparin and heparin sulphate which could lower their effective 
dosage, minimising the risks of adverse responses [277, 374-376]. Intelligent 
systems, such as the sequential release of BMP-2 in combination with another 
growth factor (such as IGF or GFG-2) have been explored but issues of 
efficacy and commercialisation difficulties have arose [377-379]. The current 
challenge would be to deliver these osteoinductive factors in ways that would 
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ensure consistent clinical success in humans, possible in an intelligent, 
customisable, localised, sustained and controlled manner at a 
pharmacologically complementing manner to the induction and chemotactic 
needs of cells and defect microenvironment. Nonetheless, any administration 
of biofactors for bone repair purposes must be suitably reinforced and 
complemented by an adequate mechanically functional and osteoblast-friendly 
scaffold system to potentiate and enhance efficient tissue regeneration. 
Localised and sustained delivery will be just one variable to the equation. It is 
likely that with appropriate carrier systems and placement, the risk of these 
complications would be reduced. In this study, the biocage system allowed for 
osteoconduction and a suitable microenvironment for cells to respond to the 
induction signals, which mineralised rapidly.  
The use of rhBMP-2 in orthopaedic applications is on the rise as 
factors of cost-effectiveness, efficacy and decreased use of autografts start to 
make social and economic sense. Polly et al. conducted a cost analysis 
comparing stand-alone ALIF with rhBMP-2 on an absorbable collagen sponge 
versus autogenous iliac crest bone graft in a tapered cylindrical cage or a 
threaded cortical bone dowel. They suggested that the initial cost of using 
rhBMP-2 for spinal fusion is likely to be offset by avoiding the complications 
associated with autologous bone graft and improved successful fusion, though 
the upfront cost was significant, within a 2 year projection [380].  
The current studied biocages (mPCL/TCP scaffold system) lyophilised 
with collagen type I, as an alternative bong graft, has demonstrated the 
efficient delivery of a clinical rhBMP-2 to achieve successful clinical spinal 
fusion and bone formation, in an ectopic and without observed heterotopic 
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bone formation. This study undoubtedly demonstrated the suitability of 
architecturally optimised scaffold system for enhancing in vivo bone formation 
[381-383]. Additionally, it was achieved in a safe and cost effective manner 
with a significantly lower dosage of rhBMP-2.  The use of this novel cost-
effective delivery system has the potential to shorten the treatment period of 
long bone distraction osteogenesis and thus could diminish the morbidity and 
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6.3. Conclusions  
This study evaluated the biological performance of a bioresorbable 
scaffold system designed for bone engineering in a load-bearing defect. 
Results indicate that the mPCL/TCP scaffold system can be an excellent 
delivery mechanism for rhBMP-2 and provides suitable environment for bone 
ingrowth and fusion in a large animal model of lumbar interbody fusion, 
which is a unique bone engineering situation because of the complexity of 
dynamic loading forces acting at this site. Significantly low dose of rhBMP-2 
(0.6 mg/scaffold/level) compare to clinical doses (12mg/level) was loaded into 
the collagen-biocage system peri-operatively and its bioactivity was retained, 
inducing excellent new bone formation with complete defect bridging as early 
as 3 months. The quality of fusion, histologically and biomechanically, was 
observed in this study to be similar if not superior to autograft bone. 
In this study, the complexity of using BMSCs with the biocage for 
ALIF highlighted the typical issues surrounding the use of autologous stem 
cells, such as expansion, maintenance of potency and quantity of cells for 
therapeutic efficacy, and strategy of maximising or maintaining cell survival 
after implantation; especially for a multi-level fusion  
The overall findings support of the strategy of using bioresorbable 
scaffold systems that are designed to encourage rapid bone ingrowth and thus, 
promptly transfer of the load-bearing/sharing dynamics to new tissues, even at 
highly demanding sites of bone regeneration like the lumbar interbody fusion 
site. Moreover, the trabecular bone system, especially in load-bearing sites, 
where the biocage device was implanted, is a complex structural material, 
anisotropic in load distribution, and constantly being stressed and loaded over 
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the lifetime, dependent on the age, systemic health status and the rate of bone 
remodeling of the individual. . As there is an imperative need for “off the 
shelf” tissue engineering products to meet the current unmet clinical needs, the 
strategy of using the commercial mPCL/TCP biocage with rhBMP-2 could 
provide an immediate viable option as a bone graft alternative for a variety of 
bone engineering situations. Thus, this strategy of tissue engineering by 
stimulating host tissue and bone regeneration clearly surpasses other 
permanent implant strategies, where the permanent implant could cause 
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CHAPTER 7 
7. Conclusions and Recommendations  
7.1. Conclusions  
In bone tissue engineering, the mechanical and effective scaffold has 
been pivotal for successful bone repair. Coupled with osteogenic factors, such 
as cells and growth factors, these scaffold system are able to tackle complex 
issues and large defects which autologous bone grafts is the gold standard. 
However, this gold standard comes in limited supply and quality. Thus, there 
is an unmet medical need for “off the shelf” bone graft alternatives which 
could be consistently efficient in treating a variety of defects, approved by the 
regulatory bodies.  
In this study, a bioresorbable scaffold system (mPCL/TCP) designed 
for bone engineering in a load-bearing defect and fabricated from FDA-
approved materials was characterised for its biocompatibility, functionality, 
internal macrostructure, extensive degradation profile and performance in 
treating a maxillo-cranial defect and orthopaedic spinal fusion. Results 
indicate that the mPCL/TCP scaffold system can be an excellent delivery 
mechanism for rhBMP-2 and provides suitable environment (architectural and 
biological) for bone ingrowth and fusion in a large animal model of lumbar 
interbody fusion, which is a unique bone engineering situation because of the 
complexity of dynamic loading forces acting at this site.    
The study has conducted experiments and drawn conclusions to fulfill 
the hypotheses and aims as stated in Chapter 1.  
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1) Characterisation of composite PCL/TCP scaffolds for bone 
engineering   
 The composite resorbable mPCL/TCP scaffold was capable of 
supporting BMSC proliferation and differentiation for bone tissue 
engineering.  
 The scaffold system is mechanically stable with mechanical 
properties in the range of cancellous bone.  
 Notable internal micro-pores were identified as inherent of the 
fabrication process, which could accelerate degradation and reduce 
the effectiveness of the reinforcement filler.  
 
2) Degradation studies: Long-term in vitro & in vivo  
 The composite scaffold system degrades via a bulk degradation 
pathway, which proceeds mainly via hydrolysis.  
 The composite scaffold system was able to maintain nominal 
strength for up to 6 months and structure up to 2 years.  
 Polymer degradation process is extremely dynamic, due to 
thermodynamic energy equilibriums of the molecular chains, and 
would vary according to design, materials used and in vivo 
environment. 
 The composite scaffold was implanted up to 2 years without 
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3) Performance of scaffold system in a small animal model 
 The composite scaffold system loaded with rhBMP-2 successfully 
restored and reconstructed a critical sized calvarial defect. 
 Full calvarial thickness was restored along with excellent 
integration to host bone.  
 
4) Performance of scaffold system in a clinical relevant spinal fusion 
model 
 The composite bone scaffold system loaded with rhBMP-2 
effectively and successfully achieved clinical fusion of the lumbar 
spine in a large animal model. 
 The design and delivery system enabled success of low dose 
rhBMP-2 to achieve fusion, within 3 months, comparable to 
autografts. 
 
Collectively, the mPCL/TCP scaffold system is a scaffold system 
which could be loaded with rhBMP-2 for bone tissue engineering and could be 
used as a bone graft alternative at a load-bearing site. Performance and results 
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7.2. Recommendations  
The results in this research study showed that using the mPCL/TCP 
scaffold system in combination with rhBMP-2 is a feasible bone graft 
alternative for bone repairs and engineering. However, the study also revealed 
some aspects which could be further developed or evaluated to improvement 
the understanding of bone engineering using the 3D scaffolds. A few 
recommendations are put forth here for future research:  
 Regenerative potential of stem cells continue to be intriguing and there 
would be a need to further characterise and optimise the conditions for 
management and use of stem cells for therapy with the scaffold system. 
Methods could be devised to enhance and study cell survival and cell 
fate in order to treat large and complex defects.  
 Micro-pores were identified within the mPCL/TCP scaffold due to 
processing methods. Material processing, fabrication or enhancement 
studies could be done to eliminate these which together could enhance 
the mechanical properties of the scaffolds. 
 There remains room for further enhancement the intelligent delivery 
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